AU7150600A - Compositions and methods for the treatment and diagnosis of breast cancer - Google Patents

Description

Q:\Opcr\Ejhovrba\2338080.mpL~wri l.d 1/00 Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION FOR A DIVISIONAL PATENT

(ORIGINAL)

0 @0p0 00*0 a. 00.. 0 0 a 0 Name of Applicant: Corixa Corporation Actual Inventors: Tony N. FRUDAKIS, John M. SMITH and Steven G. REED Address for Service: DAVIES COLLISON CAVE, Patent Attorneys, Level 3, 303 Coronation Drive, Milton, Queensland, 4064, Australia Invention Title: "Compositions and methods for the treatment and diagnosis of breast cancer" Details of Parent Application No: 16974/97 The following statement is a full description of this invention, including the best method of performing it known to us:- 1A Description COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER Technical Field The present invention relates generally to the detection and therapy of breast cancer. The invention is more specifically related to nucleotide sequences that are preferentially expressed in breast tumor tissue and to polypeptides encoded by such nucleotide sequences. The nucleotide sequences and polypeptides may be used in vaccines and pharmaceutical compositions for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of compounds, such as *o antibodies, useful for diagnosing and monitoring the progression of breast cancer in a patient.

Background of the Invention Breast cancer is a significant health problem for women in the United ooo States and throughout the world. Although advances have been made in detection and L treatment of the disease, breast cancer remains the second leading cause of cancer- 20 related deaths in women, affecting more than 180,000 women in the United States each year. For women in North America, the life-time odds of getting breast cancer are now one in eight.

No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently available. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular breast cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. See, Porter-Jordan and Lippman, Breast Cancer 8:73-100 (1994). However, the use of established markers often leads to a result that is difficult to interpret, and the high mortality observed in breast cancer patients indicates that improvements are needed in the treatment, diagnosis and prevention of the disease.

Accordingly, there is a need in the art for improved methods for therapy and diagnosis of breast cancer. The present invention fulfills these needs and further provides other related advantages.

Summary of the Invention Briefly stated, the subject invention provides compositions and methods for the diagnosis and therapy of breast cancer. In one aspect, isolated DNA molecules are provided, comprising a nucleotide sequence preferentially expressed in breast cancer tissue, relative to normal tissue; a variant of such a sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% (preferably no more than of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one of the above sequences. In one embodiment, the isolated DNA molecule comprises a human endogenous retroviral sequence recited in SEQ ID NO:1. In other embodiments, the isolated DNA molecule comprises a nucleotide sequence recited in any one of SEQ ID NO:3 SEQ ID NO:77 or SEQ ID 20 NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227.

In related embodiments, the isolated DNA molecule encodes an epitope of a polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that: (a) hybridizes to a sequence recited in any one of SEQ ID NO:1 or SEQ ID NO:3 SEQ ID NO:77 or SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200- 204, 206, 207, 209-214, 216, 218, 219, 221-227 under stringent conditions; and is at least 80% identical to a sequence recited in any one of SEQ ID NO:1 or SEQ ID NO:3 SEQ ID NO:77 or SEQ ID NOS: 142, 143, 146-152, 154-166, 168-176, 178-192, 194- 198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227; and wherein RNA corresponding to said nucleotide sequence is expressed at a greater level in human breast tumor tissue than in normal breast tissue.

In another embodiment, the present invention provides an isolated DNA molecule encoding an epitope of a polypeptide, the polypeptide being encoded by: a nucleotide sequence transcribed from the sequence of SEQ ID NO: 141; or a variant of said nucleotide sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained. Isolated DNA and RNA molecules comprising a nucleotide sequence complementary to a DNA molecule as described above are also provided.

In related aspects, the present invention provides recombinant :expression vectors comprising a DNA molecule as described above and host cells S*transformed or transfected with such expression vectors.

In further aspects, polypeptides, comprising an amino acid sequence encoded by a DNA molecule as described above, and monoclonal antibodies that bind S. 15 to such polypeptides are provided.

In yet another aspect, methods are provided for determining the presence o *of breast cancer in a patient. In one embodiment, the method comprises detecting, within a biological sample, a polypeptide as described above. In another embodiment, the method comprises detecting, within a biological sample, an RNA molecule 20 encoding a polypeptide as described above. In yet another embodiment, the method comprises intradermally injecting a patient with a polypeptide as described above; and detecting an immune response on the patient's skin and therefrom detecting the presence of breast cancer in the patient. In further embodiments, the present invention provides methods for determining the presence of breast cancer in a patient as described above wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO.: 78-86, SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize thereto under stringent conditions.

In a related aspect, diagnostic kits useful in the determination of breast cancer are provided. The diagnostic kits generally comprise either one or more monoclonal antibodies as described above, or one or more monoclonal antibodies that 4 bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NOS: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208,215, 217, 220, and a detection reagent.

Within a related aspect, the diagnostic kit comprises a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of an RNA molecule as described above, or an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220.

Within another related aspect, the diagnostic kit comprises at least one oligonucleotide probe, the probe comprising at least about 15 contiguous nucleotides of a DNA molecule as described above, or a DNA moleculd selected from the group consisting of SEQ ID NOS: 78-86 and SEQ ID NOS: 144, 145, 153, 167, 177, 193, 199, 205, 208, 215,217, 220.

15 In another related aspect, the present invention provides methods for monitoring the progression of breast cancer in a patient. In one embodiment, the i method comprises: detecting an amount, in a biological sample, of a polypeptide as described above at a first point in time; repeating step at a subsequent point in time; and comparing the amounts of polypeptide detected in steps and and 20 therefrom monitoring the progression of breast cancer in the patient. In another embodiment, the method comprises detecting an amount, within a biological sample, of an RNA molecule encoding a polypeptide as described above at a first point in time; repeating step at a subsequent point in time; and comparing the amounts of RNA molecules detected in steps and and therefrom monitoring the progression of breast cancer in the patient. In yet other embodiments, the present invention provides methods for monitoring the progression of breast cancer in a patient as described above wherein the polypeptide is encoded by a nucleotide sequence selected form the group consisting of SEQ ID NO.: 78-86, SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize thereto under stringent conditions.

In still other aspects, pharmaceutical compositions, which comprise a polypeptide as described above in combination with a physiologically acceptable carrier, and vaccines, which comprise a polypeptide as described above in combination with an immune response enhancer or adjuvant are provided. In yet other aspects, the present invention provides pharmaceutical compositions and vaccines comprising a polypeptide encoded by a nucleotide sequence selected form the group consisting of SEQ ID NO.: 78-86, SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220 and sequences that hybridize thereto under stringent conditions.

In related aspects, the present invention provides methods for inhibiting the development of breast cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All 15 references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

Brief Description of the Drawings Figure 1 shows the differential display PCR products, separated by gel electrophoresis, obtained from cDNA prepared from normal breast tissue (lanes 1 and 2) and from cDNA prepared from breast tumor tissue from the same patient (lanes 3 and The arrow indicates the band corresponding to B 18Agl.

Figure 2 is a northern blot comparing the level of B18Agl mRNA in breast tumor tissue (lane 1) with the level in normal breast tissue.

Figure 3 shows the level of B18Agl mRNA in breast tumor tissue compared to that in various normal and non-breast tumor tissues as determined by RNase protection assays.

Figure 4 is a genomic clone map showing the location of additional retroviral sequences obtained from ends of XbaI restriction digests (provided in SEQ ID NO:3 SEQ ID NO:10) relative to B18Agl.

Figures 5A and 5B show the sequencing strategy, genomic organization and predicted open reading frame for the retroviral element containing B1 8Agl.

Figure 6 shows the nucleotide sequence of the representative breast tumor-specific cDNA B18Agl.

Figure 7 shows the nucleotide sequence of the representative breast tumor-specific cDNA B 17Ag 1.

Figure 8 shows the nucleotide sequence tumor-specific cDNA B17Ag2.

Figure 9 shows the nucleotide sequence 10 tumor-specific cDNA B13Ag2a.

Figure 10 shows the nucleotide sequence of the representative breast of the representative breast of the representative breast tumor-specific cDNA B13Aglb.

Figure 11 shows the tumor-specific cDNA B13Ag a.

Figure 12 shows the tumor-specific cDNA B 1 Agl.

Figure 13 shows the tumor-specific cDNA B3CA3c.

Figure 14 shows the 20 tumor-specific cDNA B9CGI.

Figure 15 shows the tumor-specific cDNA B9CG3.

Figure 16 shows the tumor-specific cDNA B2CA2.

Figure 17 shows the tumor-specific cDNA B3CA Figure 18 shows the i tumor-specific cDNA B3CA2.

nucleotide sequence of the representative breast nucleotide sequence of the representative breast nucleotide sequence of the representative breast nucleotide sequence of the representative breast nucleotide sequence of the representative breast nucleotide sequence of the representative breast nucleotide sequence of the representative breast lucleotide sequence of the representative breast Figure 19 shows the nucleotide sequence of the representative breast tumor-specific cDNA B3CA3.

Figure 20 shows the nucleotide sequence of the representative breast tumor-specific cDNA B4CA1.

Figure 21A depicts RT-PCR analysis of breast tumor genes in breast tumor tissues (lanes 1-8) and normal breast tissues (lanes 9-13) and H20 (lane 14).

Figure 21B depicts RT-PCR analysis of breast tumor genes in prostate tumors (lane colon tumors (lane lung tumor (lane normal prostate (lane normal colon (lane normal kidney (lane normal liver (lane normal lung (lane normal ovary (lanes 10, 18), normal pancreases (lanes 11, 12), normal skeletal muscle (lane 13), normal skin (lane 14), normal stomach (lane 15), normal testes (lane 10 16), normal small intestine (lane 17), HBL-100 (lane 19), MCF-12A (lane 20), breast tumors (lanes 21-23), H 2 0 (lane 24), and colon tumor (lane .*oo Detailed Description of the Invention As noted above, the present invention is generally directed to 15 compositions and methods for the diagnosis, monitoring and therapy of breast cancer.

The compositions described herein include polypeptides, nucleic acid sequences and antibodies. Polypeptides of the present invention generally comprise at least a portion of a protein that is expressed at a greater level in human breast tumor tissue than in normal breast tissue the level of RNA encoding the polypeptide is at least 2-fold 20 higher in tumor tissue). Such polypeptides are referred to herein as breast tumorspecific polypeptides, and cDNA molecules encoding such polypeptides are referred to as breast tumor-specific cDNAs. Nucleic acid sequences of the subject invention generally comprise a DNA or RNA sequence that encodes all or a portion of a polypeptide as described above, or that is complementary to such a sequence.

Antibodies are generally immune system proteins, or fragments thereof, that are capable of binding to a portion of a polypeptide as described above. Antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies.

Polypeptides within the scope of this invention include, but are not limited to, polypeptides (and epitopes thereof) encoded by a human endogenous retroviral sequence, such as the sequence designated B18Agl (Figure 5 and SEQ ID NO:1). Also within the scope of the present invention are polypeptides encoded by other sequences within the retroviral genome containing B18Agl (SEQ ID NO: 141).

Such sequences include, but are not limited to, the sequences recited in SEQ ID NO:3 SEQ ID NO:10. B1 8Agl has homology to the gag p30 gene of the endogenous human retroviral element S71, as described in Werner et al., Virology 174:225-238 (1990) and also shows homology to about thirty other retroviral gag genes. As discussed in more detail below, the present invention also includes a number of additional breast tumorspecific polypeptides, such as those encoded by the nucleotide sequences recited in SEQ ID NO:11 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168- 176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including "full length proteins containing the sequences recited herein. A polypeptide comprising an epitope of a protein containing a sequence as described herein may consist entirely 15 of the epitope, or may contain additional sequences. The additional sequences may be derived from the native protein or may be heterologous, and such sequences may (but i need not) possess immunogenic or antigenic properties.

An "epitope," as used herein is a portion of a polypeptide that is recognized specifically bound) by a B-cell and/or T-cell surface antigen receptor.

20 Epitopes may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides derived from the native polypeptide for the ability to react with antigen-specific antisera and/or T-cell lines or clones. An epitope of a polypeptide is a portion that reacts with such antisera and/or T-cells at a level that is similar to the reactivity of the full length polypeptide in an ELISA and/or T-cell reactivity assay). Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. B-cell and T-cell epitopes may also be predicted via computer analysis. Polypeptides comprising an epitope of a polypeptide that is preferentially expressed in a tumor tissue (with or without additional amino acid sequence) are within the scope of the present invention.

The compositions and methods of the present invention also encompass variants of the above polypeptides and nucleic acid sequences encoding such polypeptides. A polypeptide "variant," as used herein, is a polypeptide that differs from the native polypeptide in substitutions and/or modifications, such that the antigenic and/or immunogenic properties of the polypeptide are retained. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antisera and/or T-cells as described above. Nucleic acid variants may contain one or more substitutions, deletions, insertions and/or modifications such that the antigenic and/or immunogenic properties of the encoded polypeptide are retained. One preferred variant of the polypeptides described herein is a variant that contains nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide 15 positions.

Preferably, a variant contains conservative substitutions.

A

"conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the 20 polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: ala, pro, gly, glu, asp, gin, asn, ser, thr; cys, ser, tyr, thr; val, ile, leu, met, ala, phe; lys, arg, his; and phe, tyr, trp, his.

Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenic or antigenic properties, secondary structure and hydropathic nature of the polypeptide.

For example, a polypeptide may be conjugated to a signal (or leader) sequence at the Nterminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

In general, nucleotide sequences encoding all or a portion of the polypeptides described herein may be prepared using any of several techniques. For example, cDNA molecules encoding such polypeptides may be cloned on the basis of the breast tumor-specific expression of the corresponding mRNAs, using differential display PCR. This technique compares the amplified products from RNA template prepared from normal and breast tumor tissue. cDNA may be prepared by reverse transcription of RNA using a (dT),,AG primer. Following amplification of the cDNA using a random primer, a band corresponding to an amplified product specific to the tumor RNA may be cut out from a silver stained gel and subcloned into a suitable vector the T-vector, Novagen, Madison, WI). Nucleotide sequences encoding all or a portion of the breast tumor-specific polypeptides disclosed herein may be amplified from cDNA prepared as described above using the random primers shown in SEQ ID 15 NO.:87-125.

Alternatively, a gene encoding a polypeptide as described herein (or a portion thereof) may be amplified from human genomic DNA, or from breast tumor cDNA, via polymerase chain reaction. For this approach, B18Agl sequence-specific primers may be designed based on the sequence provided in SEQ ID NO:1, and may be 20 purchased or synthesized. One suitable primer pair for amplification from breast tumor cDNA is (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO.:126) and GTA TCT CCT CGT GGG TAT T) (SEQ ID NO.:127). An amplified portion of B18Agl may then be used to isolate the full length gene from a human genomic DNA library or from a breast tumor cDNA library, using well known techniques, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989). Other sequences within the retroviral genome of which B18Agl is a part may be similarly prepared by screening human genomic libraries using Bl8Agl-specific sequences as probes.

Nucleotides translated into protein from the retroviral genome shown in SEQ ID NO: 141 may then be determined by cloning the corresponding cDNAs, predicting the open reading frames and cloning the appropriate cDNAs into a vector containing a viral promoter, such as T7. The resulting constructs can be employed in a translation reaction, using techniques known to those of skill in the art, to identify nucleotide sequences which result in expressed protein. Similarly, primers specific for the remaining breast tumor-specific polypeptides described herein may be designed based on the nucleotide sequences provided in SEQ ID NO: 11 SEQ ID NO:86 and SEQ ID NO: 142-SEQ ID NO:226.

Recombinant polypeptides encoded by the DNA sequences described above may be readily prepared from the DNA sequences. For example, supematants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter.

Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

In general, any of a variety of expression vectors known to those of 15 ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a 20 mammalian cell line such as COS or CHO.

Such techniques may also be used to prepare polypeptides comprising epitopes or variants of the native polypeptides. For example, variants of a native polypeptide may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides. Portions and other variants having fewer than about 100 amino acids, and generally fewer than about amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146 (1963). Equipment 12 for automated synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc., Foster City, CA, and may be operated according to the manufacturer's instructions.

In specific embodiments, polypeptides of the present invention encompass amino acid sequences encoded by a DNA molecule having a sequence recited in any one of SEQ ID NO:l or SEQ ID NO:3 SEQ ID NO:77 or SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209- 214, 216, 218, 219, 221-227, variants of such polypeptides that are encoded by DNA molecules containing one or more nucleotide substitutions, deletions, insertions and/or 10 modifications at no more than 20% of the nucleotide positions, and epitopes of the S above polypeptides. Polypeptides within the scope of the present invention also include polypeptides (and epitopes thereof) encoded by DNA. sequences that hybridize to a DNA molecule having a sequence recited in any one of SEQ ID NO:1 or SEQ ID NO:3 SEQ ID NO:77 or SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194- 15 198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227 under stringent conditions, wherein the DNA sequences are at least 80% identical in overall sequence to a recited sequence and wherein RNA corresponding to the nucleotide sequence is expressed at a greater level in human breast tumor tissue than in normal breast tissue. As used herein, S"stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2%

SDS;

20 hybridizing at 65 0 C, 6X SSC, 0.2% SDS overnight; followed by two washes of minutes each in IX SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 1 X SSC, 0.1% SDS at 65 0 C. DNA molecules according to the present invention include molecules that encode any of the above polypeptides.

In another aspect of the present invention, antibodies are provided. Such antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, Harlow and Lane, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the 13 polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J.

Immunol. 6:511-519 (1976), and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized 15 animal; A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, 20 colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Antibodies may be used, for example, in methods for detecting breast cancer in a patient. Such methods involve using an antibody to detect the presence or absence of a breast tumor-specific polypeptide as described herein in a suitable biological sample. As used herein, suitable biological samples include tumor or normal tissue biopsy, mastectomy, blood, lymph node, serum or urine samples, or other tissue, homogenate, or extract thereof obtained from a patient.

There are a variety of assay formats known to those of ordinary skill in the art for using an antibody to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, the assay may be performed in a Western blot format, wherein a protein preparation from the biological sample is submitted to gel electrophoresis, transferred to a suitable membrane and allowed to react with the antibody. The presence of the antibody on the membrane may then be detected using a suitable detection reagent, as described below.

In another embodiment, the assay involves the use of antibody immobilized on a solid support to bind to the polypeptide and remove it from the remainder of the sample. The bound polypeptide may then be detected using a second antibody or reagent that contains a reporter group. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to 20 bind to the immobilized antibody after incubation of the antibody with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the antibody is indicative of the reactivity of the sample with the immobilized antibody, and as a result, indicative of the concentration of polypeptide in the sample.

The solid support may be any material known to those of ordinary skill in the art to which the antibody may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose filter or other suitable membrane.

Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S.

Patent No. 5,359,681.

The antibody may be immobilized on the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the antibody, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, 10 but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of antibody ranging from about 10 ng to about 1 gg, and preferably about 100-200 ng, is sufficient to immobilize an adequate amount ofpolypeptide.

Covalent attachment of antibody to a solid support may also generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the antibody. For example, the antibody may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, 20 Pierce Immunotechnology Catalog and Handbook (1991) at A12-A13).

In certain embodiments, the assay for detection of polypeptide in a sample is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the biological sample, such that the polypeptide within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time incubation time) is that period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with breast cancer.

Preferably, the contact time is sufficient to achieve a level of binding that is at least of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20 T M The second antibody, which contains a reporter group, may then be added to the solid support.

Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and •biotin. The conjugation of antibody to reporter group may be achieved using standard methods known to those of ordinary skill in the art.

The second antibody is then incubated with the immobilized antibodypolypeptide complex for an amount of time sufficient to detect the bound polypeptide.

An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound second antibody is then removed and bound second antibody is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a 17 specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of breast cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value established from non-tumor tissue. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without breast cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value may be considered positive for breast cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, p. 106-7 (Little Brown and Co., 1985). Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand comer the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative S rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for breast cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, the polypeptide within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample.

The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of breast cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 pg, and more preferably from about ng to about 1 pg. Such tests can typically be performed with a very small amount of biological sample.

The presence or absence of breast cancer in a patient may also be determined by evaluating the level of mRNA encoding a breast tumor-specific polypeptide as described herein within the biological sample a biopsy, mastectomy and/or blood sample from a patient) relative to a predetermined cut-off •value. Such an evaluation may be achieved using any of a variety of methods known to those of ordinary skill in the art such as, for example, in situ hybridization and amplification by polymerase chain reaction. For example, polymerase chain reaction may be used to amplify sequences from cDNA prepared from RNA that is isolated from 20 one of the above biological samples. Sequence-specific primers for use in such amplification may be designed based on the sequences provided in any one of SEQ ID NO:1 or SEQ ID NO:11 SEQ ID NO:86 and SEQ ID NO:142-SEQ ID NO:226, and may be purchased or synthesized. In the case of B18Agl, as noted herein, one suitable primer pair is B18Agl-2 (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO.:126) and B18Agl-3 (5'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO.:127). The PCR reaction products may then be separated by gel electrophoresis and visualized according to methods well known to those of ordinary skill in the art.

Amplification is typically performed on samples obtained from matched pairs of tissue (tumor and non-tumor tissue from the same individual) or from unmatched pairs of tissue (tumor and non-tumor tissue from different individuals). The amplification reaction is preferably performed on several dilutions of cDNA spanning two orders of 19 magnitude. A two-fold or greater increase in expression in several dilutions of the tumor sample as compared to the same dilution of the non-tumor sample is considered positive.

Conventional RT-PCR protocols using agarose and ethidium bromide staining while important in defining gene specificity do not lend themselves to diagnostic kit development because of the time and effort required in making them quantitative construction of saturation and/or titration curves), and their sample throughput. This problem is overcome by the development of procedures such as real time RT-PCR which allows for assays to be performed in single tubes, and in turn can i: 10 be modified for use in 96 well plate formats. Instrumentation to perform such methodologies are available from ABI/Perkin Elmer. Alternatively, other high throughput assays using labelled probes digoxygenin) in combination with labelled enzyme fluorescent, radioactive) antibodies to such probes can also be used in the development of 96 well plate assays.

In yet another method for determining the presence or absence of breast cancer in a patient, one or more of the breast tumor-specific polypeptides described may be used in a skin test. As used herein, a "skin test" is any assay performed directly on a patient in which a delayed-type hypersensitivity (DTH) reaction (such as swelling, reddening or dermatitis) is measured following intradermal injection of one or more 20 polypeptides as described above. Such injection may be achieved using any suitable device sufficient to contact the polypeptide or polypeptides with dermal cells of the patient, such as a tuberculin syringe or 1 mL syringe. Preferably, the reaction is measured at least 48 hours after injection, more preferably 48-72 hours.

The DTH reaction is a cell-mediated immune response, which is greater in patients that have been exposed previously to a test antigen an immunogenic portion of a polypeptide employed, or a variant thereof). The response may measured visually, using a ruler. In general, a response that is greater than about 0.5 cm in diameter, preferably greater than about 5.0 cm in diameter, is a positive response, indicative of breast cancer.

The breast tumor-specific polypeptides described herein are preferably formulated, for use in a skin test, as pharmaceutical compositions containing at least one polypeptide and a physiologically acceptable carrier, such as water, saline, alcohol, or a buffer. Such compositions typically contain one or more of the above polypeptides in an amount ranging from about 1 p.g to 100 p.g, preferably from about 10 p.g to 50 p.g in a volume of 0.1 mL. Preferably, the carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and/or Tween In other aspects of the present invention, the progression and/or response to treatment of a breast cancer may be monitored by performing any of the above assays over a period of time, and evaluating the change in the level of the response the 10 amount of polypeptide or mRNA detected or, in the case of a skin test, the extent of the immune response detected). For example, the assays may be performed every month to every other month for a period of 1 to 2 years. In general, breast cancer is progressing in those patients in whom the level of the response increases over time. In contrast, breast cancer is not progressing when the signal detected either remains constant or 15 decreases with time.

In further aspects of the present invention, the compounds described herein may be used for the immunotherapy of breast cancer. In these aspects, the compounds (which may be polypeptides, antibodies or nucleic acid molecules) are preferably incorporated into pharmaceutical compositions or vaccines. Pharmaceutical 20 compositions comprise one or more such compounds and a physiologically acceptable carrier. Vaccines may comprise one or more polypeptides and an immune response enhancer, such as an adjuvant or a liposome (into which the compound is incorporated).

Pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109. Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, including one or more separate polypeptides.

Alternatively, a vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. In such vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as 10 described, for example, in Ulmer et al., Science 259:1745-1749 (1993), and reviewed by Cohen, Science 259:1691-1692 (1993). The uptake of naked DNA may be increased Sby coating the DNA onto biodegradable beads, which are efficiently transported into *the cells.

While any suitable carrier known to those of ordinary skill in the art may 15 be employed in the pharmaceutical compositions of this invention, the type of carrier Sooo will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, oooo a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, *o0 such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, 20 cellulose, glucose, sucrose, and magnesium carbonate, may be employed.

Biodegradable microspheres polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention.

Any of a variety of adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI), Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ), alum, biodegradable microspheres, monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, or -12, may also be used as adjuvants.

The above pharmaceutical compositions and vaccines may be used, for example, for the therapy of breast cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with breast cancer. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of breast cancer or to treat a patient afflicted with breast cancer. To prevent the development of breast cancer, a pharmaceutical composition or vaccine comprising one or more polypeptides as 10 described herein may be administered to a patient. Alternatively, naked DNA or 0O. plasmid or viral vector encoding the polypeptide may be administered. For treating a patient with breast cancer, the pharmaceutical composition or vaccine may comprise one or more polypeptides, antibodies or nucleotide sequences complementary to DNA *encoding a polypeptide as described herein antisense RNA or antisense deoxyribonucleotide oligonucleotides).

Routes and frequency of administration, as well as dosage, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines may be administered by injection intracutaneous, intramuscular, intravenous or subcutaneous), intranasally by aspiration) or orally. Between 1 20 and 10 doses may be administered for a 52-week period. Preferably, 6 doses are o administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients.

A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro.

Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about -23- 100 Ag to 5 mg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

The following Examples are offered by way of illustration and not by way of limitation.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other country.

o.

EXAMPLES

Example 1 Prearation of Breast Tumor-Specific cDNAs Using Differential Disla RT-PC This Example illustrates the preparation of cDNA molecules encoding breast tumor-specific polypeptides using a differential display screen.

A. Preparation of B 8A cDNA and Characterization of mRNA ressio Tissue samples were prepared from breast tumor and normal tissue of a patient with breast cancer that was confirmed by pathology after removal from the patient. Normal RNA and tumor RNA was extracted from the samples and mRNA was isolated and converted into cDNA using a (dT) 12 AG (SEQ ID NO.:130) anchored 3' primer. Differential display PCR was then executed using a randomly chosen primer (CTTCAACCTC) (SEQ ID NO.:103). Amplification conditions were standard buffer containing 1.5 mM MgCI 2 20 pmol of primer, 500 pmol dNTP, and 1 unit of Taq DNA polymerase (Perkin-Elmer, Branchburg, NJ). Forty cycles of amplification were performed using 94 0 C denaturation for 30 seconds, 42 0 C annealing for 1 minute, and 72 0 C extension for 30 seconds. An RNA fingerprint containing 76 amplified products 20 was obtained. Although the RNA fingerprint of breast tumor tissue was over 98% identical to that of the normal breast tissue, a band was repeatedly observed to be specific to the RNA fingerprint pattern of the tumor. This band was cut out of a silver stained gel, subcloned into the T-vector (Novagen, Madison, WI) and sequenced.

The sequence of the cDNA, referred to as B18Agl, is provided in SEQ ID NO:1. A database search of GENBANK and EMBL revealed that the BI8AgI fragment initially cloned is 77% identical to the endogenous human retroviral element S71, which is a truncated retroviral element homologous to the Simian Sarcoma Virus (SSV). S71 contains an incomplete gag gene, a portion of the pol gene and an LTRlike structure at the 3' terminus (see Werner et al., Virology 174:225-238 (1990)).

B18Agl is also 64% identical to SSV in the region corresponding to the P30 (gag) locus. Bl8Agl contains three separate and incomplete reading frames covering a region which shares considerable homology to a wide variety of gag proteins of retroviruses which infect mammals. In addition, the homology to S71 is not just within the gag gene, but spans several kb of sequence including an LTR.

B18Agl-specific PCR primers were synthesized using computer analysis guidelines. RT-PCR amplification (94 0 C, 30 seconds; 60 0 C 42 0 C, seconds; 72°C, 30 seconds for 40 cycles) confirmed that B18Agl represents an actual mRNA sequence present at relatively high levels in the patient's breast tumor tissue.

The primers used in amplification were B18Agl-l (CTG CCT GAG CCA CAA ATG) (SEQ ID NO.:128) and B18Agl-4 (CCG GAG GAG GAA GCT AGA GGA ATA) S. 10 (SEQ ID NO.:129) at a 3.5 mM magnesium concentration and a pH of 8.5, and B18Agl-2 (ATG GCT ATT TTC GGG GCC TGA CA) (SEQ ID NO.:126) and BI8Agl-3 (CCG GTA TCT CCT CGT GGT TATT) (SEQ ID NO.:127) at 2 mM magnesium at pH 9.5. The same experiments showed exceedingly low to nonexistent levels of expression in this patient's normal breast tissue (see Figure

RT-PCR

15 experiments were then used to show that B18Agl mRNA is present in nine other breast tumor samples (from Brazilian and American patients) but absent in, or at exceedingly low levels in, the normal breast tissue corresponding to each cancer patient. RT-PCR analysis has also shown that the B18Agl transcript is not present in various normal tissues (including lymph node, myocardium and liver) and present at relatively low 20 levels in PBMC and lung tissue. The presence of B18Agl mRNA in breast tumor samples, and its absence from normal breast tissue, has been confirmed by Northern blot analysis, as shown in Figure 2.

The differential expression of B18Agl in breast tumor tissue was also confirmed by RNase protection assays. Figure 3 shows the level of B18Ag mRNA in various tissue types as determined in four different RNase protection assays. Lanes 1 12 represent various normal breast tissue samples, lanes 13-25 represent various breast tumor samples; lanes 26-27 represent normal prostate samples; lanes 28-29 represent prostate tumor samples; lanes 30-32 represent colon tumor samples; lane 33 represents normal aorta; lane 34 represents normal small intestine; lane 35 represents normal skin, lane 36 represents normal lymph node; lane 37 represents normal ovary; lane 38 represents normal liver; lane 39 represents normal skeletal muscle; lane 40 represents a first normal stomach sample, lane 41 represents a second normal stomach sample; lane 42 represents a normal lung; lane 43 represents normal kidney; and lane 44 represents normal pancreas. Interexperimental comparison was facilitated by including a positive control RNA of known B-actin message abundance in each assay and normalizing the results of the different assays with respect to this positive control.

RT-PCR and Southern Blot analysis has shown the B18Agl locus to be present in human genomic DNA as a single copy endogenous retroviral element.

A

genomic clone of approximately 12-18 kb was isolated using the initial B18Agl sequence as a probe. Four additional subclones were also isolated by XbaI digestion.

Additional retroviral sequences obtained from the ends of the XbaI digests of these clones (located as shown in Figure 4) are shown as SEQ ID NO:3 SEQ ID NO: where SEQ ID NO:3 shows the location of the sequence labeled 10 in Figure 4, SEQ ID NO:4 shows the location of the sequence labeled 11-29, SEQ ID NO:5 shows the location of the sequence labeled 3, SEQ ID NO:6 shows the location of the sequence labeled 6, SEQ ID NO:7 shows the location of the sequence labeled 12, SEQ ID NO:8 shows the location of the sequence labeled 13, SEQ ID NO:9 shows the location of the sequence labeled 14 and SEQ ID NO:10 shows the location of the sequence labeled 11- 22.

Subsequent studies demonstrated that the 12-18 kb genomic clone contains a retroviral element of about 7.75 kb, as shown in Figures 5A and 5B. The sequence of this retroviral element is shown in SEQ ID NO: 141. The numbered line at the top of Figure 5A represents the sense strand sequence of the retroviral genomic clone. The box below this line shows the position of selected restriction sites. The arrows depict the different overlapping clones used to sequence the retroviral element.

The direction of the arrow shows whether the single-pass subclone sequence corresponded to the sense or anti-sense strand. Figure 5B is a schematic diagram of the retroviral element containing B18Agl depicting the organization of viral genes within the element. The open boxes correspond to predicted reading frames, starting with a methionine, found throughout the element. Each of the six likely reading frames is shown, as indicated to the left of the boxes, with frames 1-3 corresponding to those found on the sense strand.

Using the cDNA of SEQ ID NO:1 as a probe, a longer cDNA was obtained (SEQ ID NO:227) which contains minor nucleotide differences (less than 1%) compared to the genomic sequence shown in SEQ ID NO: 141.

B. Preparation of cDNA Molecules Encoding Other Breast Tumor-Specific Polypeptides Normal RNA and tumor RNA was prepared and mRNA was isolated and converted into cDNA using a (dT),,AG anchored 3' primer, as described above.

Differential display PCR was then executed using the randomly chosen primers

SEQ

ID NO.: 87-125. Amplification conditions were as noted above, and bands observed to be specific to the RNA fingerprint pattern of the tumor were cut out of a silver stained gel, subcloned into either the T-vector (Novagen, Madison, WI) or the pCRII vector (Invitrogen, San Diego, CA) and sequenced. The sequences are provided in SEQ ID NO:l 1 SEQ ID NO:86. Of the 79 sequences isolated, 67 were found to be novel (SEQ ID NO.:11-77) (see also Figures 6-20). Subsequent studies identified an additional 84 sequences (SEQ ID NOS:142-226), of which 72 appeared to be novel (SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227). To the best of the inventors' knowledge none of the previously identified sequences have heretofore been shown to be expressed at a greater level in human breast tumor tissue than in normal breast tissue.

Table I shows the level of representative breast tumor-specific transcripts present in normal breast tissue (columns BNI -BN7), breast tumor samples (columns BTI-BT12) and normal prostate, kidney, liver, lung, skin, small intestine, stomach, myocardium, lymph node, pancreas, skeletal muscle, ovary and aorta, as determined by RT-PCR analysis. A 0-3 grading scale for message abundance is used, with 0 denoting no detectable message and 3 a message level comparable to the control message (glyceraldehyde 3-phosphate dehydrogenase). The lack of data in a given box indicates that the tissue has not been tested for the presence or absence of that specific antigen.

V

V V V VV V V V V V V V V* VV *VV V V *V V ABLE I 0 0 00 .0 0e*0 0 0 0 *0 0 0 00* .00 0 0 0 0.00.0

CLONE]

B2CA I B2CA2 B3CAI Bg3 C A3c B3CA3 B4CAI B9CGI B9CG3 BI11AG I B1I3AG Ia B13AGIb B13AG2 B1I7AG I B18AGIa B I 6AC 1-3 BI12CA I BI12CA2 B13CAI-36 B13CAI-37 B14CAI B 16CA I B I6GC2a B22GA2 B314GA

I

L! f prostatef kidney 0 0 3 0 0 3 0 Jliverjlung] o 0 1 0 0 0 0 3 3 3 0 1 sin- si.itetn skin sm. intestine 0 0 00 33 00 it myocardium lymph node Jpancreas skel. muscl o 0 0 0 0 0 0 0 0 0 10 0 3 0 2 0 0 Example 2 Preparation of B I8Ag 1 DNA from Human Genomic DNA This Example illustrates the preparation of B18Agl DNA by amplification from human genomic DNA.

B18Agl DNA may be prepared from 250 ng human genomic DNA using 20 pmol of B18Agl specific primers, 500 pmol dNTPS and 1 unit of Taq DNA polymerase (Perkin Elmer, Branchburg, NJ) using the following amplification parameters: 94°C for 30 seconds denaturing, 30 seconds 60 0 C to 42 0 C touchdown annealing in 2°C increments every two cycles and 72°C extension for 30 seconds. The last increment (a 42 0 C annealing temperature) should cycle 25 times. Primers were selected using computer analysis. Primers synthesized were B18Agl-1, B18Agl-2, B18Agl-3, and B18Agl-4. Primer pairs that may be used are 1+3, 1+4, 2+3, and 2+4.

Following gel electrophoresis, the band corresponding to B 18Ag l DNA may be excised and cloned into a suitable vector.

o Example 3 Preparation of Bl8Agl DNA from Breast Tumor cDNA 20 This Example illustrates the preparation of BI8Ag DNA by amplification from human breast tumor cDNA.

First strand cDNA is synthesized from RNA prepared from human breast tumor tissue in a reaction mixture containing 500 ng poly A+ RNA, 200 pmol of the primer (T),1AG TTT TTT TTT TTT AG) (SEQ ID NO: 130), IX first strand reverse transcriptase buffer, 6.7 mM DTT, 500 mmol dNTPs, and 1 unit AMV or MMLV reverse transcriptase (from any supplier, such as Gibco-BRL (Grand Island, NY)) in a final volume of 30 ul. After first strand synthesis, the cDNA is diluted approximately 25 fold and 1 pl is used for amplification as described in Example 2.

While some primer pairs can result in a heterogeneous population of transcripts, the primers B18Agl-2 (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 126) and B18Agl-3 (5'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127) yield a single 151 bp amplification product.

Example 4 Identification of B-cell and T-cell Epitones of B 18Ag 1 This Example illustrates the identification of B 8Agl epitopes.

The B18Agl sequence can be screened using a variety of computer algorithms. To determine B-cell epitopes, the sequence can be screened for hydrophobicity and hydrophilicity values using the method of Hopp, Prog. Clin. Biol Res. 172B:367-77 (1985) or, alternatively, Cease et al., J Exp. Med 164:1779-84 .(1986) or Spouge et al., J. mmunol. 138:204-12 (1987). Additional Class II MHC (antibody or B-cell) epitopes can be predicted using programs such as AMPHI Margalit et al., J Immunol. 138:2213 (1987)) or the methods of Rothbard and Taylor EMBOJ. 7:93 (1988)).

Once peptides (15-20 amino acids long) are identified using these techniques, individual peptides can be synthesized using automated peptide synthesis equipment (available from manufacturers such as Applied Biosystems, Inc., Foster City, CA) and techniques such as Merrifield synthesis. Following synthesis, the peptides can used to screen sera harvested from either normal or breast cancer patients to determine whether patients with breast cancer possess antibodies reactive with the peptides. Presence of such antibodies in breast cancer patient would confirm the immunogenicity of the specific B-cell epitope in question. The peptides can also be tested for their ability to generate a serologic or humoral immune in animals (mice, rats, rabbits, chimps etc.) following immunization in vivo. Generation of a peptide-specific antiserum following such immunization further confirms the immunogenicity of the specific B-cell epitope in question.

To identify T-cell epitopes, the B18Ag 1 sequence can be screened using different computer algorithms which are useful in identifying 8-10 amino acid motifs within the B18Agl sequence which are capable of binding to HLA Class I MHC molecules. (see, Rammensee et al., Immunogenetics 41:178-228 (1995)).

Following synthesis such peptides can be tested for their ability to bind to class I MHC using standard binding assays Sette et al., J Immunol. 153:5586-92 (1994)) and more importantly can be tested for their ability to generate antigen reactive cytotoxic Tcells following in vitro stimulation of patient or normal peripheral mononuclear cells using, for example, the methods of Bakker et al., Cancer Res. 55:5330-34 (1995); Visseren et al., J Immunol. 154:3991-98 (1995); Kawakami et al., J. Immunol.

154:3961-68 (1995); and Kast et al., J. Immunol. 152:3904-12 (1994). Successful in vitro generation of T-cells capable of killing autologous (bearing the same Class I MHC molecules) tumor cells following in vitro peptide stimulation further confirms the immunogenicity of the B18Agl antigen. Furthermore, such peptides may be used to generate murine peptide and B18Agl reactive cytotoxic T-cells following in vivo immunization in mice rendered transgenic for expression of a particular human MHC SClass I haplotype (Vitiello et al., J. Exp. Med. 173:1007-15 (1991).

A representative list of predicted B18Agl B-cell and T-cell epitopes, broken down according to predicted HLA Class I MHC binding antigen, is shown below: Predicted Th Motifs (B-cell epitopes) (SEQ ID NOS.: 131-133)

SSGGRTFDDFHRYLLVGI

QGAAQKPINLSKXIEVVQGHDE

S

SPGVFLEHLQEAYRIYTPFDLSA

Predicted HLA A2.1 Motifs (T-cell epitopes) (SEQ ID NOS.: 134-140)

YLLVGIQGA

GAAQKPINL

NLSKXIEVV

EVVQGHDES

HLQEAYRIY

NLAFVAQAA

FVAQAAPDS

Example Characterization of Breast Tumor Genes Discovered by Differential Display PCR The specificity and sensitivity of the breast tumor genes discovered by differential display PCR were determined using RT-PCR. This procedure enabled the rapid evaluation of breast tumor gene mRNA expression semiquantitatively without using large amounts ofRNA. Using gene specific primers, mRNA expression levels in a variety of tissues were examined, including 8 breast tumors, 5 normal breasts, 2 prostate tumors, 2 colon tumors, 1 lung tumor, and 14 other normal adult human tissues, including normal prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach and testes.

To ensure the semiquantitative nature of the RT-PCR, P-actin was used as internal control for each of the tissues examined. Serial dilutions of the first strand cDNAs were prepared and RT-PCR assays performed using P-actin specific primers. A dilution was then selected that enabled the linear range amplification of P-actin template, and which was sensitive enough to reflect the difference in the initial copy number. Using this condition, the P-actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was minimized by DNase 20 treatment and by assuring a negative result when using first strand cDNA that was prepared without adding reverse transcriptase.

Using gene specific primers, the mRNA expression levels were determined in a variety of tissues. To date 32 genes have been successfully examined by RT-PCR, three of which exhibit good specificity and sensitivity for breast tumors.

Figures 21A and 21B depict the results for these three genes: B15AG-1 (SEQ ID NO:27), B31GAlb (SEQ ID NO:148) and B38GA2a (SEQ ID NO. 157).

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

34 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: Corixa Corporation (ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER (iii) NUMBER OF SEQUENCES: 227 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: SEED and BERRY LLP STREET: 6300 Columbia Center. 701 Fifth Avenue e CITY: Seattle STATE: Washington COUNTRY: USA ZIP: 98104-7092 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM.PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.30 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE: 10-JAN-1997

CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION: NAME: Maki, David J.

REGISTRATION NUMBER: 31.392 REFERENCE/DOCKET NUMBER: 210121.419PC 0 0 0 0* 0 000* (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: (206) 622-4900 TELEFAX: (206) 682-6031 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 363 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..363 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TA GAG ACC CAA TTG GGA CCT AAT TGG GAC CCA AAT TTC TCA AGT GGA eu Glu Thr Gin Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly 1 5 10 GGG AGA. ACT TTT GAC Gly Arg Thr Phe Asp GGA GCT GCC CAG AAA Gly Ala Ala Gin Lys GAT TTC CAC CGG TAT CTC CTC Asp Phe His Arg Tyr Leu Leu 25 CCT ATA AAC TTG TCT AAG GCG Pro Ile Asn Leu Ser Lys Ala 40 GTG GGT ATT CAG Val Gly Ile Gin ATT GAA GTC GTC Ile Glu Val Val CAG GGG CAT GAT GAG TCA CCA GGA GTG TT TTA GAG CAC CTC CAG GAG Gin Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gin Glu 55 GCT TAT CGG ATT TAC ACC CCT TTT GAC CTG GCA GCC CCC GAA AAT AGC Ala Tyr Arg Ile Tyr Thr Pro Phe Asp Leu Ala Ala Pro Glu Asn Ser 70 75 CAT GCT CTT AAT TTG GCA TTT GTG GCT CAG GCA GCC His Ala Leu Asn Leu Ala Phe Val Ala Gin Ala Ala 90 CCA GAT AGT AAA Pro Asp Ser Lys GAA TAC CAG TCA Glu Tyr Gin Ser 110 288 336 AGG AAA Arg Lys CTC CAA Leu Gin 100 AAA CTA GAG GGA TTT TGC TGG AAT Lys Leu Glu Gly Phe Cys Trp Asn 105 *fee se e '60, s 0 0 GCT TTT AGA GAT AGC CTA AAA GGT TTT Ala Phe Arg Asp Ser Leu Lys Gly Phe 115 120 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 121 amino acids TYPE: amino acid TOPOLOGY: linear (ii).MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: S S 55

S

.55.

Leu Glu Thr Gin Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly Gly Arg Thr Phe Asp Asp Gly Ala Ala Gin Lys Pro Phe His Arg Tyr Leu Leu Val Gly Ile Gin 25 Ile Asn Leu Ser Lys Ala Ile Glu Val Val Gin Giy His Asp Glu Ser Pro Gly Val Phe Leu 55 Ala Tyr Arg Ilie Tyr Thr Pro Phe Asp Leu Ala 70 75 Glu His Leu Gin Glu Ala Pro Glu Asn Ser 0S Ce S 0005 see.

e 09 @0 0 0*O 0 0000qe

C

eq @6O* 0000

S

*0*e Ce..

C

e ~.0a000

C

0 *5500e e *060 Oe Ce eec.

8

SC..

His Ala Leu Asn Leu Ala Phe Val Ala Gin Ala 90 A rg Lys Leu Gin Lys Leu Glu Gly Phe Cys Trp 100 105 Ala Phe Arg Asp Ser Leu Lys Gly Phe 115 120 INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 1101 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear Ala Pro Asp Ser Lys Asn Glu Tyr Gln Ser 110 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TCTTAGMATC TTCATACCCC GMACTCTTGG GAAAACTTTA ATCAGTCACC TACAGTCTAC CACCCATTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTA AGATCCCCCA TCTTCAMAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAMATGC CAAAAAAGGT CCTAMCCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA GTGGGAMATT GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACMAAT ACCTTCTAGT 120 180 240 300 ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCMA TATGGTAGTT AAGTTTTTAC TCAATGMAAT CATCCCTCGA CGTGGGCTGC CTGTTGCCAT AGGGTCTGAT MATGGAACGG CCTTCGCCTT GTCTATAGTT TMTCAGTCA GTAAGGCGTT AAACATTCMA TGGAAGCTCC ATTGTGCCTA TCGACCCAGA GCTCTGGGCA AGTAGMACGC ATGAACTGCA CCCTAAAAAA ACACTCTTAC AAAATTAATC TTAAAAACCG GTGTTMATTG TGTTAGTCTC CTTCCCTTAG CCCTACTTAG AGTTAAGGTG CACCCCTTAC TGGGCTGGGT TCTTTACCTT TTGAAATCAT NTTTNGGAAG GGGCTGCCTA TCTTTNCTTA ACTAAAAAAN GCCCATTTGG CAAAMTTMTC NCMACTMATT TNTACGTNCC TACGTCTCCC CAACAGGTAN AAAAATCTNC TGCCCTTTTC MAGGMCCAT CCCATCCATT CCTNAACAAA AGGCCTGCCN TTCTTCCCCC AGTTAACTNT TTTTTNTTAA AATTCCCAAA AAANGAACCN CCTGCTGGAA AAACNCCCCC CTCCAANCCC CGGCCNAAGN GGMAGGTTCC CTTGAATCCC NCCCCCNCNA ANGGCCCGGA ACCNTTAAAN TNGTTCCNGG GGGTNNGGCC TAAAAGNCCN ATTTGGTAAA CCTANAAATT TTTTCTTTTN TAAAAACCAC NNTTTNNTTT TTCTTAAACA AAACCCTNTT TNTAGNANCN TATTTCCCNC C INFORMATION FOR SEQ ID NO:4: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1087 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1101 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: TCTAGAGCTG CGCCTGGATC CCGCCACAGT GAGGAGACCT GAAGACCA-GA GAAMACACAG CAAGTAGGCC CTTTAMACTA CTCACCTGTG TTGTCTTCTA ATTTATTCTG TTMTATTTTG 120 TTTCCATCAT TTTAAGGGGT TAAAATCATC TTGTTCAGAC CTCAGCATAT AAAATGACCC 180 :ATCTGTAGAC CTCAGGCTCC MACCATACCC CAAGAGTTGT CTGGTTTTGT TTAAATVACT 240 GCCAGGTTTC AGCTGCAGAT ATCCCTGGMA GGMATATTCC AGATTCCCTG AGTAGTTTCC 300 AGGTTAAAAT CCTATAGGCT TCTTCTGTTT TGAGGAAGAG TTCCTGTCAG AGAAAAACAT 360 GATTTTGGAT TTTTMCTTT AATGCTTGTG AAACGCTATA AAAAAAATTT TCTACCCCTA 420 GCTTTAAAGT ACTGTTAGTG AGAAATTAAA ATTCCTTCAG GAGGATTAAA CTGCCATTTC 480 AGTTACCCTA ATTCCAAATG TMTGGTGGT TAGMATCTTC TTTAATGTTC TTGMAGAAGT 540 GTTTTATATT TTCCCATCNA GATAAATTCT CTCNCNCCTT NNTTTNTNT CTNNTTTTT 600 MMACGGANT CTTGCTCCGT TGTCCANGCT GGGAATTTTN TTTTGGCCAA TCTCCGCTNC 660 CTTGCAANAA TNCTGCNTCC CAMAATTACC NCCTTTTTCC CACCTCCACC CCNNGGAATT 720 ACCTGGMATT ANAGGCCCCC NCCCCCCCCC CGGCTMATTT GTTTTGTTT TTAGTAAAAM 780 ACGGGTTTCC TGTTTAGTT AGGATGGCCC ANNTCTGACC CCNTNATCNT CCCCCTCNGC 840 CCTCNAATNT TNGGNNTANG GCTTACCCCC CCCNGNNGTT TTCCTCCAT TNMAATTTTC 900 TNTGGANTCT TGAATNNCGG GTTTTCCCTT TTAAACCNAT 1TFFTTTMN NNNCCCCCAN 960 TTTTNCCTCC CCCNTNTNTA ANGGGGGFF CCCAANCCGG GTCCNCCCCC ANGTCCCCAA 1020 TTTTTCTCCC CCCCCCTCTT TTTCTTNC CCCAAAANTC CTATCTTTC CTNNAAATAT 1080 CNANTNT 1087 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 1010 base pairs TYPE: nucleic acid SRNEES:single TOPOLOGY: lna (xi) SEQUENCE DESCRIPTION: SEQ ID TCTAGACCMA GAAATGGGAG GATTMTAGAG TGACTGATGA TTTCTCTATC ATCTGCAGTT AGTAAACATT CTCCACAGTT TATGCAAMAA GTMACAAAAC CACTGCAGAT GACAAACACT 120 AGGTAACACA CATACTATCT CCCAAATACC TACCCACAAG CTCAACAATT TTAAACTGTT 180 AGGATCACTG GCTCTAATCA CCATGACATG AGGTCACCAC CAAACCATCA AGCGCTAAAC 240 AGACAGAATG TTCCACTCC TGATCCACTG TGTGGGAAGA AGCACCGAAC TTACCCACTG 300 GGGGGCCTGC NTCANMANAA AAGCCCATGC CCCCGGGTNT NCCTTTNAAC CGGAACGAAT 360 NAACCCACCA TCCCCACANC TCCTCTGTTC NTGGGCCCTG CATCTTGTGG CCTCNTNTNC 420 TTTNGGGGAN ACNTGGGGMA GGTACCCCAT TTCNTTGACC CCNCNANAAA ACCCCNGTGG 480 CCCTTTGCCC TGATTCNCNT GGGCCTTTTC TCTTTTCCCT TTTGGGTTGT TTAAATTCCC 540 AATGTCCCCN GMACCCTCTC CNTNCTGCCC AAAACCTACC TMAATTNCTC NCTANGNNTT 600 41 TTCTTGGTGT TNCTTTTCAA AGGTNACCTT NCCTGTTCAN NCCCNACNMA MTTTNTTCC 660 NTATNNTGGN CCCNNAAAAA NNNATCNNCC CNMATTGCCC GMATTGGTTN GGTTTTCCT 720 NCTGGGGGAA ACCCTTTAAA TTCCCCCTT GGCCGGCCCC CCTFTTTCC CCCCTTNGA 780 AGGCAGGNGG TTCTTCCCGA ACTTCCAATT NCAACAGCCN TGCCCATTGN TGMAACCCTT 840 TTCCTAAAAT TAAAAMATAN CCGGTTNNGG NNGGCCTCTT TCCCCTCCNG GNGGGNNGNG 900 AAANTCCTTA CCCCNAMAAA GGTTGCTTAG CCCCCNGTCC CCACTCCCCC NGGAAAAATN 960 AACCT1TCN AAAAMAGGMA TATAANTTTN CCACTCCTTN GTTCTCTTCC 1010 INFORMATION FOR SEQ ID NO:6: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 950 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ 10 NO:6: TCTAGAGCTC GCGGCCGCGA GCTCTAATAC GACTCACTAT AGGGCGTCGA CTCGATCTCA GCTCACTGCA ATCTCTGCCC CCGGGGTCAT GCGATTCTCC TGCCTCAGCC TTCCMAGTAG 120 CTGGGATTAC AGGCGTGCAA CACCACACCC GGCTAATFVT GTATTTMA TAGAGATGGG 180 GTTTTCCCTT GTTGGCCANN ATGGTCTCNA ACCCCTGACC TCNNGTGATC CCCCCNCCCN 240 NGANCTCNNA CTGCTGGGGA TNNCCGNNNN NNNCCTCCCN NCNCNNNNNN NCNCNNTCCN 300 TNNTCCTTNC TCNNNNNNNN CNNTCNNTCC NNC CNNNCCNCNT NCCCNCNNNT TCNCNTNCNN TNT CCNNTACNTC NTNNNCNNNT CCNTCTNTNN CCT NTNNNNNNCT CCNNNNNTCT CNTCNCNNCN TNC CTNNTTTNNN CNNCNNNTCC NTNCCNTTCN NNT CCNCCNNTTC CTTNCNCNTN NNNTNTCNNN CNCi TCNNTTCNCC CNNNTCCNCC CCCCNCCTNT CTC1 TNTCNCNTTC NTCNNTNCNT TNCTNTCNNC NNCN TCNCNTNTCN CCNTCCNTTN CTNTCTCCTN TNTC CCNNTNTNTN TNNCNCCNNT NCTNNNCNNC CNTC NNCCCNTNCC CTNNTNCNCT NCTNNTACCN TNCT INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 1086 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear

TTCTCNC

CCNNCNN

CNNCNNT

CTCNNTN

CCNNTNN

NTCNNTC

FCNCCCN

INTNCNC

:CTTCCC

NTTTCN

NCTCCN

CNNNTNTTNT CNNCNNCCNN I NNTCNNCNNN CNNNNCNTNN CNCTNCNCNT TNTCTCCTCN NCCNCNCCCC NCCTCNCNNC CNNCNTCNCN NNCNTTNTTC NTTTNCTCCT NNNTCCCNNC NNTNNNTNTN NNNCNTCCNC TNCCNTNTNT CTNNNTCNCN CTCNCCTNCT CNTTCNCCNC TCTCTNCTNN NNNTNNCCTC

TCTTCCTTCC

360 420 480 540 600 660 720 780 840 900' 950 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: TCTAGAGCTC GCGGCCGCGA GCTCAATTAA CCCTCACTAA AGGGAGTCGA CTCGATCAGA CTGTTACTGT GTCTATGTAG AAAGAAGTAG ACATAAGAGA TTCCATTTTG TTCTGTACTA AGAAAAATTC TTCTGCCTTG AGATGCTGTT MTCTGTAAC CCTAGCCCCA ACCCTGTGCT CACAGAGACA TGTGCTGTGT TGACTCAAGG TTCAATGGAT TTAGGGCTAT GCTFVGTTMA MAAAGTGCTT GAAGATAATA TGCTTGTTMA MGTCATCAC CATTCTCTAA TCTCAAGTAC CCAGGGACAC AATACACTGC GGAAGGCCGC AGGGACCTCT GTCTAGGAAA GCCAGGTATT GTCCAAGATT TCTCCCCATG TGATAGCCTG AGATATGGCC TCATGGGAAG GGTAAGACCT GACTGTCCCC CAGCCCGACA TCCCCCAGCC CGACATCCCC'CAGCCCGACA

CCCGAMAAGG

GTCTGTGCTG AGGAAGATTA NTMAAAGAGG AAGGCTCTTT GCATTGAAGT AAGAAGAAGG CTCTGTCTCC TGCTCGTCCC TGGGCAATMA AATGTCTTGG TGTTAAACCC GAATGTATGT TCTACTTACT GAGAATAGGA GAAAACATCC TTAGGGCTGG AGGTGAGACA CCCTGGCGGC ATACTGCTCT TTAATGCACG AGATGTTTGT NTAATTGCCA TCCAGGGCCA NCCCCTTTCC TTAACTTTTT ATGANACAAA AACTTTGTTC NCTTTTCCTG CGMACCTCTC CCCCTATTAN CCTATTGGCC TGCCCATCCC CTCCCCAAAN GGTGAAAANA TGTTCNTAAA TNCGAGGGAA TCCAMAACNT TTTCCCGTTG GTCCCCTTTC CMACCCCGTC CCTGGGCCNN TTTCCTCCCC MACNTGTCCC GGNTCCTTCN TTCCCNCCCC CTTCCCNGAN AAAAMACCCC GTNTGANGGN GCCCCCTCAA ATTATMACCT TTCCNAAACA MNNGGTTCN AAGGTGGTTT GNTTCCGGTG CGGCTGGCCT TGAGGTCCCC CCTNCACCCC MATTTGGMN CCNGTTTTTT TTATTGCCCN

NTCCCC

INFORMATION FOR SEQ ID NO:8: 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1086 Mi SEQUENCE CHARACTERISTICS: CA) LENGTH: 1177 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: NCCNTTTAGA TGTTGACAAN NTAAACMAGC NGCTCAGGCA GCTGAAAAA AAGCATCCTG GAGTATCAGA GTTACTGTT AGATCAGCCT CATTTGACT ATGGTGTTTA MATCCAGCTA CACTACTTCC TGACTCAAAC TCCACTATT( CTGTCAGGAA CTGTTGGAAA CTACTGAAAC TGGCCGACCT GATCTTCAAJ AGGAAAGGTG GATGCCACCG TGTTCACAGA CAGTACCNCC TTCCTCGAGA AGGGGCCGGT GCANCTGTTA CCAAGGAGAC TNATGTGTTG TGGGCTCAGG AAACACCTCA NCNCNNMAGG CTGAATTGAT CGCCCTCACT CAGGCTCTCG GGGATATTMA CGTTAACACT GACAGCAGGT ACGCCTTTGC TACTGTGCAT CCATCTACCA GGAGCGTGGG CTACTCACTC GGCAGGTGGC TGTNATCCAC CATCAAAAGG AAMACNNGGC TGTTGCCCGT GGTMACCANA MNCTGATCN GATGCTGTGT TGACTTTCAC TCNCNCCTCT TAAACTTGCT GCCCACANTC ACCAGATCTG CCTGACAATC CCCATACTCA AAAAAAAN AANACTGGCC ACCAATAAAA ACGGGGANGG TNGGTNGANC NNCCTGACCC AAAAATAATG A GCCACTGATA T CCCCTCCCAC

CTGTTCATGA

k ATGTGCCCCT

SAGGGACTACG

CTTTACCANC

GATGGGGTAA

GTACGTGGAG

TGTAMANGGA

NCAGCTCNAA

TCCTTTCCCA

CCGAACCCNA

GATCCCCCGG

120 180 240 300 360 420 480 540 600 660 720 780 GCTGCAGGAA TTCAATTCAN CCTTATCNAT ACCCCCMACN NGGNGGGGGG GGCCNGTNCC 840 CATTNCCCCT NTATTNATTC TTTNNCCCCC CCCCCGGCNT CCTTTTTNMA CTCGTGAAAG 900 GGAMAACCTG NCTTACCAAN TTATCNCCTG GACCNTCCCC TTCCNCGGTN GNTTANAAMA 960 MAAAGCCCNC ANTCCCNTCC NAAATTTGCA CNGAMAGGNA AGGAATTAA CCTTTATTTT 1020 TTNNTCCTTTr ANTTTGTNNN CCCCCTTTTA CCCAGGCGAA CNGCCATCNT TTMANAAAAA 1080 AAANAGAANG TTTATTTTTC CTTNGMACCA TCCCMTANA AANCACCCGC NGGGGAACGG 1140 :GGNGGNAGGC CNCTCACCCC CTTNTGTNG GNGGGNC 1'177 INFORMATION FOR SEQ ID NO:9: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 1146 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: NCCNNTTNNT GATGTTGTCT TTTTGGCCTC TCTTTGGATA CTTTCCCTCT CTTCAGAGGT GAAAAGGGTC AAAAGGAGCT GTTGACAGTC ATCCCAGGTG GGCCAATGTG TCCAGAGTAC 120 AGACTCCATC AGTGAGGTCA MAGCCTGGGG CTTTTCAGAG MAGGGAGGAT TATGGGTTTT 180 CCAATTATAC MAGTCAGMAG TAGAMAGAAG GGACATAAAC CAGGAAGGGG GTGGAGCACT 240 CATCACCCAG AGGGACTTGT GCCTCTCTCA GTGGTAGTAG AGGGGCTACT TCCTCCCACC 300 ACGGTTGCAA CCMAGAGGCA ATGGGTGATG AGCCTACAGG GGACATANCC. GAGGAGACAT 360 GGGATGACCC TAAGGGAGTA GGCTGGTTTT AAGGCGG TGG GACTGGGTGA GGGAAACTCT 420 CCTCTTCTTC AGAGAGMAGC AGTACAGGGC GAGCTGAACC GGCTGAAGGT CGAGGCGAAA 480 ACACGGTCTG GCTCAGGAAG ACCTTGGAAG TAAAAT-TATG AATGGTGCAT GAATGGAGCC 540 ATGGAAGGGG TGCTCCTGAC CAMACTCAGC CATTGATCMA TGTTAGGGAA ACTGATCAGG 600 GAAGCCGGGA ATTCATTAA CAACCCGCCA CACAGCTTGA ACATTGTGAG GTTCAGTGAC 660 0***CCTTCAAGGG GCCACTCCAC TCCAACTTTG GCCATTCTAC TFVGCNAAAT TTCCAAAACT 720 TCCTTTTA AGGCCGAATC CNTANTCCCT NAAAAACNAA AAAAAATCTG CNCCTATTCT 780 GGAAAAGGCC CANCCCTTAC CAGGCTGGAA GAAATTTTNC CTTTTTTTTT TTTTTGAAGG 840 ~*CNTTTNTTMA ATTGAACCTN AATTCNCCCC CCCAAAAAAA AACCCNCCNG GGGGGCGGAT 900 TTCCAAAAAC NAATTCCCTT ACCAAAAAAC AAMAACCCNC CCTTNTTCCC TTCCNCCCTN 960 TTCTTTTAAT TAGGGAGAGA TNAAGCCCCC CMATTTCCNG GNCTNGATNN GTTTCCCCCC 1020 S...CCCCCATTTT CCNAAACTT TTCCCANCNA GGAANCCNCC CTTTTTTTNG GTCNGATTNA 1080 NCAACCTTCC MACCATTTT TCCNNAAAAA NTTTGNTNGG NGGGAAAAAN ACCTNNTITT 1140 ATAGAN 1146 INFORMATION FOR SEQ ID SEQUENCE

CHARACTERISTICS:

LENGTH: 545 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:10: CTTCATTGGG TACGGGCCCC CTCGAGGTCG ACGGTATCGA TAAGCTTGAT ATCGAATTCC TGCAGCCCGG GGGATCCACT AGTTCTAGAG TCAGGAAGAA CCACCAACCT TCCTGATTTT 120 TATTGGCTCT GAGTTCTGAG GCCAGTTTTC TTCTTCTGTT GAGTATGCGG GATTGTCAGG 180 :CAGATCTGGC TGTGGAAAGG AGACTGTGGG CAGCAAGTTT AGAGGCGTGA CTGAAAGTCA 240 *CACTGCATCT TGAGCTGCTG AATCAGCTTT CTGGTTACCA CGGGCAACAG CCGTGTTTTC 300 CTTTTGATGT CCTTTACAGT GGATTACAGC CACCTGCTGA GGTGAGTAGC CCACGCTCCT 360 see*. GGTAGATGGC TCCACGTACA TGCACAGTAG CAAAGGCGTA CCTGCTGTCA GTGTTAACGT 420 TAATATCCTT ACCCCATCGG AGAGCCTGAG TGAGGGCGAT CAATTCAGCC CTTTTGTGCT 480 GAGGTGTTG CTGGTTAAGC CCTGAACCCA CAACACATCT GTCTCCATGG TAACAGCTGC 540 :ACCGG 545 INFORMATION FOR SEQ ID NO:11: SEQUENCE CHARACTERISTICS: LENGTH: 196 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: TCTCCTAGGC TGGGCACAGT GGCTCATACC TGTMATCCTG ACCG TTCAG AGGCTCAGGT GGGGGGATCG CTTGAGCCCA AGATTTCMAG ACTAGTCTGG GTAACATAGT GAGACCCTAT 120 CTCTACGAAA AAATAAAAAA ATGAGCCTGG TGTAGTGGCA CACACCAGCT GAGGAGGGAG 180 AATCGAGCCT AGGAGA 196 INFORMATION FOR SEQ ID NO:12: SEQUENCE CHARACTERISTICS: LENGTH: 388 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: TCTCCTAGGC TTGGGGGCTC TGACTAGAAA TTCAAGGAAC CTGGGATTCA AGTCCAACTG TGACACCAAC TTACACTGTG GNCTCCAATA AACTGCTTCT TTCCTATTCC CTCTCTATTA 120 AATAAAATAA GGAAAACGAT GTCTGTGTAT AGCCAAGTCA GNTATCCTAA AAGGAGATAC 180 TAAGTGACAT TAAATATCAG AATGTAAAAC CTGGGAACCA GGTTCCCAGC CTGGGATTAA 240 ACTGACAGCA AGAAGACTGA ACAGTACTAC TGTGAAAAGC CCGAAGNGGC AATATGTTCA 300 CTCTACCGTT GAAGGATGGC TGGGAGAATG AATGCTCTGT CCCCCAGTCC CAAGCTCACT 360 TACTATACCT CCTTTATAGC CTAGGAGA 388 INFORMATION FOR SEQ ID NO:13: SEQUENCE CHARACTERISTICS: LENGTH: 337 base pairs 49 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: TAGTAGTTGC CTATAATCAT GTTTCTCATT ATTTTCACAT TTTATTAACC AATTTCTGTT TACCCTGAAA AATATGAGGG AAATATATGA AACAGGGAGG CAATGTTCAG ATAATTGATC 120 ACAAGATATG ATTTCTACAT CAGATGCTCT TTCCTTTCCT GTTTATTTCC TTTTATTTC 180 GGTTGTGGGG TCGAATGTAA TAGCTTTGTT TCAAGAGAGA GTTTTGGCAG TTTCTGTAGC 240 TTCTGACACT GCTCATGTCT CCAGGCATCT ATTTGCACTT TAGGAGGTGT CGTGGGAGAC 300 TGAGAGGTCT ATTTTTCCA TATTTGGGCA ACTACTA 337 INFORMATION FOR SEQ ID NO:14: SEQUENCE CHARACTERISTICS: LENGTH: 571 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: TAGTAGTTGC CATACAGTGC CTTTCCATTT ATTTAACCCC CACCTGAACG GCATAAACTG AGTGTTCAGC TGGTGTTTT TACTGTAAAC AATAAGGAGA CTTTGCTCTT CATTTAAACC 120 AAAATCATAT TTCATATTTT ACGCTCGAGG GTTTACCG GTTCCTTTTT ACACTCCTTA 180 AAACAGT1TT TMAGTCGTTT GGAACAAGAT ATTTTCTT TCCTGGCAGC TTTAACATT 240 ATAGCAAATT TGTGTCTGGG GGACTGCTGG TCACTGTTTC TCACAGTTGC AAATCMAGGC 300 ATTTGCMACC MAGAAAAAAA AATTTTTTG TTTATTTGA MCTGGACCG GATAAACGGT 360 GTTTGGAGCG GCTGCTGTAT ATAGTTTTMA ATGGTTATT GGACCTCCTFT AAGTTGCACT 420 TATGTGGGGG GGGGNTTTTG NATAGAAAGT NTTTANTCAC ANAGTCACAG GGACTTTTNT 480 *.CTTTTGGNNA CTGAGCTAAA AAGGGCTGNT TTTCGdGTGG GGGCAGATGA AGGCTCACAG 540 GAGGCCTTTC TCTTAGAGGG GGGAACTNCT A 571 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 548 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TATATATTA ATAACTTAAA TATATTTTGA TCACCCACTG GGGTGA TAAG ACMATAGATA TAAAAGTATT TCCMAAAGC ATAAAACCAA AGTATCATAC CAAACCAAAT TCATACTGCT 120 TCCCCCACCC GCACTGAAAC TTCACCTTCT MACTGTCTAC CTMACCAAAT TCTACCCTTC 180 AAGTCTTGG TGCGTGCTCA CTACTCTTT ITFTITFFFITIT TTTNTTTTGG AGATGGAGTC 240 TGGCTGTGCA GCCCAGGGGT GGAGTACMAT GGCACAACCT CAGCTCACTG NAACCTCCGC 300 CTCCCAGGTT CATGAGATFC TCCTGNTTCA GCCTTCCCAG; TAGCTGGGAC TACAGGTGTG 360 CATCACCATG CCTGGNTAAT CTTTTTTNGT TTTNGGGTAG AGATGGGGGT TTTACATGTT GGCCAGGNTG GTNTCGAACT CCTGACCTCA AGTGATCCAC CCACCTCAGG CTCCCAAAGT GCTAGGATTA CAGACATGAG CCACTGNGCC CAGNCCTGGT GCATGCTCAC TTCTCTAGGC

AACTACTA

INFORMATION FOR SEQ ID NO:16: SEQUENCE CHARACTERISTICS: LENGTH: 638 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear r r (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: TTCCGTTATG CACATGCAGA ATATTCTATC GGTACTTCAG CTATTACTCA TTTTGATGGC GCAATCCGAG CCTATCCTCA AGATGAGTAT TTAGAAAGAA TTGATTTAGC GATAGACCAA GCTGGTAAGC ACTCTGACTA CACGAAATTG TTCAGATGTG ATGGATTTAT GACAGTTGAT C1GGAAGA GATTATTAAG TGATTATTTT AAAGGGMATC CATAATTCC AGAATATCTT GGTTTAGCTC AAGATGATAT AGAAATAGAA CAGAAAGAGA CTACAAATGA AGATGTATCA CCAACTGATA TTGAAGAGCC TATAGTAGAA AATGAATTAG CTGCATTTAT TAGCCT[ACA CATAGCGATT TTCCTGATGA ATCTTATATT CAGCCATCGA CATAGCATTA CCTGATGGGC AACCTTACGA ATAATAGAAA CTGGGTGCGG GGCTATTGAT GAATTCATCC NCAGTAAATT 420 480 540 548 120 180 240 300 360 420 480 52 TGGATATNAC AAAATATAAC TCGATTGCAT TTGGATGATG GAATACTAAA TCTGGCAAAA 540 GTAACTTTGG AGCTACTAGT AACCTCTCTT TGAGATGC AAAATTTCT TTTAGGGTTT 600 CTTATTCTCT ACTTACGGA TATTGGAGCA TAACGGGA 638 INFORMATION FOR SEQ ID NO:17: SEQUENCE CHARACTERISTICS: LENGTH: 286 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ACTGATGGAT GTCGCCGGAG GCGAGGGGCC TTATCTGATG CTCGGCTGCC TGTTCGTGAT GTGCGCGGCG ATTGGGCTGT TTATCTCAAA CACCGCCACG GCGGTGCTGA TGGCGCCTAT 120 TGCCTTAGCG GCGGCGAAGT CAATGGGCGT CTCACCCTAT CCTTTTGCCA TGGTGGTGGC 180 GATGGCGGCT TCGGCGGCGT TTATGACCCC GGTCTCCTCG CCGGTTAACA CCCTGGTGCT 240 TGGCCCTGGC AAGTACTCAT TTAGCGATTT TGTCAAAATA GGCGTG 286 INFORMATION FOR SEQ ID NQ:18: SEQUENCE CHARACTERISTICS: LENGTH: 262 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: TCGGTCATAG CAGCCCCTTC TTCTCAATTT CATCTGTCAC TACCCTGGTG TAGTATCTCA TAGCCTTACA TTTTTATAGC CTCCTCCCTG GTCTGTCTTT TGATTTTCCT GCCTGTAATC 120 CATATCACAC ATAACTGCAA GTAAACATTT CTAAAGTGTG GTTATGCTCA TGTCACTCCT 180 GTGNCAAGAA ATAGTTTCCA TTACCGTCTT AATAAAATTC GGATTTGTTC TTTNCTATTN 240 TCACTCTTCA CCTATGACCG AA 262 INFORMATION FOR SEQ ID NO:19: SEQUENCE CHARACTERISTICS: LENGTH: 261 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: TCGGTCATAG CAAAGCCAGT GGTTTGAGCT CTCTACTGTG TAAACTCCTA AACCAAGGCC ATTTATGATA AATGGTGGCA GGATTTTTAT TATAAACATG TACCCATGCA AATTTCCTAT 120 AACTCTGAGA TATATTCTTC TACATTTAAA CAATAAAAAT AATCTATTTT TAAAAGCCTA 180 ATTTGCGTAG TTAGGTAAGA GTGTTTAATG AGAGGGTATA AGGTATAAAT CACCAGTCAA 240 CGTTTCTCTG CCTATGACCG A 261 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 294 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TACAACGAGG CGACGTCGGT AAAATCGGAC ATGAAGCCAC CGCTGGTCTT TTCGTCCGAG CGATAGGCGC CGGCCAGCCA GCGGAACGGT TGCCCGGATG GCGAAGCGAG CCGGAGTTCT 120 *TCGGACTGAG TATGAATCTT GTTGTGAAAA TACTCGCCGC CTTCGTTCGA CGACGTCGCG 180 TCGAAATCTT CGANCTCCTT ACGATCGAAG TCTTCGTGGG CGACGATCGC GGTCAGTTCC 240 GCCCCACCGA AATCATGGTT GAGCCGGATG CTGNCCCCGA AGNCCTCGTT TGTN 294 INFORMATION FOR SEQ ID NO:21: SEQUENCE CHARACTERISTICS: LENGTH: 208 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: TTGGTAAAGG GCATGGACGC AGACGCCTGA CGTTTGGCTG AAAATCTTTC ATTGATTCGT ATCAATGAAT AGGAAAATTC CCAAAGAGGG AATGTCCTGT TGCTCGCCAG TTTTTNTGTT 120 GTTCTCATGG ANAAGGCAAN GAGCTCTTCA GACTATTGGN ATTNTCGTTC GGTCTTCTGC 180 CAACTAGTCG NCTTGCNANG ATCTTCAT 208 INFORMATION FOR SEQ ID NO:22: SEQUENCE CHARACTERISTICS: LENGTH: 287 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: NCCNTTGAGC TGAGTGATTG AGATNTGTAA TGGTTGTAAG GGTGATTCAG GCGGATTAGG GTGGCGGGTC ACCCGGCAGT GGGTCTCCCG ACAGGCCAGC AGGATTTGGG GCAGGTACGG 120 NGTGCGCATC GCTCGACTAT ATGCTATGGC AGGCGAGCCG TGGAAGGNGG ATCAGGTCAC 180 GGCGCTGGAG CTTTCCACGG TCCATGNATT GNGATGGCTG TTCTAGGCGG CTGTTGCCAA 240 GCGTGATGGT ACGCTGGCTG GAGCATTGAT TTCTGGTGCC AAGGTGG 287 INFORMATION FOR SEQ ID NO:23: SEQUENCE CHARACTERISTICS: LENGTH: 204 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: TTGGGTAAAG GGAGCAAGGA GAAGGCATGG AGAGGCTCAN GCTGGTCCTG GCCTACGACT GGGCCAAGCT GTCGCCGGGG ATGGTGGAGA ACTGAAGCGG GACCTCCTCG AGGTCCTCCG 120 NCGTTACTTC NCCGTCCAGG AGGAGGGTCT TTCCGTGGTC TNGGAGGAGC GGGGGGAGAA 180 GATNCTCCTC ATGGTCNACA TCCC 204 INFORMATION FOR SEQ ID NO:24: SEQUENCE CHARACTERISTICS: LENGTH: 264 base pairs TYPE: nucleic acid STADDES single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: *00* TGGATTGGTC AGGAGCGGGT AGAGTGGCAC CATTGAGGGG ATATTCAAAA ATATTATTT GTCCTAAATG ATAGTTGCTG AGTTTTTCTT TGACCCATGA GTTATATTGG AGTTTATTTT 120 TTAACTTCr, AATCGCtATr'r ACATGTITAG-A CTATTTGTTAATGATT NTTM 8 *.TTAAATGGA TTTGAAAT TGGTTNTTAT TATATCMATT TTGGTAM~ GTTGAGTTG 240 ACATTATAGC TTAGTATGTG ACCA 264 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 376 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TTACAACGAG GGGAMACTCC GTCTCTACAA AAATTAAAAA ATTAGCCAGG TGTGGTGGTG TGCACCCGCA ATCCCAGCTA CTTGGGAGGT TGAGACACAA GANTCACCTA NATGTGGGAG 120 GTCMAGGTTG CATGAGTCAT GATTGTGCCA CTGCACTCCA GCCTGGGTGA CAGACCGAGA 180 CCCTGCCTCA ANAGANAANG AATAGGAAGT TCAGAAATCN TGGNTGTGGN GCCCAGCAAT 240 CTGCATCTAT NCMACCCCTG CAGGCMANGC TGATGCAGCC TANGTTCMAG AGCTGCTGTT 300 TCTGGAGGCA GCAGTTNGGG CTTCCATCCA GTATCACGGC CACACTCGCA CNAGCCATCT 360 GTCCTCCGTN TGTNAC 376 INFORMATION FOR SEQ ID NO:26: SEQUENCE CHARACTERISTICS: LENGTH: 372 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (x)SQENEDSRPTO:.. DN:6 TTCACA GGAACC GTTTCAAATAA TTGCG GGT G 6 TCTACACGAG GAACTCC GCTCTCAA AAATTGAA CTGTAA ATAC AGTTGTGTG 0 TCTGGAGGCA GNAGTAAGGG CTTCCATCCA GCATCACGGN CAACACTGCA AAAGCACCTG 360 TCCTCGTTGG TA 372 INFORMATION FOR SEQ ID NO:27: SEQUENCE

CHARACTERISTICS:

LENGTH: 477 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: TTCTGTCCAC ATCTACAAGT TIATTTATT TTGTGGGTTT TCAGGGTGAC TAAGTTTTTC CCTACATTGA AAAGAGAAGT TGCTAAAAGG TGCACAGGAA ATCATTTTTT TAAGTGAATA 120 TGATMATATG GGTCCGTGCT TAATACAACT GAGACATATT TGTTCTCTGT TTTrTAGAG 180 TCACCTCTTA AAGTCCAATC CCACAATGGT GAAAAAAAAA TAGAAAGTAT TTGTTCTACC 240 TTTAAGGAGA CTGCAGGGAT TCTCCTTGAA MACGGAGTAT GGAATCAATC TTAAATAAAT 300 ATGAAATTGG TTGGTCTTCT GGGATAAGMA ATTCCCAACT CAGTGTGCTG AAATTCACCT 360 GACTTTTTTT GGGMAAAAAT AGTCGAAMAT GTCAATTTGG TCCATAAAAT ACATGTTACT 420 ATTAAMAGAT ATTTAMAGAC AAATTCTTTC AGAGCTCTMA GATTGGTGTG GACAGAA 477 INFORMATION FOR SEQ ID NO:28: SEQUENCE

CHARACTERISTICS:

LENGTH: 438 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: TCTNCMACCT CTTGANTGTC AAAAACCTTN TAGGCTATCT CTAAAAGCTG ACTGGTATTC ATTCCAGCAA AATCCCTCTA GTTTTTGGAG TTTCC TTTA CTATCTGGGG CTGCCTGAGC 120 CACMAATGCC AAATTAAGAG CATGGCTATT TTCGGGGGCT GACAGGTCAA AAGGGGTGTA 180 TCCGATAA GCCTCCTGGA GGTGCTCTAA AAACACTCCT GGTGACTCAT CATGCCCCTG 240 GACGACTTCA ATCGNCTTAG ACAAGTTTAT AGGTTTCTGG GCAGCTCCCT GMATACCCAC 300 GAGGAGATAC CGGTGGAAAT CGTCAAAAGT TCTCCCTCCA CTTGAGAAAT TTGGGTCCCA 360 ATTAGGTCCC MATTGGGTCT CTAATCACTA TTCCTCTAGC TTCCTCCTCC GGNCTAFTGG 420 0 0:090 TTGATGTGAG GTTGMAGA 438 INFORMATION FOR SEQ ID NO:29: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 620 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: MGAGGGTAC CAGCCCCMAG CCTTGACAAC TTCCATAGGG TGTCAAGCCT GTGGGTGCAC AGAAGTCAAA AATTGAGTT TGGGATCCTC AGCCTAGATF TCAGAGGATA TMAAGAAACA 120 CCTAACACCT AGATATTCAG ACMAAAGTT ACTACAGGGA TGMAGCTTC ACGGAAAACC 180 TCTACTAGGA AAGTACAGAA GAGAAATGTG GGTTTGGAGC CCCCAAACAG MATCCCCTCT 240 AGMACACTGC CTAATGAAAC TGTGAGAAGA TGGCCACTGT CATCCAGACA CCAGAATGAT 300 AGACCCACCA AAAACTTATG CCATATTGCC TATMAAACCT ACAGACACTC MATGCCAGCC 360 CCATGAAAAA AAAACTGAGA AGAAGACTGT NCCCTACAAT GCCACCGGAG CAGMACTGCC 420 *CCAGGCCATG GMAGCACAGC TCTTATATCA ATGTGACCTG GATGTTGAGA CATGGAATCC 480 NANGAAATCN TTTTAANACT TCCACGGTTN MATGACTGCC CTATTANATT CNGMACTTAN 540 ATCCNGGCCT GTGACCTCTT TGCTTTGGCC ATTCCCCCTT TTTGGMATGG CTNTTTTTTT 600 CCCATGCCTG TNCCCTCTTA 620 INFORMATION FOR SEQ ID Ci) SEQUENCE CHARACTERISTICS: LENGTH: 100 base pairs *00040(B) TYPE: nucleic acid STRANDEDNESS: singl~e TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ I0 TTACAACGAG GGGGTCAATG TCATMAATGT CACAATAAAA CAATCTCTTC TTTTTTTTTI TTTTT1TFVT TTTTTFITTT TTFITTTTT TTTTTTTTTT 100 INFORMATION FOR SEQ ID NO:31: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 762 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear

S

005@ 0 0 0 0 0 00 .0 OS Cxi) SEQUENCE DESCRIPTION: SEQ ID NO:31: TAGTCTATGC GCCGGACAGA GCAGAATTAA ATTGGAAGTT GCCCTCCGGA CTTTCTACCC ACACTCTTCC TGAAAAGAGA AAGAAAAGAG GCAGGAAAGA GGTTAGGATT TCATTTTCAA GAGTCAGCTA ATTAGGAGAG CAGAGTTTAG ACAGCAGTAG GCACCCCATG ATACAAACCA TGGACAAAGT CCCTGTTTAG TAACTGCCAG ACATGATCCT GCTCAGGTTT TGAAATCTCT CTGCCCATAA AAGATGGAGA GCAGGAGTGC CATCCACATC AACACGTGTC CAAGAAAGAG TCTCAGGGAG ACAAGGGTAT CAAAAAACAA GATTCTTAAT GGGAAGGAAA TCAAACCAAA AMATTAGATT TTTCTCTACA TATATATAAT ATACAGATAT TTAACACATT ATTCCAGAGG TGGCTCCAGT CCTTGGGGCT TGAGAGATGG TGAAAACTTT TGTTCCACAT TAACTTCTGC TCTCAAATTC TGAAGTATAT CAGAATGGGA CAGGCAATGT TTTGCTCCAC

ACTGGGGCAC

AGACCCAAAT GGTTCTGTGC CCGAAGAAGA GAAGCCCGAA AGACATGAAG GATGCTTAAG GGGGGTTGGG AAAGCCAAAT TGGTANTATC TTTTCCTCCT GCCTGTGTTC CNGAAGTCTC CNCTGAAGGA ATTCTTAAAA CCCTTTGTGA GGAAATGCCC CCTTACCATG ACAANTGGTC CCATTGCTTT TAGGGNGATG GAAACACCAA GGGTTTTGAT CC INFORMATION FOR SEQ ID NO:32: 120 180 240 300 360 420 480 540 600 660 720 762 62 SEQUENCE CHARACTERISTICS: LENGTH: 276 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: TAGTCTATGC GTGTATTAAC CTCCCCTCCC TCAGTAACAA CCAAAGAGGC AGGAGCTGTT ATTACCAACC CCATTTTACA GATGCATCAA TAATGACAGA GAAGTGAAGT GACTTGCGCA 120 CACAACCAGT AAATTGGCAG AGTCAGATTT GAATCCATGG AGTCTGGTCT GCACTTTCAA 180 TCACCGAATA CCCTTTCTAA GAAACGTGTG CTGAATGAGT GCATGGATAA ATCAGTGTCT 240 ACTCAACATC TTTGCCTAGA TATCCCGCAT AGACTA 276 INFORMATION FOR SEQ ID NO:33: SEQUENCE CHARACTERISTICS: LENGTH: 477 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: TAGTAGTTGC CAAATATTTG AAAATTTACC CAGAAGTGAT TGAAAACTTT TTGGAAACAA AAACAAATAA AGCCAAAAGG TAAAATAAAA ATATCTTTGC ACTCTCGTTA TTACCTATCC 120 ATAACTTTTT CACCGTAAGC TCTCCTGCTT GTTAGTGTAG TGTGGTTATA TTAAACTTTT 180 TAGTTATTAT TTTTTATTCA CTTTTCCACT TGATCTCATT TCATTTTTTC 1TTTTATAGG CAAGCCCATT ATCTTTTTTC CCCCCGAAAT TCCCATTAAA AAATTGTAAA TATGTTCAGT MATTGTGTTT ACTTGAGCTG CTGATTGTAA INFORMATION FOR SEQ ID NO:34: SEQUENCE CHARACTERISTICS.

LENGTH: 631 base pal TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear AGAAAGTCAT TATTGATT-TA GCACACATGT CAMAT MTGA TGCTATGCAA CAAAAATACT CTGAAMATTG CAGGGGACAG AGGGAAGTTA TTATGTTTAA AMATGCACAA AACATAAGAA GCAGTTTTAT CTCAGGGGCA ACTACTA 240 300 360 420 477 120 180 240 300 360 420 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: TAGTAGTTGC CAATTCAGAT GATCAGAAAT GCTGCTTTCC TCAGCATTGT CTTGTTAAAC CGCATGCCAT TTGGMCTTT GGCAGTGAGA AGCCAAAAGG AAGAGGTGAA TGACATATAT ATATATATAT ATTCAATGMA AGTAAAATGT ATATGCTCAT ATACTTTCTA GTTATCAGAA TGAGTTAAGC TTTATGCCAT TGGGCTGCTG CATATTTTM TCAGAAGATA MAGAAAATC TGGGCAT1T TAGAATGTGA TACATGTTTT TTTAMAACTG TTAAATATTA TTTCGATATT TGTCTMAGM CCGGMATGTT CTTAAAATTT ACTAAMACAG TATTGTTTGA GGMAGAGAAA ACTGTACTGT TTGCCATTAT TACAGTCGTA CAAGTGCATG TCMAGTCACC CACTCTCTCA 64 GGCATCAGTA TCCACCTCAT AGCTTTACAC ATTTTGACGG GGAATATTGC AGCATCCTCA 480 GGCCTGACAT CTGGGAAAGG CTCAGATCCA CCTACTGCTC CTTGCTCGTT GATT7GTTT 540 AAAATATTGT GCCTGGTGTC ACTTTTAAGC CACAGCCCTG CCTAAAAGC C AGCAGAGAAC 600 AGAACCCGCA CCATTCTATA GGCAACTACT A 631 INFORMATION FOR SEQ ID Ci) SEQUENCE CHARACTERISTICS: LENGTH: 578 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TAGTAGTTGC CATCCCATAT TACAGAAGGC TCTGTATACA TGACTTATTT GGAAGTGATC TGTTTTCTCT CCAAACCCAT TTATCGTAAT TTCACCAGTC TTGGATCAAT CTTGGTTTCC 120 ACTATCC TGAAACCTAC TTGGAGCAG CATTGCACAG TTTTCTGTGG TAAAAACTAA 180 AGGTTTATTT GCTAAGCTGT CATCTTATGC TTAGTATTTT TTTTTTACAG TGGGGMATTG 240 CTGAGATTAC ATTTTGTTAT TCATTAGATA CTTGGGATA ACTIGACACT GTCTTCTTTT 300 TTTCGCTTTT M1TTGCTATC ATCATGCTTT TGAAACAAGA ACACATTAGT CCTCAAGTAT 360 TACATMAGCT TGCTTGTTAC GCCTGGTGGT TTAAAGGACT ATCTTTGGCC TCAGGTTCAC 420 AAGMATGGGC AAAGTGTTTC CTTATGTTCT GTAGTTCTCA ATAAAAGATT GCCAGGGGCC 480 GGGTACTGTG GCTCGCACTG TAATCCCAGC ACTTTGGGAA GCTGAGGCTG GCGGATCATG 540 TTAGGGCAGG TGTTCGAAAC CAGCCTGGGC-AACTACTA 578 INFORMATION FOR SEQ ID NO:36: SEQUENCE CHARACTERISTICS: CA) LENGTH: 583 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: TAGTAGTTGC CTGTAATCCC AGCAACTCAG GAGGCTGGGG CAGGAGAATC AGTTGAACCT GGGAGGCAGA AGTTGTAATT AGCAAAGATC GCACCATTGC ACTTCAGCCT GGGCAACAAG 120 AGTGAGATTC CATCTCAAAA ACAAAAAAAA GAAAAAGAAA AGAAAAGGAA AAAACGTATA 180 AACCCAGCCA AAACAAAATG ATCATTCTTT TAATAAGCM GACTMATTTA ATGTGTTTAT 240 TTAATCAAAG CAGTTGAATC TTCTGAGTTA TTGGTGAAAA TACCCATGTA GTTAATTTAG 300 GGTTCTTACT TGGGTGAACG TTTGATGTTC ACAGGTTATA AAATGGTTAA CAAGGAAAAT 360 GATGCATAAA GAATCTTATA AACTACTAAA AATAMATAAA ATATAAATGG ATAGGTGCTA 420 TGGATGGAGT TTTTGTGTAA TTTAAAATCT TGAAGTCATT TTGGATGCTC ATTGGTTGTC 480 TGGTAATTTC CATTAGGAAA AGGTTATGAT ATGGGGAAAC TGTTTCTGGA AATTGCGGAA 540 TGTTTCTCAT CTGTAAAATG CTAGTATCTC AGGGCAACTA CTA 583 INFORMATION FOR SEQ ID NO:37: SEQUENCE CHARACTERISTICS: LENGTH: 716 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear r r (xi) SEQUENCE DESCRIPTION:* SEQ ID NO:37: GATCTACTAG TCATNTGGAT TCTATCCATG GCAGCTAAGC CTTTCTGAAT GGATTCTACT GCTTTCTTGT TCTTTAATCC AGACCCTTAT ATATGTTTAT GTTCACAGGC AGGGCAATGT TTAGTGAAAA CAATTCTAAA TTTMATTT TGCATCA TGCTAATTTC CGTCACACTC CAGCAGGCTT CCTGGGAGAA TAAGGAGAAA TACAGCTAAA GACATTGTCC CTGCTTACTT ACAGCCTAAT GGTATGCAAA ACCACTTCAA TAAAGTAACA GGAAAAGTAC TAACCAGGTA GAATGGACCA AAACTGATAT AGAAAAATCA GAGGAAGAGA GGAACAAATA TTTACTGAGT CCTAGAATGT ACAAGGCTTT TTAATTACAT ATTTTATGTA AGGCCTGCAA AAAACAGGTG AGTAATCAAC ATTTGTCCCA TTTTACATAT AAGGAAACTG AAGCTTAAAT TGAATAATTT AATGCATAGA TTTTATAGTT AGACCATGTT CAGGTCCCTA TGTTATACTT ACTAGCTGTA TGAATATGAG AAAATAATTT TGTTATTTTC TTGGCATCAG TAT1TTCATC TGCAAAATAA AGCTAAAGTT ATAGCAAA CAGTCAGCAT AGTGCCTGAT ACATAGTAGG TGCTCCAMC ATGATTACNC TANTATTNGG TATTANAAAA ATCCAATATA GGCNTGGATA AAACCG INFORMATION FOR SEQ ID NO:38: SEQUENCE CHARACTERISTICS: 120 180 240 300 360 420 480 540 600 660 716 LENGTH: 688 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: TTCTGTCCAC ATATCATCCC ACTTTAATTG TTAATCAGCA AAACTTTCAA TGMAAAATCA TCCATTTTAA CCAGGATCAC ACCAGGAAAC TGAAGGTGTA TTT1TTTTTTA CCTTAAAAAA 120 AAAAAAAAAA ACCAAACAAA CCAAAACAGA TTAACAGCMA AGAGTTCTAA MAAATTTACA 180 TTCTCTTAC MCTGTCATT CAGAGAACAA TAGTTCTTAA GTCTGTTAAA TCTTGGCATT 240 MACAGAGAAA CTTGATGAAN AGTTGTACTT GGAATATTGT GGATFTTTT TTTTGTCTAA 300 *.*TCTCCCCCTA TTGTTTTGCC AACAGTAATT TAAGTTTGTG TGGAACATCC CCGTAGTTGA 360 AGTGTAAACA ATGTATAGGA AGGAATATAT GATMAGATGA TGCATCACAT ATGCATTACA 420 TGTAGGGACC TTCACAACTT CATGCACTCA GMAAACATGC TTGAAGAGGA GGAGAGGACG 480 GCCCAGGGTC ACCATCCAGG TGCCTTGAGG ACAGAGAATG CAGAAGTGGC ACTGTTGMAA 540 TTTAGAAGAC CATGTGTGMA TGGTTCAGG CCTGGGATGT TTGCCACCAA GMAGTGCCTC 600 CGAGMAATTT CTTTCCCATT TGGMATACAG GGTGGCTTGA TGGGTACGGT GGGTGACCCA 660 ACGMAGAAAA TGAAATTCTG CCCTTTCC 688 INFORMATION FOR SEQ ID NO:39: SEQUENCE CHARACTERISTICS: LENGTH: 585 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear r r r r r (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: TAGTAGTTGC CGCNNACCTA AAANTTGGAA AGCATGATGT CTAGGAAACA TANTAAAATA GGGTATGCCT ATGTGCTACA GAGAGATGTT AGCATTTAAA GTGCATANTT TTATGTATTT TGACAAATGC ATATNCCTCT ATAATCCACA ACTGATTACG AAGCTATTAC AATTPAAAAG TTTGGCCGGG CGTGGTGGGC GGTGGCTGAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA GGCACGCGGA TCACGAGGTC GGGAGTTCAA GACCATCCTG GCTAACACGG TGAAAGTCCA TCTCTACTAA AAATACGAAA AAATTACCCC GGCGTGGTGG CGGGCGCCTG TAGTCCCAGC TACTCCGGAG GCTGAGGCAG GAGAATGGCG TGAACCCAGG ACACGGAGCT TGCAGTGTGC CAACATCACG TCACTGCCCT CCAGCCTGGG GGACAGGMAC AAGANTCCCG TCCTCANAAA AGAAAAATAC TACTNATANT TTCNACTTTA TTTTAANTTA CACAGAACTN CCTC1TGGTA CCCCCTTACC ATTCATCTCA CCCACCTCCT ATAGGGCACN NCTAA INFORMATION FOR SEQ ID Ci) SEQUENCE CHARACTERISTICS: LENGTH: 475 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 120 180 240 300 360 420 480 540 585 69 (xi) SEQUENCE DESCRIPTION: SEQ ID TCTGTCCACA CCAATCTTAG AAGCTCTGMA MGAATTGT CTTTAAATAT CTTTTMATAG TAACATGTAT TTTATGGACC AAATTGACAT TTTCGACTGT TITTCCAAA AAAGTCAGGT 120 GAATTTCAGC ACACTGAGTT GGGAATTTCT TATCCCAGAA GACCAACCAA TTTCATATTT 180 ATTTAAGATT GATTCCATAC TCCGTTTTCA AGGAGMATCC CTGCAGTCTC CTTAAAGGTA 240 GMACAAATAC TTCCTATTT TTTTTCACCA TTGTGGGATT GGACTTTAAG AGGTGACTCT 300 *AAAAAAACAG AGAACAMATA TGTCTCAGTT GTATTAAGCA CGGACCCATA TTATCATATT 360 CACTTAAAAA AATGATTTCC TGTGCACCTT TTGGCAACTT CTCTTTTCAA TGTAGGGAAA 420 AACTTAGTCA CCCTGAAAAC CCACAAAATA AATAAAACTT GTAGATGTGG ACAGA 475 INFORMATION FOR SEQ ID NO:41: 0I) SEQUENCE CHARACTERISTICS: LENGTH: 423 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: TMAGAGGGTA CATCGGGTAA GMACGTAGGC ACATCTAGAG CTTAGAGAAG TCTGGGGTAG GAAAAAAATC TAAGTATTTA TMGGGTATA GGTMACATTT AAAAGTAGGG CTAGCTGACA 120 TTATTTAGAA AGAACACATA CGGAGAGATA AGGGCAAAGG ACTAAGACCA GAGGMACACT 180 MTATTTAGT GATCACTTCC ATTCTTGGTA AMAATAGTAA CTTTAAGTT AGCTTCAAGG 240 AAGATTTTG GCCATGATTA GTTGTCAAAA GTTAGTTCTC TTGGGTFFAT ATTACTAATT 300 TTGTTTTAAG ATCCTTGTTA GTGCTTTMAT MAAGTCATGT TATATCAAAC GCTCTMAAC 360 ATTGTAGCAT GTTAAATGTC ACAATATACT TACCATTTGT TGTATATGGC TGTACCCTCT 420 CTA 423 INFORMATION FOR SEQ ID NO:42: SEQUENCE CHARACTERISTICS: LENGTH: 527 base pairs TYPE: nucleic aci~d STRANDEDNESS: single TOPOLOGY: linear SEQUENCE DESCRIPTION: SEQ ID NO:42: TCTCCTAGGC TAATGTGTGT GTTTCTGTMA MGTAAAAAG TTAAAAATTT TAAAAATAGA AAAAAGCTTA TAGMATAAGA ATATGAAGAA AGAAAATATT TTTGTACATT TGCACAATGA 120 GTTTATGTTT TAAGCTAAGT GTTATTACAA AAGAGCCAAA AAGGTTr-AA AAATTAAAAC 180 GTTTGTAAAG TTACAGTACC CTTATGTTAA TTTATAATTG AAGAAAGAAA AACTT1TTTT 240 TATAAATGTA GTGTAGCCTA AGCATACAGT ATTTATAAAG TCTGGCAGTG TTCMATAATG 300 TCCTAGGCCT TCACATTCAC TCACTGACTC ACCCAGAGCA ACTTCCAGTC CTGTAAGCTC 360 CATTCGTGGT AAGTGCCCTA TACAGGTGCA CCATT-TATT TACAGTATTT TTACTGTACC 420 TTCTCTATGT TTCCATATGT TTCGATATAC MATACCACT GGTTACTATN GCCCNACAGG 480 71 TAATTCCAGT AACACGGCCT GTATACGTCT GGTANCCCTA GNGAAGA 527 INFORMATION FOR SEQ ID NO:43: SEQUENCE CHARACTERISTICS: LENGTH: 331 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: TCTTCAACCT CGTAGGACAA CTCTCATATG CCTGGGCACT ATTTTTAGGT TACTACCTTG GCTGCCCTTC TTTAAGAAAA AAAAAAGAAG AAAAAAGAAC TTTTCCACAA GTTTCTCTTC 120 CTCTAGTTGG AAAATTAGAG AAATCATGTT TTTAATTTTG TGTTATTTCA GATCACAAAT 180 TCAAACACTT GTAAACATTA AGCTTCTGTT CAATCCCCTG GGAAGAGGAT TCATTCTGAT 240 *o ATTTACGGTT CAAAAGAAGT TGTAATATTG TGCTTGGAAC ACAGAGAACC AGTTATTAAC 300 TTCCTACTAC TATTATATAA TAAATAATAA C 331 INFORMATION FOR SEQ ID NO:44: SEQUENCE CHARACTERISTICS: LENGTH: 592 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: GGCTTAGTAG TTGCCAGGCA MAATARCGTT GATTCTCCTC AGGAGCCACC CCCAACACCC CTGTTTGCTT CTAGACCTAT ACCTAGACTA AAGTCCCAGC AGACCCCTAG AGGTGAGGTT 120 CAGAGTGACC CTTGAGGAGA TGTGCTACAC TAGAAMAGAA CTGCTTGAGT TTCTAM 180 ATATAAGCAG AMATCTGGAG MGAGTCATA GGAATGGATA TTAAGGGTGT GAGATMATGG 240 CGGAAGGAAT ATAGAGTTGG ATCAGGCTGG ACTTATTGAT TTGAACCCAC TMAGTAGAGA 300 TTCTGCTTTT GATGTTGCAG CTCAGGGAGT TAMAAAGGT TTTAATGGTT CTAATAGMT 360 ATTTGCTTGG TTAGCTGAAA TATGGATAAA AGATGGCCCA CTGTGAGCAA GCTGGAAATG 420 CCTGATCTCT CTCAGTTTAA TGTAGAGGAA GGGATCCAAA AGTTAGGGA GANTTGGATG 480 CTGGRAKTGG ATTGGTCACT TTGRGACCTA CCCWTCCCAG CTGGGAGGGT CCAGAAGATA 540 CACCCTTGAC CAACGCTTTG CGAAATGGAT TTGTGATGGC GGCAACTACT AA 592 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 567 base pair-s TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GGCTTAGTAG TTGCCATTGC GAGTGCTTGC TCAACGAGCG TTGAACATGG CGGATTGTCT AGATTCMACG GATTTGAGTT TTACCAGCMA AGCGMACCAA GCGCGGCCCA GAGAATTATG 120 GGTTGGTTGG CTTTGAAAAG ATGGAAATCC TGTAGGCCTA GTCAGAMAAG CCTTCTTGCA 180 73 GMACAGTTGG TTCTCGGGCG MACGCTCATC AAGATGCCCA TTGGAAAGGC TAGCGTGTAT 240 TTGGGAGAGC CTGATAGCGT GTCTTCTGAT GATGTTGTG CTTGGACAGT GACAAAAGAT 300 ATGCAAAGCA AGTCCGAACT AGACGTCAAG CTTCGTGAGC AAATTATTGT AGACTCCTAC 360 TTATACTGTG AGGMATGATA GCCMAGGGTG GGGACTFTAA GACTAAGGTG GTMTGTACTT 420 GCGCCGATGA TCCCAGGCAG AAAGAMCTGA TCGCTAGTTT TATACGGGCA ACTACTMAGC 480 .CGMATTCCAG CACACTGGCG GCCGTTACTA ATTGGATCCG ANCTCGGTAC CAGCTTGATG 540 :::CATASCTTGA GTTWTCTATA NTGTCNC 567 INFORMATION FOR SEQ IO NO:46: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 908 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: GAGCGAAAGA CCGAGGGCAG NGNNTANGNG CGANGAAGCG GAGAGGGCCA AAAAGCAACC GCTTCCCCG GGGGGTGCCG ATTCATTMAG GCAGGTGGAG GACAGGTTTC CCGATGGAAG 120 GCGGCAGGGG CGCMAGCMAT TAATGTGAGT AGGCCATTCA TTAGCACCCG GGCT[AACAT 180 TTAAGCTTCG GGTTGGTATG TGGTGGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA 240 CAGCTATGAC CATGATTACG CCMAGCTATT TAGGTGACAT TATAGMATAA CTCMGTTAT 300 GCATCAAGCT TGGTACCGAG TTCGGATCCA C GCTTAGTAGT TGCCGACCAT GGAGTGCTAC C CCTCACTCAC ATTAAATTGT ATCTTTTCTA C~ TGGACWATCG ATMAATTMAT CCTGATAGGA T GTTAATGTGT CATCCCTCCT ATATMACGTA Ti MATCCCTGMA GGCAAAGGAA TGMATCTTGA G GCAGTTGTGG GAGAAGGTGA TATTATGTAT GT *0 O CTAAGCCCGA ATTCCAGCAC ACTGGCGGGC GT f CTTGATGCAT AGCTTGAGTA TCTATAGTGT CA( AGCTGTTCC TGTGTGAMAT TGTTATCCGC TC(

CATAAAGT

INFORMATION FOR SEQ ID NO:47: 9 SEQUENCE CHARACTERISTICS: LENGTH: 480 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear

*TAGTMACG

TAGGCTAG)

ATTAGATG1

ATAGCAGC

TGCATFFT

GTGAGAAA

CTCAGAAG

TACTAATG

'TAMATAG

CAATTCC

G CCGCCAGTGT GTGGMATTCG SATACCTGAGY TCCTCCCTAG -CCTCAGCGCC TTATTCTGC AGATTAATTA CTGAGAGTAT AATGGAGCAA TTCTGGAGAT GCCAGAATCA GTGTCCAGCT TGACACCATA TGGGCAACTA GATCCGAGCT CGGTACCAAG CCTGGCGTTA TCATGGTCAT CCCCACCATA CGAGCCGGAA 360 420 480 540 600 660 720 780 840 900 908 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: TGCCAACAAG GAAAGT1TTA AMCCCCT TGAGGATTCT TGGTGATCAT CAAATTCAGT GGTTTTTMG GTTGTTTCT GTCAMATMC TCTAACTTA AGCCAAACAG TATATGGAAG CACAGATAKA ATATTACACA GATAAMAGAG GAGTTGATCT AAAGTARAGA TAGTTGGGGG CTTTMATTTC TGGAACCTAG GTCTCCCCAT CTTCTTCTGT GCTGAGGAAC TTCTTGGMAG CGGGGATTCT AAAGTTCTTT GGMAGACAGT TTGMAAACCA CCATGTTGTT CTCAGTACCT TTATTTTTAA AAAGTAGGTG MCATTTTGA GAGAGAAAAG GGCTTGGTTG AGATGMAGTC CCCCCCCCCC CTT1TFFVTT TTTTAGCTGA MATAGATACC CTATGTTNMA RGAARGGATT ATTATTACC ATGCCAYTAR SCACATGCTC TTTGATGGGC NYCTCCSTAC CCTCCTTAAG 180 240 300 360 420 480 90004 0 @00 00 to.* ego INFORMATION FOR SEQ ID NO:48: SEQUENCE CHARACTERISTICS: LENGTH: 591 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: AAGAGGGTAC CGAGTGGMAT TTCCGCTTCA CTAGTCTGGT GTG GCTAGTC GGTTTCGTGG TGGCCAACAT TACGMACTTC CAACTCAACC GTTCTTGGAC GTTCAAGCGG GAGTACCGGC GAGGATGGTG GCGTGAATTC TGGCCTTTCT TTGCCGTGGG ATCGGTAGCC GCCATCATCG GTATGTTTAT CAAGATCTTC TTTACTAACC CGACCTCTCC GATTTACCTG CCCGAGCCGT GGTTTMCGA GGGGAGGGGG ATCCAGTCAC GCGAGTACTG GTCCCAGATC TTCGCCATCG TCGTGACAAT GCCTATCMAC TTCGTCGTCA ATMAGTTGTG GACCTTCCGA ACGGTGMAGC 120 180 240 300 360 ACTCCGAAAA CGTCCGGTGG CTGCTGTGCG GTGACTCCCA AAATCTTGAT AACAACAAGG 420 TAACCGAATC GCGCTAAGGA ACCCCGGCAT CTCGGGTACT CTGCATATGC GTACCCCTTA 480 AGCCGAATTC CAGCACACTG GCGGCCGTTA CTAATTGGAT CCGMACTCCG TAACCAAGCC 540 TGATGCGTAA CTTGAGTTAT TCTATAGTGT CCCTAAAATA ACCTGGCGTT A 591 INFORMATION FOR SEQ ID NO:49: SEQUENCE CHARACTERISTICS: LENGTH: 454 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: AAGAGGGTAC CTGCCTTGAA ATTTAAATGT CTAAGGAAAR TGGGAGATGA TTAAGAGTTG GTGTGGCYTA GTCACACCAA AATGTATTTA TTACATCCTG CTCCTTTCTA GTTGACAGGA 120 AAGPAAGCTG CTGTGGGGAA AGGAGGGATA AATACTGAAG GGATTTACTA AACAAATGTC 180 CATCACAGAG TTTTCCTTTT TTTTTTTTTG AGACAGAGTC TTGCTCTGTC ACCCAGGCTG 240 GAATGAAGWG GTATGATCTC AGTTGAATGC AACCTCTACC TCCTAGGTTC AAGCGATTCT 300 CATGCCTCAG CCTCCTGAGC AGCTGGGACT ATAGGCGCAT GCTACCATGC CAGGCTAATT 360 TTTATATTTT TATTAGAGAC GGGGTGTTGC CATGTTGGCC AGGCAGGTCT CGAACTCCTG 420 GGCCTCAGAT GATCTGCCCC ACCGTACCCT CTTA 454 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 463 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID AAGAGGGTAC CAAAAAAAAG AAAAAGGAAA AAAAGAAAAA CAACTTGTAT AAGGCTTTCT GCTGCATACA GCTTTTTTTT TTTAAATAAA TGGTGCCAAC AAATGTTTTT GCATTCACAC 120 CAATTGCTGG TTTTGAAATC GTACTCTTCA AAGGTATTTG TGCAGATCAA TCCAATAGTG 180 ATGCCCCGTA GGTTTTGTGG ACTGCCCACG TTGTCTACCT TCTCATGTAG GAGCCATTGA 240 GAGACTGTTT GGACATGCCT GTGTTCATGT AGCCGTGATG TCCGGGGGCC GTGTACATCA 300 TGTTACCGTG GGGTGGGGTC TGCATTGGCT GCTGGGCATA TGGCTGGGTG CCCATCATGC 360 CCATCTGCAT CTGCATAGGG TATTGGGGCG TTTGATCCAT ATAGCCATGA TTGCTGTGGT 420 AGCCACTGTT CATCATTGGC TGGGACATGC TGTTACCCTC TTA 463 INFORMATION FOR SEQ ID NO:51: SEQUENCE CHARACTERISTICS: LENGTH: 399 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 78 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: CTTCAACCTC CCAMAGTGCT GGGATTACAG GACTGAGCCA CCACGCTCAG CCTAAGCCTC TTTTTCACTA CCCTCTMAGC GATCTACCAC AGTGATGAGG GGCTAAAGAG CAGTGCAATT 120 TGATTACMAT AATGGAACTT AGATTATTA ATTAACAATT TTTCCTTAGC ATGTTGGTTC. 180 CATMATTATT AAGAGTATGG ACTTACTTAG AAATGAGCTT TCATTTTAAG AMCATCT 240 TTGACCTTCT CTATTAGTCT GAGCAGTATG ACACTATACG TATTMfATTT AACTMACCTA 300 CCTTGAGCTA TTACTTTTTA MAAGGCTATA TACATGAATG TGTATTGTCA ACTGTMAAGC 360 CCCACAGTAT TTMATTATAT CATGATGTCT TTGAGGTTG 399 INFORMATION FOR SEQ ID NO:52: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 392 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: CTTCMACCTC MATCMCCTT GGTMATTGAT AAMATCATCA CTTMACTTTC TGATATAATG GCAATAATTA TCTGAGAAAA AAAAGTGGTG AAAGATTMAA CTTGCATTTC TCTCAGMATC 120 TTGMGGATA TTTGAATAAT TCAAAAGCGG MTCAGTAGT ATCAGCCGMA GMAACTCACT 180 TAGCTAGAAC GTTGGACCCA TGGATCTMAG TCCCTGCCCT TCCACTMACC AGCTGATTGG 240 TTMTGTGTAA ACCTCCTACA CGCTTGGGCT TGGTCGCCTC ATMTGTCAAA GTAAAGGCTG 300 79 AAATAGGAAG ATAATGAACC GTGTCTTTTT GGTCTCTTTT CCATCCATTA CTCTGATTTT 360 ACAAAGAGGC CTGTATTCCC CTGGTGAGGT TG 392 INFORMATION FOR SEQ ID NO:53: SEQUENCE CHARACTERISTICS: LENGTH: 179 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: TTCGGGTGAT GCCTCCTCAG GCTACAGTGA AGACTGGATT ACAGAAAGGT GCCAGCGAGA TTTCAGATTC CTGTAAACCT CTAAAGAAAA GGAGTCGCGC CTCAACTGAT GTAGAAATGA 120 CTAGTTCAGC ATACNGAGAC ACNTCTGACT CCGATTCTAG AGGACTGAGT GACCTGCAN 179 INFORMATION FOR SEQ ID NO:54: SEQUENCE CHARACTERISTICS: LENGTH: 112 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: TTCGGGTGAT GCCTCCTCAG GCTACATCAT NATAGAAGCA AAGTAGAANA ATCNNGTTTG TGCATTTTCC CACANACAAA ATTCAAATGA NTGGAAGAAA TTGGGANAGT AT 112 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 225 base pairs TYPE: nucleic acid 0 STRANDEDNESS: single TOPOLOGY: linear S(xi) SEQUENCE DESCRIPTION: SEQ ID TGAGCTTCCG CTTCTGACAA CTCAATAGAT AATCAAAGGA CAACTTTAAC AGGGATTCAC AAAGGAGTAT ATCCAAATGC CAATAAACAT ATAAAAAGGA ATTCAGCTTC ATCATCATCA 120 GAAGWATGCA AATTAAAACC ATAATGAGAA ACCACTATGT CCCACTAGAA TAGATAAAAT 180 CTTAAAAGAC TGGTAAAACC AAGTGTTGGT AAGGCAAGAG GAGCA 225 INFORMATION FOR SEQ ID NO:56: SEQUENCE CHARACTERISTICS: LENGTH: 175 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: GCTCCTCTTG CCTTACCAAC ACATTCTCAA AAACCTGTTA GAGTCCTAAG CATTCTCCTG TTAGTATTGG GATTTTACCC CTGTCCTATA AAGATGTTAT GTACCAAAAA TGAAGTGGAG 120 GGCCATACCC TGAGGGAGGG GAGGGATCTC TAGTGTTGTC AGAAGCGGAA GCTCA 175 INFORMATION FOR SEQ ID NO:57: SEQUENCE CHARACTERISTICS: LENGTH: 223 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear S. (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: AGCCATTTAC CACCCATGGA TGAATGGATT TTGTAATTCT AGCTGTTGTA TTTTGTGAAT TTGTTAATTT TGTTGTTTTT CTGTGAAACA CATACATTGG ATATGGGAGG TAAAGGAGTG 120 TCCCAGTTGC TCCTGGTCAC TCCCTTTATA GCCATTACTG TCTTGTTTCT TGTAACTCAG 180 GTTAGGTTTT GGTCTCTCTT GCTCCACTGC AAAAAAAAAA AAA 223 INFORMATION FOR SEQ ID NO:58: SEQUENCE CHARACTERISTICS: LENGTH: 211 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: GTTCGAAGGT GAACGTGTAG GTAGCGGATC TCACAACTGG GGAACTGTCA AAGACGAATT AACTGACTTG GATCAATCAA ATGTGACTGA GGAAACACCT GAAGGTGAAG AACATCATCC 120 AGTGGCAGAC ACTGAAAATA AGGAGAATGA AGTTGAAGAG GTAAAAGAGG AGGGTCCAAA 180 AGAGATGACT TTGGATGGGT GGTAAATGGC T 211 INFORMATION FOR SEQ ID NO:59: SEQUENCE CHARACTERISTICS: LENGTH: 208 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQUENCE DESCRIPTION: SEQ ID NO:59: GCTCCTCTTG CCTTACCAAC TTTGCACCCA TCATCAACCA TGTGGCCAGG TTTGCAGCCC AGGCTGCACA TCAGGGGACT GCCTCGCAAT ACTTCATGCT GTTGCTGCTG ACTGATGGTG 120 CTGTGACGGA TGTGGAAGCC ACACGTGAGG CTGTGGTGCG TGCCTCGAAC CTGCCCATGT 180 CAGTGATCAT TATGGGTGGT AAATGGCT 208 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 171 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID AGCCATTTAC CACCCATACT AAATTCTAGT TCAAACTCCA ACTTCTTCCA TAAAACATCT AACCACTGAC ACCAGTTGGC AATAGCTTCT TCCTTCTTTA ACCTCTTAGA GTATTTATGG 120 83 TCAATGCCAC ACATTTCTGC AACTGAATAA AGTTGGTAAG GCAAGAGGAG C 171 INFORMATION FOR SEQ ID NO:61: SEQUENCE CHARACTERISTICS: LENGTH: 134 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: CGGGTGATGC CTCCTCAGGC TTTGGTGTGT CCACTCNACT CACTGGCCTC TTCTCCAGCA ACTGGTGAAN ATGTCCTCAN GAAAANCNCC ACACGCNGCT CAGGGTGGGG TGGGAANCAT 120 CANAATCATC NGGC 134 INFORMATION FOR SEQ ID NO:62: SEQUENCE CHARACTERISTICS: LENGTH: 145 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: AGAGGGTACA TATGCAACAG TATATAAAGG AAGAAGTGCA CTGAGAGGAA CTTCATCAAG GCCATTTAAT CAATAAGTGA TAGAGTCAAG GCTCAACCCA GGTGTGACGG ATTCCAGGTC 120 CCAAGCTCCT TACTGGTACC CTCTT 145 84 INFORMATION FOR SEQ ID NO:63: SEQUENCE CHARACTERISTICS: LENGTH: 297 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: TGCACTGAGA GGAATTCAAA GGGTTTATGC CAAAGAACAA ACCAGTCCTC TGCAGCCTAA °ooo* CTCATTTGTT TTTGGGCTGC GAAGCCATGT AGAGGGCGAT CAGGCAGTAG ATGGTCCCTC 120 CCACAGTCAG CGCCATGGTG GTCCGGTAAA GCATTTGGTC AGGCAGGCCT CGTTTCAGGT 180 AGACGGGCAC ACATCAGCTT TCTGGAAAAA CTTTTGTAGC TCTGGAGCTT TGTTTTTCCC 240 AGCATAATCA TACACTGTGG AATCGGAGGT CAGTTTAGTT GGTAAGGCAA GAGGAGC 297 INFORMATION FOR SEQ ID NO:64: SEQUENCE CHARACTERISTICS: LENGTH: 300 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEO ID NO:64: GCACTGAGAG GAACTTCCAA TACTATGTTG AATAGGAGTG GTGAGAGAGG GCATCCTTGT CTTGTGCCGG TTTTCAAAGG GAATGCTTCC AGCTTTTGCC CATTCAGTAT AATATTAAAG 120 AATGTTTTAC CATTTTCTGT CTTGCCTGTT TTTCTGTGTT TTTGTTGGTC TCTTCATTCT 180 CCATTTTTAG GCCTTTACAT GTTAGGAATA TATTTCTTTT AATGATACTT CACCTTTGGT 240 ATCTTTTGTG AGACTCTACT CATAGTGTGA TAAGCACTGG GTTGGTAAGG CAAGAGGAGC 300 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 203 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT 120 CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG 180 TCGATAGAAG TTCCTCTCAG TGC 203 INFORMATION FOR SEQ ID NO:66: SEQUENCE CHARACTERISTICS: LENGTH: 344 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 86 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: TACGGGGACC CCTGCATTGA GAAAGCGAGA CTCACTCTGA AGCTGAAATG CTGTTGCCCT TGCAGTGCTG GTAGCAGGAG TTCTGTGCTT TGTGGGCTMA GGCTCCTGGA TGACCCCTGA 120 CATGGAGAAG GCAGAGTTGT GTGCCCCTTC TCATGGCCTC GTCAAGGCAT CATGGACTGC 180 CACACACAAA ATGCCGTTTT TATTAACGAC ATGAAATTGA AGGAGAGAAC ACAATTCACT 240 GATGTGGCTC GTAACCATGG ATATGGTCAC ATACAGAGGT GTGATTATGT AAAGGTTAAT 30*0 SSTCCACCCACC TCATGTGGAA ACTAGCCTCA ATGCAGGGGT CCCA 344 INFORMATION FOR SEQ ID NO:67: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 157 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: GCACTGAGAG GAACTTCGTA GGGAGGTTGA ACTGGCTGCT GAGGAGGGGG AACAACAGGG TAACCAGACT GATAGCCATT GGATGGATAA TATGGTGGTT GAGGAGGGAC ACTACTTATA 120 GCAGAGGGTT GTGTATAGCC TGAGGAGGCA TCACCCG 157 INFORMATION FOR SEQ ID NO:68: SEQUENCE

CHARACTERISTICS:

LENGTH: 137 base pairs TYPE: nucleic acid 87 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: GCACTGAGAG GAACTTCTAG AAAGTGAAAG TCTAGACATA AAATAAAATA AAAATTTAAA ACTCAGGAGA GACAGCCCAG CACGGTGGCT CACGCCTGTA ATCCCAGAAC TTTGGGAGCC 120 TGAGGAGGCA TCACCCG 137 INFORMATION FOR SEQ ID NO:69: SEQUENCE CHARACTERISTICS: *o S LENGTH: 137 base pairs 4• TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: CGGGTGATGC CTCCTCAGGC TGTATTTTGA AGACTATCGA CTGGACTTCT TATCAACTGA AGAATCCGTT AAAAATACCA GTTGTATTAT TTCTACCTGT CAAAATCCAT TTCAAATGTT 120 GAAGTTCCTC TCAGTGC 137 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 220 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 88 SEQUENCE DESCRIPTION: SEQ ID NO: AGCATGTTGA GCCCAGACAC GCAATCTGAA TGAGTGTGCA CCTCMAGTAA ATGTCTACAC GCTGCCTGGT CTGACATGGC ACACCATCNC GTGGAGGGCA CASCTCTGCT CNGCCTACWA 120 CGAGGGCANT CTCATWGACA GGTTCCACCC ACCAAACTGC AAGAGGCTCA NNMAGTACTR 180 ::.CCAGGGTMYA SGGACMASGG TGGGAYTYCA YCACWCATCT 220 INFORMATION FOR SEQ ID NO:71: SEQUENCE CHARACTERISTICS: LENGTH: 353 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: *CGTTAGGGTC TCTATCCACT GCTAAACCAT ACACCTGGGT AAACAGGGAC CATTTAACAT *TCCCANCTAA ATATGCCAAG TGACTTCACA TGTTTATCTT AAAGATGTCC MAAACGCAAC 120 TGATTTTCTC CCCTAAACCT GTGATGGTGG GATGATTMAN CCTGAGTGGT CTACAGCAAG 180 TTMAGTGCAA GGTGCTAAAT GMANGTGACC TGAGATACAG CATCTACMAG GCAGTACCTC 240 TCAACNCAGG GCAACTTTGC TTCTCANAGG GCATTTAGCA GTGTCTGPAG TAATTTCTGT 300 ATTACAACTC ACGGGGCGGG GGGTGMATAT CTANTGGANA GNAGACCCTA ACG 353 INFORMATION FOR SEQ ID NO:72: 89 SEQUENCE CHARACTERISTICS: LENGTH: 343 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: GCACTGAGAG GAACTTCCAA TACYATKATC AGAGTGAACA RGCARCCYAC AGAACAGGAG :AAAATGTTYG CAATCTCTCC ATCTGACAAA AGGCTAATAT CCAGAWTCTA AWAGGAACTT 120 AAACATTT ATGAGAAAAG AACARACAAC CTCAWCAAAA AGTGGGTGAA GGAWATGCTS 180 AAARGAAGAC ATYTATTCAG CCAGTAAACA YATGAAAAAA AGGCTCATSA TCACTGAWCA 240 TTAGAGAAAT GCAAATCAAA ACCACAATGA GATACCATCT YAYRCCAGTT AGAAYGGTGA 300 TCATTAAAAR STCAGGAAAC AACAGATGCT GGACAAGGTG TCA 343 *T INFORMATION FOR SEQ ID NO:73: SEQUENCE CHARACTERISTICS: LENGTH: 321 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC AGAAGGTGAG AAAGTCTTTG GTTCTGAAGC AGCTTCTAAG ATCTTTTCAT TTGCTTCATT 120 TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG 180 ATAACTCATT TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCTT AAAAAGGTGG 240 CTTGAGTTCA GCCTTMATA CCATCTTGAA ATGACACAGA GAAAGMANGA TGTTGGGTGG 300 GAGTGGATAG AGACCCTAAC G 321 INFORMATION FOR SEQ ID NO:74: SEQUENCE CHARACTERISTICS: LENGTH: 321 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: *GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC *.AGAAGGTGAG AAAGTCTTTG GTTCTGMAGC AGCTTCTAAG ATCTTTTCAT TTGCTTCATT 120 TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG 180 ATAACTCATT TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCTT AAAAAGGTGG 240 C1TGAGTTCA GYCTTAAATA CCATCTTGMA ATGAMACAGA GAAAGAAGGA TGTTGGGTGG 300 GAGTGGATAG AGACCCTMAC G 321 INFORMATION FOR SEQ 10 Ci) SEQUENCE

CHARACTERISTICS:

LENGTH: 317 base pairs.

TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCACTGAGAG GAACTTCCAC ATGCACTGAG AAATGCATGT TCACAAGGAC TGAAGTCTGG MCTCAGTT CTCAGTTCCA ATCCTGATTC AGGTG1TTAC CAGGTACACA ACCTTMAGCA 120 AGTCAGATAA CCTTAGCTTC CTCATATGCA AAATGAGAAT GPAAAGTACT CATCGCTGAA 180 TTGTTTTGAG GATTAGAAAA ACATCTGGCA TGCAGTAGAA ATTCAATTAG TATTCATTTT 240 CATTCTTCTA AATTAAACAA ATAGGATTTT TAGTGGTGGA AC1TCAGACA CCAGAAATGG 300 GAGTGGATAG AGACCCT 317 INFORMATION FOR SEQ ID NO:76: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 244 base pairs TYPE: nucleic acid STRANDEDNES: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: CGTTAGGGTC TCTATCCACT CCCACTACTG ATCAAACTCT ATTATTTAA TTATTTTTAT CATACTTTMA GTTCTGGGAT ACACGTGCAG CATGCGCAGG TTTGTTGCAT AGGTATACAC 120 TTGCCATGGT GGTTTGCTGC ACCCATCAGT CCATCATCTA CATTAGGTAT TTCTCCTAAT 180 GCTATCCCTC CCCTAGCCCC TTACACCCCC AACAGGCTCT AGTGTGTGAA GTTCCTCTCA 240

GTGC

244 INFORMATION FOR SEQ ID NO:77: SEQUENCE CHARACTERISTICS: LENGTH: 254 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear *GTGC 254 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:77: CGTTAGGGTC TCTATCCACT GAAATCTGAA GCACAGGAGG AAGAGAAGCAGTYCTAGTGA GATGGCAAGT TCWTTTACCA CACTCTTTAA CATTTYGTTT AGTTTTAACC TTTATTTATG 120 GATAATAAAG GTTAATATTA ATAATGATTT ATTTTAAGGC ATTCCCRAAT TTGCATAATT 180 CTCCTTTTGG AGATACCCTT TTATCTCCAG TGCAAGTCTG GATCAAAGTG ATASAMAGAA 240 GTTCCTCTCA

GTGC

254 INFORMATION FOR SEQ ID N0:78: SEQUENCE CHARACTERISTICS: LENGTH: 355 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: TTCGATACAG GCAAACATGA ACTGCAGGAG GGTGGTGACG ATCATGATGT TGCCGATGGT CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTTITGCTC TGTTGATGGC 120 CCTGAGGGGA CGCAGGACCC TTATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG 180 ATTGANTCCC ANTGACACCA GAGACACCCC AACCACCAGN ATATCANTAT ATTGATGTAG 240 TTCCTGTAGA NGGCCCCCTT GTGGAGGAAA GCTCCATNAG TTGGTCATCT TCAACAGGAT 300 CTCAACAGTT TCCGATGGCT GTGATGGGCA TAGTCATANT TMACCNTGTN TCGAA 355 INFORMATION FOR SEQ ID NO:79: Ci) SEQUENCE

CHARACTERISTICS:

LENGTH: 406 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:79: *TAAGAGGGTA CCAGCAGAAA GGTTAGTATC ATCAGATAGC ATCTTATACG AGTMTATGC CTGCTATTTG AAGTGTMATT GAGAAGGAMA ATTTTAGCGT GCTCACTGAC CTGCCTGTAG 120 CCCCAGTGAC AGCTAGGATG TGCATTCTCC AGCCATCAAG AGACTGAGTC AAGTTGTTCC 180 TTMAGTCAGA ACAGCAGACT CAGCTCTGAC ATTCTGATTC GAATGACACT GTTCAGGAAT 240 CGGAATCCTG TCGATTAGAC TGGACAGCTT GTGGCMAGTG AATTTGCCTG TAACAAGCCA 300 GATFTfTTMA MTTTATATT GTMATAATG TGTGTGTGTG TGTGTGTATA TATATATATA 360 TGTACAGTTA TCTMAGTTMA TTTAAAAGTT GTTGGTACC CTCTTA 406 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 327 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TTTTTTTTTT TTTACTCGGC TCAGTCTAAT CCTTTTTGTA GTCACTCATA GGCCAGACTT AGGGCTAGGA TGATGATTAA TAAGAGGGAT GACATAACTA TTAGTGGCAG GTTAGTTGTT 120 TGTAGGGCTC ATGGTAGGGG TAAAAGGAGG GCAATTTCTA GATCAAATAA TAAGAAGGTA 180 ATAGCTACTA AGAAGAATTT TATGGAGAAA GGGACGCGGG CGGGGGATAT AGGGTCGAAG 240 CCGCACTCGT AAGGGGTGGA TTTTTCTATG TAGCCGTTGA GTTGTGGTAG TCAAAATGTA 300 ATAATTATTA GTAGTAAGCC TAGGAGA 327 INFORMATION FOR SEQ ID NO:81: SEQUENCE CHARACTERISTICS: LENGTH: 318 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: TAGTCTATGC GGTTGATTCG GCAATCCATT ATTTGCTGGA TTTTGTCATG TGTTTTGCCA ATTGCATTCA TAATTTATTA TGCATTATG CTTGTATCTC CTMAGTCATG

GTATATAATC

CATGCTTTTT ATGTTTTGTC TGACATAAAC TCTTATCAGA GCCCTTTGCA

CACAGGGATT

CAATAAATAT TAACACAGTC TACATTTATT TGGTGMATAT TGCATATCTG

CTGTACTGAA

AGCACATTAA GTAACAAAGG CAAGTGAGAA GAATGMAAAG CACTACTCAC

MACAGTTATC

ATGATTGCGC

ATAGACTA

INFORMATION FOR SEQ ID NO:82: SEQUENCE CHARACTERISTICS: LENGTH: 338 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 9 9 9**9 9 9**9 9.

9 9 999999 9 9 99.999 99 9 9.9.

.9.9 120 180 240 300 318 120 180 240 300 338 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: TCTTCAACCT CTACTCCCAC TMATAGCTTT TTGATGACTT CTAGCAAGCC TCGCTMACCT CGCCTTACCC CCCACTATTA ACCTACTGGG AGMACTCTCT GTGCTAGTAA CCACGTTCTC CTGATCAMAT ATCACTCTCC TACTTACAGG ACTCAACATA CTAGTCACAG

CCCTATACTC

CCTCTACATA TMTACCACMA CACMATGGGG CTCACTCACC CACCACATTA ACAACATAAA ACCCTCATTC ACACGAGAAA ACACCCTCAT GTTCATACAC CTATCCCCCA TTCTCCTCCT ATCCCTCAAC CCCGACATCA TTACCGGGTT TTCCTCTT INFORMATION FOR SEQ ID NO:83: SEQUENCE CHARACTERISTICS: LENGTH: 111 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA to ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G 111 INFORMATION FOR SEQ ID NO:84: :00*0 SEQUENCE CHARACTERISTICS: LENGTH: 224 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 0 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: 0 TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATTTCCAAA AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGTTCCGA AGGGTCAGGG AGGAGGAAAT 120 TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA 180 CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC 224 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 348 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID GCACTGAGAG GAACTTCGTT GGAAACGGGT TFFFTrCATG TAAGGCTAGA CAGAAGMATT CTCAGTAACT TCCTTGTGTT GTGTGTATTC AACTCACASA GTTGAACGAT CCTTACACA 120 :GAGCAGACTT GTAACACTCT TWTTGTGGMA TTTGCMAGTG GAGATTTCAG SCGCTTTGAA 180 GTSAAAGGTA GAAAAGGAMA TATCTTCCTA TAAAAACTAG ACAGAATGAT TCTCAGAAAC 240 TCCTTTGTGA TGTGTGCGTT CAACTCACAG AGTTAACCT TTCWTTTCAT AGAAGCAGTT 300 AGGAAACACT CTGTTTGTMA AGTCTGCAAG TGGATAGAGA CCCTAACG 348 INFORMATION FOR SEQ ID NO:86: SEQUENCE CHARACTERISTICS: LENGTH: 293 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: GCACTGAGAG GMACTTCYTT GTGWTGTKTG YATTCMACTC ACAGAGTTGA ASSWTSHTT ACABAGWKCA GGCTTKCAAA CACTCTTTT GTMGAATYTG CAAGWGGAKA TTTSRRCCRC 120 TTTGWGGYCW WYSKTMGMAW MGGRWATATC TTCWYATMRA AMCTAGACAG MAKSATTCTC 180 98 AKAAWSTYYY YTGTGAWGWS TGCRTTCAAC TCACAGAGKT KAACMWTYCT KYTSATRGAG 240 CAGTTWKGAA ACTCTMTTTC TTTGGATTCT GCAAGTGGAT AGAGACCCTA ACG 293 INFORMATION FOR SEQ ID NO:87: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

CTCCTAGGCT

INFORMATION FOR SEQ ID NO:88: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs S* TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

AGTAGTTGCC

INFORMATION FOR SEQ ID NO:89: SEQUENCE CHARACTERISTICS: LENGTH: 11 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: TTCCGTTATG C INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TGGTAAAGGG INFORMATION FOR SEQ ID NO:91: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: TCGGTCATAG INFORMATION FOR SEQ ID NO:92: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

TACAACGAGG

INFORMATION FOR SEQ ID NO:93: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

TGGATTGGTC

INFORMATION FOR SEQ ID NO:94: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

CTTTCTACCC

101 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TTTTGGCTCC INFORMATION FOR SEQ ID NO:96: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: GGAACCAATC INFORMATION FOR SEQ ID NO:97: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: 102

TCGATACAGG

INFORMATION FOR SEQ ID NO:98: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

GGTACTAAGG

INFORMATION FOR SEQ ID NO:99: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs S(B) TYPE: nucleic acid S(C) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: AGTCTATGCG INFORMATION FOR SEQ ID NO:100: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 103 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

CTATCCATGG

INFORMATION FOR SEQ ID NO:101:.

SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: TCTGTCCACA INFORMATION FOR SEQ ID NO:102: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102: AAGAGGGTAC INFORMATION FOR SEQ ID NO:103: SEQUENCE CHARACTERISTICS: LENGTH: 10 base pairs 104 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

CTTCAACCTC

INFORMATION FOR SEQ ID NO:104: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQUENCE DESCRIPTION: SEQ ID NO:104: GCTCCTCTTG CCTTACCAAC INFORMATION FOR SEQ ID NO:105: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: GTAAGTCGAG CAGTGTGATG INFORMATION FOR SEQ ID NO:106: 105 SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: GTAAGTCGAG CAGTCTGATG INFORMATION FOR SEQ ID NO:107: SEQUENCE

CHARACTERISTICS:

LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: GACTTAGTGG AAAGAATGTA INFORMATION FOR SEQ ID NO:108: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108: 106 GTAATTCCGC

CAACCGTAGT

INFORMATION FOR SEQ ID NO:109: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109: ATGGTTGATC

GATAGTGGAA

*2 INFORMATION FOR SEQ ID NO:110: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110: ACGGGGACCC CTGCATTGAG INFORMATION FOR SEQ ID NO:111: SEQUENCE

CHARACTERISTICS:

LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 107 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111: TATTCTAGAC CATTCGCTAC INFORMATION FOR SEQ ID NO:112: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112: ACATAACCAC TTTAGCGTTC INFORMATION FOR SEQ ID NO:113: a SEQUENCE CHARACTERISTICS: 0* 0* LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113: CGGGTGATGC CTCCTCAGGC INFORMATION FOR SEQ ID NO:114: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid 108 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: AGCATGTTGA GCCCAGACAC INFORMATION FOR SEQ ID NO:115: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs o* TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: GACACCTTGT CCAGCATCTG INFORMATION FOR SEQ ID NO:116: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116: TACGCTGCAA CACTGTGGAG 20(2) INFORMATION FOR SEQ ID N117 INFORMATION FOR SEQ ID NO:117: 109 SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117: CGTTAGGGTC TCTATCCACT INFORMATION FOR SEQ ID NO:118: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEO ID NO:118: AGACTGACTC ATGTCCCCTA INFORMATION FOR SEQ ID NO:119: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119: TCATCGCTCG GTGACTCAAG in 110 INFORMATION FOR SEQ ID NO:120: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120: CAAGATTCCA TAGGCTGACC INFORMATION FOR SEQ ID NO:121: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121: ACGTACTGGT

CTTGAAGGTC

INFORMATION FOR SEQ ID NO:122: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear Ill (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122: GACGCTTGGC CACTTGACAC INFORMATION FOR SEQ ID NO:123: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123: GTATCGACGT AGTGGTCTCC INFORMATION FOR SEQ ID NO:124: o SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: TAGTGACATT ACGACGCTGG INFORMATION FOR SEQ ID NO:125: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single 112 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: CGGGTGATGC CTCCTCAGGC INFORMATION FOR SEQ ID NO:126: SEQUENCE CHARACTERISTICS: LENGTH: 23 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126: ATGGCTATTT TCGGGGGCTG ACA 23 INFORMATION FOR SEQ ID NO:127: SEQUENCE CHARACTERISTICS: LENGTH: 22 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127: CCGGTATCTC CTCGTGGGTA TT 22 INFORMATION FOR SEQ ID NO:128: SEQUENCE CHARACTERISTICS: 113 LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: CTGCCTGAGC CACAAATG 18 INFORMATION FOR SEQ ID NO:129: SEQUENCE CHARACTERISTICS: LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: CCGGAGGAGG AAGCTAGAGG AATA 24 INFORMATION FOR SEQ ID NO:130: SEQUENCE CHARACTERISTICS: LENGTH: 14 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130: T1I 1 1 11 TTAG 114 INFORMATION FOR SEQ ID NO:131: SEQUENCE CHARACTERISTICS: LENGTH: 18 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131: Ser Ser Gly Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val 1 5 10 Gly Ile INFORMATION FOR SEQ ID NO:132: SEQUENCE CHARACTERISTICS: LENGTH: 22 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132: Gln Gly Ala Ala Gin Lys Pro lle Asn Leu Ser Lys Xaa Ile Glu Val 1 5 10 Val Gin Gly His Asp Glu INFORMATION FOR SEQ ID NO:133: 115 SEQUENCE CHARACTERISTICS: LENGTH: 23 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133: Ser Pro Gly Val Phe Leu Glu His Leu Gin Glu Ala Tyr Arg Ile Tyr 1 5 10 Thr Pro Phe Asp Leu Ser Ala INFORMATION FOR SEQ ID NO:134: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134: Tyr Leu Leu Val Gly Ile Gin Gly Ala 1 INFORMATION FOR SEQ ID NO:135: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear 116 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135: Gly Ala Ala Gin Lys Pro Ile Asn Leu 1 INFORMATION FOR SEQ ID NO:136: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single S. TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136: Asn Leu Ser Lys Xaa Ile Glu Val Val 1 INFORMATION FOR SEQ ID NO:137: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137: Glu Val Val Gin Gly His Asp Glu Ser 1 INFORMATION FOR SEQ ID NO:138: 117 SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138: His Leu Gin Glu Ala Tyr Arg Ile Tyr 1 INFORMATION FOR SEQ ID NO:139: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139: .m •Asn Leu Ala Phe Val Ala Gin Ala Ala 1 INFORMATION FOR SEQ ID NO:140: SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear 118 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140: Phe Val Ala Gin Ala Ala Pro Asp Ser 1 INFORMATION FOR SEQ ID NO:141: SEQUENCE CHARACTERISTICS: LENGTH: 9388 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141: GCTCGCGGCC GCGAGCTCAA TTAACCCTCA CTAAAGGGAG TCGACTCGAT CAGACTGTTA CTGTGTCTAT GTAGAAAGAA GTAGACATAA GAGATTCCAT 1TTGTTCTGT ACTAAGAAA 120 ATTCTTCTGC CTTGAGATGC TGTTMTCTG TAACCCTAGC CCCAACCCTG TGCTCACAGA 180 GACATGTGCT GTGTTGACTC AAGGTTCAAT GGATTTAGGG CTATGCTTTG TTAAAAAAGT 240 GCTTGAAGAT AATATGCTTG TTAAAAGTCA TCACCATTCT CTAATCTCAA GTACCCAGGG 300 ACACAATACA CTGCGGAAGG CCGCAGGGAC CTCTGTCTAG GAAAGCCAGG TATTGTCCAA 360 GATTTCTCCC CATGTGATAG CCTGAGATAT GGCCTCATGG GAAGGGTAAG ACCTGACTGT 420 CCCCCAGCCC GACATCCCCC AGCCCGACAT CCCCCAGCCC GACACCCGAA AAGGGTCTGT 480 GCTGAGGAGG ATTAGTAAAA GAGGAAGGCC TCTTTGCAGT TGAGGTAAGA GGAAGGCATC 540 TGTCTCCTGC TCGTCCCTGG GCAATAGAAT GTCTTGGTGT AAAACCCGAT TGTATGTTCT 600 ACTTACTGAG ATAGGAGA CTGCTCTTTA ATGCACCG~ TMAACTTATT TATGACACj ATTACCCTAT TGGCCTGC( TACTGAGGGA ACTCAGAGA CTTGGGCTCA CTTTCTT TCGTTCCACC TGACGAGAAj TTACTAGCCT GTTCGCTGA( CCGGGTGGCA GGCATGGGCC MAGTGCAGGA AACAGCACCA TTCCAGCGCA AAAATGCGCA CACTTCTTAT TGGCTMATGT TTTGAGGCT6 ACTGAGCGCG AGTMACATCT GATCACGTTT CGGMAGCCTG GCGCMAGGTT GTCCTCAGTC TTGGGCTATT CAGCGTGGAG TCCTGGCCTT AACTGGGACT CAGGCTGCCC AACATCCTTAG GGCTGGAGGT GAGACACGCT AG ATGTTTGTAT MGTGCACAT CAAGGCACAG kG AGACCTTTGT TCACGTTTTC CTGCTGACCC ;A CATCCCCCTC TCCGAGATGG TAGAGATMAT C CAGTGTCCCT GTAGGTCCTC CGTGTGCTGA C TCTATACTT GTCTCTGTGT CTCTTTCTT STACCCACAGG TGTGGAGGGG CAGGCCACCC C MACAAGACTG GTGGTGCAGA AGGTTGGGTCT AGGTGGGAGG GTCTCCAGCG CCTGGTGCMA A AGGGTGATTG TAAATTTTGA TTTGGCGCGG C, GGAAAGCTTT TGCTGTGCTT GTAGGCAGGT A GGAGGGMACC TGCACATCCA TTGGCTGAAA T( TTCCTTTCTT CTGTGTTGCC TGGAAACGGA CT CCCATTGGCC GCCGTTTCCG GAAGCCCGCC CT GGTCTGCAGG TGGCCTCCAG GTGCMAAGTG GG CGGCCACGTG CCTGCCGGAC ATGGGACGCT GG, TTGCGTCCAC GGGTGGGAAA TTGGCCATTG CM CCCGGCCGTT TCTCATCCGT CCACCGGACT CG1

GGCGGCAATA

CACCTTTCCT

TCTCCCCACT

GATCAATAAA

GCGCCGGTCC

FCTCAGTCTC

:TTCAATAAT

TGGTGTTCA

TCTCCMAGA

AGGTAGCCA

~GCCCCAAG

;TCCGTCTA

GTCTGCCT

CCCATTTC

AAGTGTGA

AGGGTCAG

\CGGCGGG

'GGGCGCT

660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 120 CGCACTGGCG CTGATGTAGT TTCCTGACCT CTGACCCGTA TTGTCTCCAG ATTAMAGGTA 1740 AAAACGGGGC TTTTCAGCC CACTCGGGTA AAACGCCTT TGATTCTAG GCAGGTGTTT 1800 TGTTGCACGC CTGGGAGGGA GTGACCCGCA GGTTGAGGTT TATTAAAATA CATTCCTGGT 1860 TTATGTTATG TTTATMATAA AGCACCCCAA CCTTTACAAA ATCTCACTTT TTGCCAGTTG 1920 TATTATTTAG TGGACTGTCT CTGATAAGGA CAGCCAGTTA AAATGGAATT TTGTTGTTGC 1980 TAATTAMACC AATTTTAGT TTGGTGTTT GTCCTMATAG CAACAACTTC TCAGGCTTTA 2040 *TAAAACCATA MTTCTTGGGG GAAMCTG TGTMAGGCAC AGCGAGTTAG TTTGGMATTG 2100a *TTTTAAAGGA AGTAAGTTCC TGGTTTTGAT ATCTTAGTAG TGTAATGCCC MCCTGGTTT 2160 *TTACTAACCC TGTTTTTAGA CTCTCCCTTT CCTTAAATCA CCTAGCCTTG TTCCACCTG 2220 MTTGACTCT CCCTTAGCTA AGAGCGCCAG ATGGACTCCA TCTTGGCTCT TTCACTGGCA 2280 GCCCCTTCCT CAAGGACTTA ACTTGTGCAA GCTGACTCCC AGCACATCCA AGAATGCAAT 2340 *TMACTGTTAA GATACTGTGG CMCGCTATAT CCGCAGTTCC GAGGAATTCA TCCGATTGAT 2400 .TATGCCCMAA AGCCCCGCGT CTATCACCTT GTMATMTCT TAAAGCCCCT GCACCTGGAA 2460 CTATTAACTT TCCTGTAACC A1TATCCTT TTAACTTJ TGCTTACTT ATTTGTGTAA 2520 MTTGTTTTA ACTAGACCTC CCCTCCCCTT TCTPAACCAA AGTATMAAAG MAGATCTAGC 2580 CCCTTCTTCA GAGCGGAGAG AATTTTGAGC ATTAGCCATC TCTTGGCGGC CAGCTMAATA 2640 MTGGACTTT TMATTTGTCT CAAAGTGTGG CGT1TfCTCT AACTCGCTCA GGTACGACAT 2700 TTGGAGGCCC CAGCGAGAMA CGTCACCGGG AGAAACGTCA CCGGGCGAGA GCCGGGCCCG 2760 121 CTGTGTGCTC CCCCGGMAGG ACAGCCAGCT TGTAGGGGGG AGTGCCACCT GAAAAAAA 2820 TTTCCAGGTC CCCAAAGGGT GACCGTCTTC CGGAGGACAG CGGATCGACT ACCATGCGGG 2880 TGCCCACCMA AATTCCACCT CTGAGTCCTC AACTGCTGAC CCCGGGGTCA GGTAGGTCAG 2940 ATTTGACTTT GGTTCTGGCA GAGGGAAGCG ACCCTGATGA GGGTGTCCCT CTTTTGACTC 3000 TGCCCATTTC TCTAGGATGC TAGAGGGTAG AGCCCTGGTT TTCTGTTAGA CGCCTCTGTG 3060 TCTCTGTCTG GGAGGGMAGT GGCCCTGACA GGGGCCATCC CTTGAGTCAG TCCACATCCC 3120 *AGGATGCTGG GGGACTGAGT CCTGGTTTCT GGCAGACTGG TCTCTCTCTC TCTCTTTTTC 3180 SSTATCTCTMAT CTTTCCTTGT TCAGGTTCT TGGAGMATCT CTGGGMAAGA AAMAGAAAA 3240 ACTGTTATMA ACTCTGTGTG AATGGTGMAT GMTGGGGGA GGACAAGGGC TTGCGCTTGT 3300 CCTCCAGTTT GTAGCTCCAC GGCGAAAGCT ACGGAGTTCA AGTGGGCCCT CACCTGCGGT 3360 TCCGTGGCGA CCTCATMAGG CTTMAGGCAG CATCCGGCAT AGCTCGATCC GAGCCGGGGG 3420 TTTATACCGG CCTGTCAATG CTMAGAGGAG CCCAAGTCCC CTAAGGGGGA GCGGCCAGGC 3480 GGGCATCTGA CTGATCCCAT CACGGGACCC CCTCCCCTTG TTGTCTAAA AAAAAAAAMA 3540 GAAGAAACTG TCATAACTGT TTACATGCCC TAGGGTCMAC TGTTGTTTT ATGTTATTG 3600 TTCTGTTCGG TGTCTATTGT CTTGTTTAGT GGTTGTCMAG G]TFVGCATG TCAGGACGTC 3660 GATATTGCCC MGACGTCTG GGTMAGAACT TCTGCMAGGT CCTTAGTGCT GATTTTTGT 3720 CACAGGAGGT TMATTTCTC ATCMATCATT TAGGCTGGCC ACCACAGTCC TGTCTTTCT 3780 GCCAGMAGCA AGTCAGGTGT TGTTACGGGA ATGAGTGTMA AAAAAGATTC GCCTGATTGG 3840 122 GATTTCTGGt ACCATGATGG TTGTATTAG ATTGTCATAC CCCACATCCA GGTTGATTGG 3900 ACCTCCTCTA MACTAAACTG GTGGTGGGTT CAAAACAGCC ACCCTGCAGA TTTCCTTGCT 3960 CACCTCTTTG GTCATTCTGT AACTTTCCT GTGCCCT-TAA ATAGCACACT GTGTAGGGAA 4020 ACCTACCCTC GTACTGCTTT ACTTCGTTTA GATTCTTACT GTGTTCCTCT GTGGCTACTC 4080 TCCCATCTTA AAAACGATCC AAGTGGTCCT MTCCTCCTC CCTGCCCCCT ACCCCACACA 4140 TCTCGTTTTC CAGTGCGACA GCAAGTTCAG CGTCTCCAGG ACTTGGCTCT GCTCTCACTC 4200 CTTGAACCCT TAAAIXGAAAA AGCTGGGTT GAGCTATTG CCTTTGAGTC ATGGAGACAC 4260 ***AMAAGGTATT TAGGGTACAG ATCTAGAAGA AGAGAGAGAA CACCTAGATC CAACTGACCC 4320 AGGAGATCTC GGGCTGGCCT CTAGTCCTCC TCCCTCAATC TTAAAGCTAC AGTGATGTGG 4380 CAAGTGGTAT TTAGCTGTTG TGGTT11CT GCTCTTTCTG GTCATGTTGA TTCTGTTCTT 4440 *TCGATACTCC AGCCCCCCAG GGAGTGAGTT TCTCTGTCTG TGCTGGGTT GATATCTATG 4500 TTCAAATCTT ATTAMATTGC CTTCMAAAAA AAAAAAAAA GGGAMACACT TCCTCCCAGC 4560 CTTGTAAGGG, TTGGAGCCCT CTCCAGTATA TGCTGCAGAA TTTTTCTCTC GGTTCTCAG 4620 AGGATTATGG AGTCCGCCTT AMAAAGGCA AGCTCTGGAC ACTCTGCAAA GTAGAATGGC 4680 CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGAA CCTCACAATT GTTCAAGCTG 4740 TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA GTTTCCCTAC ATTGATCAAT 4800 GGCTGAGTTT GGTCAGGAGC ACCCCTTCCA TGGCTCCACT CATGCACCAT TCATMTFTr 4860 ACCTCCAAGG TCCTCCTGAG CCAGACCGTG TTTCGCCTC GACCCTCAGC CGGTTCAGCT 4920 123 CGCCCTGTAC TGCCTCTCTC TGMAGAAGAG GAGAGTCTCC CTCACCCAGT CCCACCGCCT 4980 TAAMACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT CGGCTATGTC CCCTGTAGGC 5040 TCATCACCCA TTGCCTCTTG GTTGCAACCG TGGTGGGAGG MGTAGCCCC TCTACTACCA 5100 CTGAGAGAGG CACMAGTCCC TCTGGGTGAT GAGTGCTCCA CCCCCTTCCT GGTTTATGTC 5160 CCTTCTTTCT ACTTCTGACT TGTATMATTG GAAAACCCAT MTCCTCCCT TCTCTGAAAA 5220 GCCCCAGGCT TTGACCTCAC TGATGGAGTC TGTACTCTGG ACACATTGGC CCACCTGGGA 5280 0*TGACTGTCMA CAGCTCCTTT TGACCCTTTT CACCTCTGAA GAGAGGGAAA GTATCCAAAG 5340 :AGAGGCCAAA AAGTACAACC TCACATCMAC CMATAGGCCG GAGGAGGAAG CTAGAGGAAT 5400 AGTGATTAGA GACCCAATTG GGACCTMATT GGGACCCMAA TTCTCMAGT GGAGGGAGMA 5460 CTTTGACGA TTCCACCGG TATCTCCTCG TGGGTATTCA GGGAGCTGCT CAGAMACCTA 5520

S

005 TAAACTTGTC TAAGGCGACT GMAGTCGTCC AGGGGCATGA TGAGTCACCA GGAGTG1TTT 5580 00S TAGAGCACCT CCAGGAGGCT TATCGGATTT ACACCCCTTT TGACCTGGCA GCCCCCGAAA 5640 Goee 0 0 *0 0 ATAGCCATGC TCTTAMG GCATTTGTGG CTCAGGCAGC CCCAGATAGT MAAAGGAAAC 5700

SOSO

TCCAAAAACT AGAGGGATT TGCTGGAATG AATACCAGTC AGCTTTTAGA GATAGCCTMA 5760 MAGGT1TTTG ACAGTCMAGA GGTTGAAAAA CAMAACAAG CAGCTCAGGC AGCTGAMAAA 5820 AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT TAGATCAGCC TCATMTGACT 5880 TCCCCTCCCA CATGGTGTT AAATCCAGCT ACACTACTTC CTGACTCAAA CTCCACTATT 5940 CCTGTTCATG ACTGTCAGGA ACTGTTGGMA ACTACTGAAA CTGGCCGACC TGATCTTCMA 6000 124 AATGTGCCCC TAGGAMCGGT GGATGCCACC GTGTTCACAG ACAGTAGCAG CTTCCTCGAG 6060 MAGGGACTAC GAMAGGCCGG TGCAGCTGTT ACCATGGAGA CAGATGTGTT GTGGGCTCAG 6120 GCTTTACCAG CAAACACCTC AGCACAAAAG GCTGMATTGA TCGCCCTCAC TCAGGCTCTC 6180 CGATGGGGTA AGGATATTMA CGTTAACACT GACAGCAGf3T ACGCCTTGC TACTGTGCAT 6240 GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT CAGCAGGTGG CTGTMATCCA 6300 :CTGTAAAGGA CATCPAAAGG AAMACACGGC TGTTGCCCGT GGTMACCAGA AAGCTGATTC 6360 AGCAGCTCAA GATGCAGTGT GACTT-TCAGT CACGCCTCTA MACTTGCTGC CCACAGTCTC 6420 CTTTCCACAG CCAGATCTGC CTGACMATCC CGCATACTCA ACAGAAGAAG AAMACTGGCC 6480 TCAGMACTCA GAGCCAATAA AMATCAGGAA GGTTGGTGGA TTCTTCCTGA CTCTAGAATC 6540 TTCATACCCC GMACTCTTGG GAAAACTTA ATCAGTCACC TACAGTCTAC CACCCATTTA 6600 GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCGGTTTTA AGATCCCCCA TCTTCAAAGC 6660 CTMCAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC CAAAAAAGGT 6720 a...CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA GTGGGAAATT 6780 GACTTTACAG MAGTAAAACC ACACCGGGCT GGGTACAMAT ACCTTCTAGT ACTGGTAGAC 6840 ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCAA TATGGTAGTT 6900 MGTTTTAC TCMATGMAAT CATCCCTCGA CGTGGGCTGC CTGTTGCCAT AGGGTCTGAT 6960 AATGGACCGG CCTTCGCCTT GTCTATAGTT TAGTCAGTCA GTAAGGCGTT AAACATTCAA 7020 TGGMAGCTCC AT-TGTGCCTA TCGACCCCAG AGCTCTGGGG AAGTAGAACG CATGMACTGC 7080 ACCCTAAAMA ACACTCTTAC MAAATTMATC TTAGAAACCG GTGTAMATTG TGTMAGTCTC CTTCCTTTAG CCCTACTTAG AGTAAGGTGC ACCCCTTACT GGGCTGGGTT CTTACCTTT GAAATCATGT ATGGGAGGGC GCTGCCTATC TTGCCTMAGC TMAGAGATGC GCAATTGGCA MAAATATCAC AAACTAM ATTACAGTAC CTACAGTCTC CCCMACAGGT ACMGATATC ATCCTGCCAC TTGTTCGAGG AACCCATCCC MATCCMITTC CTGMCAGAC AGGGCCCTGC CATTCATTCC CGCCAGGTGA CCTGTTGTTT GTTAAAAAGT TCCAGAGAGA AGGACTCCCT CCTGCTTGGA AGAGACCTCA CACCGTCATC ACGATGCCAA CGGCTCTGAA GGTGGATGGC ATTCCTGCGT GGATTCATCA CTCCCGCATC AAAAAGGCCA ACGGAGCCCA ACTAGAAACA TGGGTCCCCA GGGCTGGGTC AGGCCCCTTA AAACTGCACC TMAGTTGGGT GMAGCCATTA GATTAATTCT TTTTCTTMAT TTTGTAAMAC AATGCATAGC TTCTGTCAAA CTTATGTATC TTMAGACTCA ATATMACCCC CTTGTTATMA CTGAGGAATC AATGATTTGA TTCCCCAAAA ACACMAGTGG GGAATGTAGT GTCCMACCTG GTFTTACTA ACCCTGTTTT TAGACTCTCC CTTTCCTTTA ATCACTCAGC CTTG1M CCA CCTGAATTGA CTCTCCCTTA GCTAAGAGCG CCAGATGGAC TCCATCTTGG CTCTTCACT GGCAGCCGCT TCCTCAAGGA CTTMCTTGT GCAAGCTGAC TCCCAGCACA TCCMAGAATG CPATTAACTG ATMAGATACT GTGGCMAGCT ATATCCGCAG TTCCCAGGAA TTCGTCCAAT TGATTACACC CAMAAGCCCC GCGTCTATCA CCTTGTMATA ATCTTMAAGC CCCTGCACCT GGAACTATTA ACGTTCCTGT MCCATTTAT CCTTTAACT TTTTTGCCTA C1TAMTCT GTAAAATTGT TTTAACTAGA CCCCCCCTCT 7140 7200 7260 7320 7380 7440 7500 7560 7620 7680 7740 7800 7860 7920 7980 8040 8100 8160 126 CCTTTCTAMA CCAAAGTATA AAAGCAMATC TAGCCCCTTC: TTCAGGCCGA GAGAATTTCG 8220 AGCGTTAGCC GTCTCTTGGC CACCAGCTAA ATAAACGGAT TCTTCATGTG TCTCAAAGTG 8280 TGGCGTTTTC TCTAACTCGC TCAGGTACGA CCGTGGTAGT A1TFTTCCCCA ACGTCTTATT 8340 TTTAGGGCAC GTATGTAGAG TMACTTTTAT GAAAGAAACC AGTMAGGAG GTTTTGGGAT 8400 TTCCTTTATC AACTGTAATA CTGGTTTTGA TTATTTAMT AMTATT-TAT TTTTGAG 8460 AAGGAGTTTC ACTCTTGTTG CCCAGGCTGG AGTGCAA.TGG TGCGATCTTG GCTCACTGCA 8520 :::*ACTTCCGCCT CCCAGGTTCA AGCGATTCTC CTGCCTCAGC CTCGAGAGTA GCTGGGATTA 8580 TAGGCATGCG CCACCACACC CAGCTAM TGTATTTTA GTAMAGATGG GGTTCTTCA 8640 TGTTGGTCMA GCTGGTCTGG MCTCCCCGC CTCGGGTGAT CTGCCCGCCT CGGCCTCCGA 8700 **AAGTGCTGGG AT-TACAGGTG TGATCCACCA CACCCAGCCG ATTTATATGT ATATAAATCA 8760 CATTCCTCTA ACC/AAAATGT AGTGTTTCCT TCCATCTTGA ATATAGGCTG TAGACCCCGT 8820 GGGTATGGGA CATTGTTMAC AGTGAGACCA CAGCAGT1T TATGTCATCT GACAGCATCT 83860 *CCMAATAGCC TTCATGGTTG TCACTGCTTC CCMAGACAAT TCCMAATMAC ACTTCCCAGT 8940 'GATGACT-TGC TACTTGCTAT TGTTACTTMA TGTGTTMAGG TGGCTGTTAC AGACACTAIT 9000 AGTATGTCAG GAATTACACC AAAATTTAGT GGCTCAMACA ATCATTTAT TATGTATGTG 9060 GATTCTCATG GTCAGGTCAG GATTTCAGAC AGGGCACAAG GGTAGCCCAC TTGTCTCTGT 9120 CTATGATGTC TGGCCTCAGC ACAGGAGACT CMCAGCTGG GGTCTGGGAC CATTTGGAGG 9180 CTTGTTCCCT CACATCTGAT ACCTGGCTTG GGATGTTGGA AGAGGGGGTG AGCTGAGACT 9240 GAGTGCCTAT ATGTAGTGTT TCCATATGGC CTTGAC1TCC TrACAGCCTG GCAGCCTCAG GGTAGTCAGA ATTCTTAGGA GGCACAGGGC TCCAGGGCAG ATGCTGAGGG GTCTTTTATG AGGTAGCACA GCAAATCCAC CCAGGATC INFORMATION FOR SEQ ID NO:142: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 419 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear c 9300 9360 9388 120 180 240 300 360 419 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142: TGTAAGTCGA GCAGTGTGAT GGAAGGAATG GTCT1TGGAG AGAGCATATC CATCTCCTCC TCACTGCCTC CTAATGTCAT GAGGTACACT GAGCAGAATT AAACAGGGTA GTCTTAACCA CACTATTTTT AGCTACCTTG TCAAGCTAAT GGTTAAAGAA CACTTTTGGT TTACAC1TGT TGGGTCATAG AAGTTGCTTT CCGCCATCAC GCAATAAGTT TGTGTGTAAT CAGAAGGAGT TACCTTATGG TTTCAGTGTC ATTCTTTAGT TAACTTGGGA GCTGTGTAAT TTAGGCTTTG CGTATTATTT CACTTCTGTT CTCCACTTAT GAAGTGATTG TGTGTTCGCG TGTGTGTGCG TGCGCATGTG CTTCCGGCAG TTAACATAAG CAAATACCCA ACATCACACT GCTCGACTT INFORMATION FOR SEQ ID NO:143: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 402 base pairs TYPE: nucleic acid 128 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143: TGTAAGTCGA GCAGTGTGAT GTCCACTGCA GTGTGTTGCT GGGAACAGTT AATGAGCAAA TTGTATACAA TGGCTAGTAC ATTGACCGGG ATTTGTTGAA GCTGGTGAGT GTTATGACTT 120 AGCCTGTTAG ACTAGTCTAT GCACATGGCT CTGGTCAACT ACCGCTCTCT CATTTCTCCA 180 GATAAATCCC CCATGCTTTA TATTCTCTTC CAAACATACT ATCCTCATCA CCACATAGTT 240 CCTTTGTTAA TGCTTTGTTC TAGACTCC CTTTTCTGTT TTCTTATTCA AACCTATATC 300 TCTTTGCATA GATTGTAAAT TCAAATGCCC TCAGGGTGCA GGCAGTTCAT GTAAGGGAGG 360 GAGGCTAGCC AGTGAGATCT GCATCACACT GCTCGACTTA CA 402 INFORMATION FOR SEQ ID NO:144: SEQUENCE CHARACTERISTICS: LENGTH: 224 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144: TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CA1TrCCAAA AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGTTCCGA AGGGTCAGGG AGGAGGAAAT 120 TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA 180 129 CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC 224 INFORMATION FOR SEQ ID NO:145: SEQUENCE CHARACTERISTICS: LENGTH: 111 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145: AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAG AAAAATATCA AGGAATAAAA ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G 111 INFORMATION FOR SEQ ID NO:146: S SEQUENCE CHARACTERISTICS: LENGTH: 585 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146: TAGCATGTTG AGCCCAGACA CTTGTAGAGA GAGGAGGACA GTTAGAAGAA GAAGAAAAGT TTTTAAATGC TGAAAGTTAC TATAAGAAAG CTTTGGCTTT GGATGAGACT TTTAAAGATG 120 CAGAGGATGC TTTGCAGAAA CTTCATAAAT ATATGCAGGT GATTCCTTAT TTCCTCCTAG 180 AAATTTAGTG ATATTTGAAA TAATGCCCAA ACTTAATTTT CTCCTGAGGA AAACTATTCT 240 130 ACATTACTTA AGTAAGGCAT TATGAAAAGT TTCT1TTAG GTATAGTTTT TCCTAATTGG 300 GTTTGACATT GCTTCATAGT GCCTCTGTTT flGTCCATMA TCGAAAGTAA AGATAGCTGT 360 GAGAAAACTA TTACCTMAAT TTGGTATGTT GTTTTGAGAA ATGTCCTTAT AGGGAGCTCA 420 CCTGGTGGTT TTTAAATTAT TGTTGCTACT ATMATTGAGC TAATTATAAA AACCTTTTTG 480 AGACATATTT TAAATTGTCT TTTCCTGTAA TACTGATGAT GATGTTTTCT CATGCATTT 540 .CTTCTGMATT GGGACCATTG CTGCTGTGTC TGGG.CTCACA TGCTA 585 INFORMATION FOR SEQ ID NO:147: 0i) SEQUENCE

CHARACTERISTICS:

LENGTH: 579 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147: TAGCATGTTG AGCCCAGACA CTGGGCAGCG GGGGTGGCCA CGGCAGCTCC TGCCGAGCCC MAGCGTGTTT GTCTGTGMAG GACCCTGACG TCACCTGCCA GGCTAGGGAG GGGTCAATGT 120 GGAGTGMATG TTCACCGACT TTCGCAGGAG TGTGCAGAAG CCAGGTGCAA CT[GGTTTGC 180 TTGTGTTCAT CACCCCTCMA GATATGCACA CTGCTTTCCA AATAMAGCAT CMACTGTCAT 240 CTCCAGATGG GGMAGACTT TTCTCCMACC AGCAGGCAGG TCCCCATCCA CTCAGACACC 300 AGCACGTCCA CCTTCTCGGG CAGCACCACG TCCTCCACCT TCTGCTGGTA CACGGTGATG 360 131 ATGTCAGCAA AGCCGTTCTG CANGACCAGC TGCCCCGTGT GCTGTGCCAT CTCACTGGCC 420 TCCACCGCGT ACACCGCTCT AGGCCGCGCA TANTGTGCAC AGAANAAATG ATGATCCAGT 480 CCCACAGCCC ACGTCCAAGA NGACTTTATC CGTCAGGGAT TCTTTATTCT GCAGGATGAC 540 CTGTGGTATT AATTGTTCGT GTCTGGGCTC AACATGCTA 579 INFORMATION FOR SEQ ID NO:148: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 249 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148: TGACACCTTG TCCAGCATCT GCAAGCCAGG AAGAGAGTCC TCACCAAGAT CCCCACCCCG TTGGCACCAG GATCTTGGAC TTCCAATCTC CAGAACTGTG AGAAATAAGT ATTTGTCGCT 120 AAATAAATCT TTGTGGTC AGATATTTAG CTATAGCAGA TCAGGGTGAC TAAGAGAAAC 180 CCCATAAGAG TTACATACTC ATTAATCTCC GTCTCTATCC CCAGGTCTCA GATGCTGGAC 240 AAGGTGTCA 249 INFORMATION FOR SEQ ID NO:149: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 255 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 132 (xi).SEQUENCE DESCRIPTION: SEQ ID NO:149: TGACACCTTG TCCAGCATCT GCTATTTGT GACTTTTTMA TAATAGCCAT TCTGACTGGT GTGAGATGGT AACTCATTGT GGGTTTGGTC TGCATTTCTC TAATGATCAG TGATATTAAG 120 CTTTTTTTAA ATATGCTTGT TGACCACATG TATATCATCT TTTGAGAAGT GTCTGTTCAT 180 ATCCTTTGCC CACTTTTTAA TTTTTATC TTGTAAATTT GTTTMATTTC CTTACAGATG 240 CTGGACAAGG TGTCA 255 INFORMATION FOR SEQ ID NO:1 Ci) SEQUENCE CHARACTERISTICS: LENGTH: 318 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID TTACGCTGCA. ACACTGTGGA GGCCMAGCTG GGATCACTTC TTCATTCTAA CTGGAGAGGA GGGAAGTTCA AGTCCAGCAG AGGGTGGGTG GGTAGACAGT GGCACTCAGA AATGTCAGCT 120 GGACCCCTGT CCCCGCATAG GCAGGACAGC AAGGCTGTGG CTCTCCAGGG CCAGCTGAAG 180 AACAGGACAC TGTCTCCGCT GCCACAAAGC GTCAGAGACT CCCATCTTTG MAGCACGGCC 240 TTCTTGGTCT TCCTGCACTT CCCTGTTCTG TTAGAGACCT GGTTATAGA4C MGGCTTCTC 300 CACAGTGTTG CAGCGTAA 318 INFORMATION FOR SEQ ID NO:151: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 323 base pairs TYPE: nucleic acid STRANDEDNESS: single CD) TOPOLOGY: linear 9 9.

99.999 *999 9 .9.99.

S 9 *9 9 Cxi) SEQUENCE DESCRIPTION: SEQ ID NO:151: TNACGCNGCN ACNNTGTAGA GANGGNAAGG CNTTCCCCAC ATTNCCCCTT TTATTCNACC MAGNNTGACC NATGCCNTTT ATGACTTACA TGCNNACTNC TCNNGCCTTA AAAGCNNNTC CACTACATGC NTCANCACTG TNTGTGTNAC GTCNGNMATA GGGGCNCATA ACTACAGAAA TGCANTTCAT ACTGCTTCCA CGTGTGGCCT TNCCTACTCT TCTTNTATTC CAAGTAGCAT CTCTGGANTG CTCCACATTG TTGCAGCNAT MAT INFORMATION FOR SEQ ID NO:152: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 311 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear

CATNANAGAA

NTMATCTGTN

NTCATNMACT

NTGCCATCNG

CTTCCCCACT

120 180 240 300 323 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152: TCAAGATTCC ATAGGCTGAC CAGTCCMAGG AGAGTTGAAA TCATGMAGGA GAGTCTATCT 134 GGAGAGAGCT GTAGTTTTGA. GGGTTGCAAA GACTTAGGAT GGAGTTGGTG GGTGTGGTTA 120 GTCTCTAAGG TTGATTTGT TCATMAATTT CATGCCCTGA ATGCCTTGCT TGCCTCACCC 180 TGGTCCMAGC CTTAGTGMAC ACCTAAMAGT CTCTGTCTTC TTGCTCTCCA AACT[CTCCT 240 GAGGATTTCC TCAGATTGTC TACATTCAGA TCGMAGCCAG TTGGCAAACA AGATGCAGTC 300 CAGAGGGTCA G 311 INFORMATION FOR SEQ ID NO:153: ()SEQUENCE CHARACTERISTICS: LENGTH: 332 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153: CAAGATTCCA TAGGCTGACC AGGAGGCTAT TCMWGATCTC TGGCAGTTGA GGAAGTCTCT 9.TTAAGAAAAT AGTTTAAACA ATTTGTTAAA ATTTTTCTGT CTTACTTCAT TTCTGTAGCA 120 GTTGATATCT GGCTGTCCTT TTTATMATGC AGAGTGGGAA CTTCCCTAC CATGTTTGAT 180 MATGTTGTC CAGGCTCCAT TGCCAATMAT GTGTTGTCCA MAATGCCTGT TTAGT1TTA 240 AAGACGGAAC TCCACCCTT GCTTGGTCTT AAGTATGTAT GGAATGTTAT GATAGGACAT 300 AGTAGTAGCG GTGGTCAGCC TATGGMATCT TG 332 INFORMATION FOR SEQ ID NO:154: 135 SEQUENCE CHARACTERISTICS: LENGTH: 345 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154: TCAAGATTCC ATAGGCTGAC CTGGACAGAG ATCTCCTGGG TCTGGCCCAG GACAGCAGGC TCAAGCTCAG TGGAGAAGGT TTCCATGACC CTCAGATTCC CCCAAACCTT GGATTGGGTG 120 s*e* ACATTGCATC TCCTCAGAGA GGGAGGAGAT GTANGTCTGG GCTTCCACAG GGACCTGGTA 180 TTTTAGGATC AGGGTACCGC TGGCCTGAGG CTTGGATCAT TCANAGCCTG GGGGTGGAAT 240 GGCTGGCAGC CTGTGGCCCC ATTGAAATAG GCTCTGGGGC ACTCCCTCTG TTCCTANTTG 300 AACTTGGGTA AGGAACAGGA ATGTGGTCAN CCTATGGAAT CTTGA 345 S* INFORMATION FOR SEQ ID NO:155: 9 SEQUENCE CHARACTERISTICS: LENGTH: 295 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155: GACGCTTGGC CACTTGACAC ATTAAACAGT TTTGCATAAT CACTANCATG TATTTCTAGT TTGCTGTCTG CTGTGATGCC CTGCCCTGAT TCTCTGGCGT TAATGATGGC AAGCATAATC 120 136 AAACGCTGTT CTGTTAATTC CAAGTTATAA CTGGCATTGA TTAAAGCATT ATClTFCACA 180 ACTAAACTGT TCTTCATANA ACAGCCCATA TTATTATCAA ATTAAGAGAC AATGTATTCC 240 AATATCCTTT ANGGCCAATA TATTTNATGT CCCTTAATTA AGAGCTACTG TCCGT 295 INFORMATION FOR SEQ ID NO:156: SEQUENCE CHARACTERISTICS: LENGTH: 406 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear see* (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156: S GACGCTTGGC CACTTGACAC TGCAGTGGGA AAACCAGCAT GAGCCGCTGC CCCCAAGGAA sees CCTCGAAGCC CAGGCAGAGG ACCAGCCATC CCAGCCTGCA GGTAAAGTGT GTCACCTGTC 120 *:S*Se AGGTGGGCTT GGGGTGAGTG GGTGGGGGAA GTGTGTGTGC AAAGGGGGTG TNAATGTNTA 180 TGCGTGTGAG CATGAGTGAT GGCTAGTGTG ACTGCATGTC AGGGAGTGTG AACAAGCGTG 240 a* *S CGGGGGTGTG TGTGCAAGTG CGTATGCATA TGAGAATATG TGTCTGTGGA TGAGTGCATT 300 TGAAAGTCTG TGTGTGTGCG TGTGGTCATG ANGGTAANTT ANTGACTGCG CAGGATGTGT 360 GAGTGTGCAT GGAACACTCA NTGTGTGTGT CAAGTGGCCN ANCGTC 406 INFORMATION FOR SEQ ID NO:157: SEQUENCE CHARACTERISTICS: LENGTH: 208 base pairs TYPE: nucleic acid .137 STRANDEDNESS: single TOPOLOGY: linear I. (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157: TGACGCTTGG CCACTTGACA CACTAAAGGG TGTTACTCAT CACTTTCTTC TCTCCTCGGT GGCATGTGAG TGCATCTATT CACTTGGCAC TCATTTGTTT GGCAGTGACT GTMANCCANA TCTGATGCAT ACACCAGCTT GTAAATTGAA TMAATGTCTC TMTACTATG TGCTCACMAT ANGGTANGGG TGAGGAGMAG GGGAGAGA INFORMATION FOR SEQ ID NO:158: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 547 base pairs TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear 120 180 208 120 180 240 300 360 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158: CTTCMACCTC CTTCMACCTC CTTCAACCTC CTGGATTCAA ACMATCATCC TCCTTAG;TAG CTGAGACTAC AGACTCACGC CACTACATCT GGCTAAATT AGGGTTTCAT CATGTTGCCC TGGCTGGTCT CAAACTCCTG ACCTCAAGCA CTCAGCCTCC CAMAGTGCTG GGATTACAGG CATAAGCCAC CATGCCCAGT TC1TTCCTAC CACATTCTTA CCACACTTTC TTTTATGTT AGATACATAA TTATGATACA ATTGCCCACA GTATTMAGAC AGTMACATGC TGCACAGGTT

CACCTCAGAC

TTGTAGAGAT

ATGTGCCCAC

CCATNTTTMA

AIGGITACCA

TGTAGCCTAG

138 GAACAGTAGG CAATACCACA TAGCTTAGGT GTGTGGTAGA CTATACCATC TAGGTTTGTG 420 TAAGTTACAC TTTATGCTGT TTACACAATG ACAAAACCAT CTAATGATGC ATTTCTCAGA 480 ATGTATCCTT GTCAGTAAGC TATGATGTAC AGGGAACACT GCCCAAGGAC ACAGATATTG 540 TACCTGT 547 INFORMATION FOR SEQ ID NO:159: SEQUENCE CHARACTERISTICS: LENGTH: 203 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159: GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT 120 CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG 180 TCGATAGAAG TTCCTCTCAG TGC 203 INFORMATION FOR SEQ ID NO:160: SEQUENCE CHARACTERISTICS: LENGTH: 402 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160: TGTAAGTCGA GCAGTGTGAT GGGTGGMACA GGGTTGTMAG CAGTAATTGC MAACTGTATT TAAACAATMA TAATAATATT TAGCATTTAT AGAGCACTTT ATATCTTCAA AGTACTTGCA 120 MCATTAYCT MATTAAATAC CCTCTCTGAT TATAATCTGG ATACAAATGC ACTTAAACTC 180 AGGACAGGGT CATGAGARAA GTATGCATTT GAAAGTTGGT GCTAGCTATG CTTTAAMAAC 240 CTAACAT ATGGGRAAGT TAGAGTTCAG ATTCTGTTGG ACTGTTG TG.CATTCAG 300 :TrCAGCCTGA TGGCAGAATT AGATCATATC TGCACTCGAT GACTYTGCTT GATAACTTAT 360 .**CACTGAAATC TGAGTGTTGA TCATCACACT GCTCGACTTA CA 402 INFORMATION FOR SEQ ID NO:161: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 193 base pairs" TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: AGCATGTTGA GCCCAGACAC TGACCAGGAG AAAAACCAAC CAATAGMAAC ACGCCCAGAC ACTGACCAGG AGAMAAACCA ACCAATAAAA ACAGGCCCGG ACATAAGACA MATAATAAAA 120 TTAGCGGACA AGGACATGMA AACAGCTATT GTMGAGCGG ATATAGTGGT GTGTGTCTGG 180 GCTCMACATG CTA 193 140 INFORMATION FOR SEQ ID NO:162: SEQUENCE CHARACTERISTICS: LENGTH: 147 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162: TGTTGAGCCC AGACACTGAC CAGGAGAAAA ACCAACCAAT AAAAACAGGC CCGGACATAA GACAAATAAT AAAATTAGCG GACAAGGACA TGAAAACAGC TATTGTAAGA GCGGATATAG 120 TGGTGTGTGT CTGGGCTCAA CATGCTA 147 INFORMATION-FOR SEQ ID NO:163: SEQUENCE CHARACTERISTICS: LENGTH: 294 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear a (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163: TAGCATGTTG AGCCCAGACA CAAATCTTTC CTTAAGCAAT AAATCATTTC TGCATATGTT TTTAAAACCA CAGCTAAGCC ATGATTATTC AAAAGGACTA TTGTATTGGG TATTTTGATT 120 TGGGTTCTTA TCTCCCTCAC ATTATCTTCA TTTCTATCAT TGACCTCTTA TCCCAGAGAC 180 TCTCAAACTT TTATGTTATA CAAATCACAT TCTGTCTCAA AAAATATCTC ACCCACTTCT 240 141 CTTCTGTTTC TGCGTGTGTA TGTGTGTGTG TGTGTGTCTG GGCTCAACAT GCTA 294 INFORMATION FOR SEQ ID NO:164: SEQUENCE CHARACTERISTICS: LENGTH: 412 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164: .:*CGGGATTGGC TTTGAGCTGC AGATGCTGCC TGTGACCGCA CCCGGCGTGG AACAGAAAGC CACCTGGCTG CAAGTGCGCC AGAGCCGCCC TGACTACGTG CTGCTGTGGG GCTGGGGCGT 120 GATGAACTCC ACCGCCCTGA AGGAAGCCCA GGCCACCGGA TACCCCCGCG ACAAGATGTA 180 CGGCGTGTGG TGGGCCGGTG CGGAGCCCGA TGTGCGTGAC GTGGGCGAAG GCGCCAAGGG 240 CTACAACGCG CTGGCTCTGA ACGGCTACGG CACGCAGTCC AAGGTGATCC ANGACATCCT 300 GAAACACGTG CACGACAAGG GCCAGGGCAC GGGGCCCAAA GACGAAGTGG GCTCGGTGCT 360 GTACACCCGC GGCGTGATCA TCCAGATGCT GGACAAGGTG TCAATCACTA AT 412 INFORMATION FOR SEQ ID NO:165: SEQUENCE CHARACTERISTICS: LENGTH: 361 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ 10 NO:165: TTGACACCTT GTCCAGCATC TGCATCTGAT GAGAGCCTCA GATGGCTACC ACTAATGGCA GMAGGCAMAG GAGAACAGGC ATTGTATGGC MAGAAAGGAA GAAAGAGAGA GGGGAGAAAG 120 GTGCTAGGTT CTTTTCAACA ACCAGTTCTT GATGGAACTG AGAGTMAGAG CTCAAGGCCA 180 GGTGTGGTGA CTCCAACCAG TAATCCCAAC ATTTTAGGAG GCTGAGGCAG GCAGATGTCT 240 TGACCCCATG AGTTTGTGAC CAGCCTGAAC AACATCATGA GACTCCATCT CTACAATMAT 300 TACMAAAATT AATCAGGCAT TGTGGTATGC CCTGTAGTCC CAGATGCTGG ACAAGGTGTC 360 A 361 INFORMATION FOR SEQ ID NO:166: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 427 base pairs CB) TYPE: nucleic acid CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166: TWGACTGACT CATGTCCCCT ACACCCMACT ATCTTCTCCA GGTGGCCAGG CATGATAGMA TCTGATCCTG ACTTAGGGGA ATATTTTCTT TTTACTTCCC ATCTTGATTC CCTGCCGGTG 120 AGTTTCCTGG TTCAGGGTMA GAAAGGAGCT CAGGCCAAAG TAATGAACMA ATCCATCCTC 180 ACAGACGTAC AGMATMGAG MACWTGGACW TAGCCAGCAG AACMCAAKTG AAAMCAGMAC 240 MCTTAMCTAG GATRACAAMC MCRRARATAR KTGCYCMCMC WTATMATAGA AACCAMACTT 300 '143 GTATCTAATT AAATATTTAT CCACYGTCAG GGCATTAGTG GTT1TGATAA ATACGCTTTG 360 GCTAGGATTC CTGAGGTTAG MATGGMARAA CAATTGCAHC GAGGGTAGGG GACATGAGTC 420 AKTCTMA 427 INFORMATION FOR SEQ 10 NO:167: SEQUENCE CHARACTERISTICS: LENGTH: 500 base pairs TYPE: nucleic acid STRANDEDNESS: single 0.0 TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167: 9.0099 0 MCGTCGCAT GCTCCCGGCC GCCATGGCCG CGGGATAGAC TGACTCATGT CCCCTAAGAT .AGAGGAGACA CCTGCTAGGT GTAAGGAGMA GATGGTTAGG TCTACGGAGG CTCCAGGGTG 120 GGAGTAGTTC CCTGCTAAGG GAGGGTAGAC TGTTCMACCT GTTCCTGCTC CGGCCTCCAC 180 TATAGCAGAT GCGAGCAGGA GTAGGAGAGA GGGAGGTAAG AGTCAGAAGC TTATG1TGTT 240 TATGCGGGGA AACGCCRTAT CGGGGGCAGC CRAGTTATTA GGGGACANTR TAGWYARTCW 300 AGNTAGCATC CAAAGCGNGG GAGTTNTCCC ATATGGTTGG ACCTGCAGGC GGCCGCATTA 360 GTGATTAGCA TGTGAGCCCC AGACACGCAT AGCMACAAGG ACCTAAACTC AGATCCTGTG 420 CTGATTACTT MCATGAATT ATTGTATTTA JMfMCAACT TTGAGTTATG; AGGCATATTA 480 144 TTAGGTCCAT ATTACCTGGA 500 INFORMATION FOR SEQ ID NO:168: SEQUENCE CHARACTERISTICS: LENGTH: 358 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168: TTCATCGCTC GGTGACTCAA GCCTGTAATC CCAGAACTTT GGGAGGCCGA GGGGAGCAGA TCACCTGAGG TTGGGAGTTT GAGACCAGCC TGGCCAACAT GGTGACAACC CGTCTCTGCT 120 AAAAATACAA AAATTAGCCA AGCATGGTGG CATGCACTTG TAATCCCAGC TACTCGGGAG 180 GCTGAGGCAG GAGAATCACT TGAGGCCAGG AGGCAGAGGT TGCAGTGAGG CAGAGGTTGA 240 GATCATGCCA CTGCACTCCA GCCTGGGCAA CAGAGTAAGA CTCCATCTCA AAAAAAAAAA 300 AAAAAAAGAA TGATCAGAGC CACAAATACA GAAAACCTTG AGTCACCGAG CGATGAAA 358 INFORMATION FOR SEQ ID NO:169: SEQUENCE CHARACTERISTICS: LENGTH: 1265 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169: TTCTGTCCAC ACCMATCTTA GAGCTCTGMA AGAATTTGTC TTTAMATATC TTTTMTAGT AACATGTATT TTATGGACCA MATTGACATT TTCGACTATT T1TTCCCAAA AAAAGTCAGG TGMTTT CAG CACACTGAGT TGGGAATTTC TTATCCCAGA AGWCGGCACG AGCAATTCA TATTTATTTA AGATTGATTC CATACTCCGT TTCAAGGAG AATCCCTGCA GTCTCCTTAA AGGTAGAACA AATACTTTCT ATTTTTTTT CACCATTGTG GGATTGGACT TTMAGAGGTG ACTCTAAAM. AACAGAGMAC AAATATGTCT CAGTTGTATT MAGCACGGAC CCATATTATC ATATTCACTT AAAMAAATGA MTCCTGTGC ACCTTTTGGC AAC1TCTCTT TTCAATGTAG GGAAAAACTT AGTCACCCTG AAAACCCACA AAATAAATMA MCTTGTAGA TGTGGGCAGA ARGTTTGGGG GTGGACATTG TATGTGTTTA AATTAAACCC TGTATCACTG AGMAGCTGTT GTATGGGTCA GAGAAAATGA ATGCTTAGMA GCTGTTCACA TCTTCMAGAG CAGMAGCA CCACATGTCT CAGCTATATT ATTATTTATT TTTTATGCAT MAAGTGAATC ATTTCTTCTG TATTAAMTC CAAAGGGTTT TACCCTCTAT TTAAATGCTT TGAAAAACAG TGCATTGACA ATGGGTTGAT ATTTTTCTT AMAAGMAAA TATMTlTATG MAAGCCAAGA TAATCTGMAG CCTGTTTAT TTTAAAACTTF TTATGTTCT GTGGTTGATG 1TGMTGTTT GTTGTTTCT ATTTTGTTGG TTTTMACTT TGTTTMGT TTGTTTTGT TTGGTTDG CATACTACAT GCAGTTTCTT TAACCAATGT CTGTTTGGCT MTGTAATTA AAGTTGTTM TTTATATGAG TGCATTCMA CTATGTCMAT GGTTTCTTMA TATTTATTGT GTAGMAGTAC TGGTMATTTT TTATTTACA ATATGTTTMA AGAGATMACA GTTTGATATG TTTTCATGTG TTATAGCAG 120 180 240 300 360 420 480 540 600 660 720 780 840 900 .960 1020 1080 146 AAGTTATTTA TTCTATGGC ATTCCAGCGG ATATTTTGGT GTTTGCGAGG CATGCAGTCA 1140 ATATTTTGTA CAGTTAGTGG ACAGTATTCA GCAACGCCTG ATAGCTTCTT TGGCCTTATG 1200 TTAMATAAAA AGACCTGTTT GGGATGTAAA AAAAAAAA AAAAAAAAA AAAAAAAAAA 1260 AAAAA 1265 INFORMATION FOR SEQ ID NO:170: 0i) SEQUENCE CHARACTERISTICS: LENGTH: 383 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170: TGTMAGTCGA GCAGTGTGAT GACGATATTC TTCTTATTAA TGTGGTAATT GAACAAATGA TCTGTGATAC TGATCCTGAG CTAGGAGGCG CTGTTCAGTT .MATGGGACTT CTTCGTACTC 120 TAATTGATCC AGAGAACATG CTGGCTACMA CTMATAAAAC CGAAAAAAGT GAATTCTMA 180 ATTTTTTCTA CMACCAFTGT ATGCATGTTC TCACAGCACC ACTTTGACC MATACTTCAG 240 MAGACAAATG TGAAAAGGAT MATATAGTTG GATCAAACAA MAACAACACA ATTTGTCCCG 300 ATMATTATCA AACAGCACAG CTACTTGCCT TAATTTAGA GTTACTCACA TTTTGTGTGG 360 MCATCACAC TGCTCGACTT ACA 383 INFORMATION FOR SEQ ID NO:171: 147 SEQUENCE CHARACTERISTICS: LENGTH: 383 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171: TGGGCACCTT CAATATCGCA AGTTAAAAAT AATGTTGAGT TTATTATACT TTTGACCTGT TTAGCTCAAC AGGGTGAAGG CATGTAAAGA ATGTGGACTT CTGAGGAATT TTCTTTTAAA AAGAACATAA TGAAGTAACA TTTTAATTAC TCAAGGACTA CTTTTGGTTG AAGTTTATAA TCTAGATACC TCTACTTTTT GTTTTTGCTG TTCGACAGTT CACAAAGACC TTCAGCAATT TACAGGGTAA AATCGTTGAA GTAGTGGAGG TGAAACTGAA ATTTAAAATT ATTCTGTAAA TACTATAGGG AAAGAGGCTG AGCTTAGAAT CTTTTGGTTG TTCATGTGTT CTGTGCTCTT ATCATCACAC TGCTCGACTT ACA INFORMATION FOR SEQ ID NO:172: SEQUENCE CHARACTERISTICS: LENGTH: 699 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 120 180 240 300 360 383 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172: TCGGGTGATG CCTCCTCAGG CTTGTCGTTA GTGTACACAG AGCTGCTCAT GAAGCGACAG 148 CGGCTGCCCC TGGCACTTCA GAACCTCTTC CTCTACACTT TTGGTGCGCT TCTGAATCTA 120 GGTCTGCATG CTGGCGGCGG CTCTGGCCCA GGCCTCCTGG AAAGTICTC AGGATGGGCA 180 GCACTCGTGG TGCTGAGCCA GGCACTAMAT GGACTGCTCA TGTCTGCTGT CATGGAGCAT 240 GGCAGCAGCA TCACACGCCT CTTTGTGGTG TCCTGCTCGC TGGTGGTCAA CGCCGTGCTC 300 TCAGCAGTCC TGCTACGGCT GCAGCTCACA GCCGCCTTCT TCCTGGCCAC ATTGCTCATT 360 GGCCTGGCCA TGCGCCTGTA CTATGGCAGC CGCTAGTCCC TGACAACTTC CACCCTGATT 420 **CCGGACCCTG TAGATTGGGC GCCACCACCA GATCCCCCTC CCAGGCCTTC CTCCCTCTCC 480 CATCAGCGGC CCTGTMACM GTGCCTTGTG AGAAAAGCTG GAGAAGTGAG GGCAGCCAGG 540 :0TTATTCTCTG GAGGTTGGTG GATGMAGGGG TACCCCTAGG AGATGTGAAG TGTGGGTTTG 600 GTTAAGGAAA TGCTTACCAT CCCCCACCCC CAACCMAGTT NTTCCAGACT AAAGMATTAA 660 *00GGTAACATCA ATACCTAGGC CTGAGGAGGC ATCACCCGA 699 INFORMATION FOR SEQ ID NO:173: SEQUENCE CHARACTERISTICS: LENGTH: 701 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173: TCGGGTGATG CCTCCTCAGG CCAGATCAMA CTTGGGGTTG AAAACTGTGC MAAGAAATCA ATGTCGGAGA MAGAATTTTG CAAAAGAAAA ATGCCTAATC AGTACTAATFT TAATAGGTCA 120 149 CATTAGCAGT GGMAGMGAA ATGTTGATAT TTATGTCAG CTAT[TTATA ATCACCAGAG 180 TGCTTAGCTT CATGTMAGCC ATCTCGTATT CATTAGAMAT MAGAACAATT TTATTCGTCG 240 GAAAGAACTT TTCMATTTAT AGCATCTTMA TTGCTCAGGA TTTTAAATTT TGATAAAGAA 300 AGCTCCACTT TTGGCAGGAG TAGGGGGCAG GGAGAGAGGA GGCTCCATCC ACAAGGACAG 360 AGACACCAGG GCCAGTAGGG TAGCTGGTGG CTGGATCAGT CACPACGGAC TGACTTATGC 420 CATGAGMAGA MACMCCTCC AAATCTCAGT TGCTTMATAC AACACAAGCT CATTTCTTGC 480 .0:TCACGTTACA TGTCCTATGT AGATCMACAG CAGGTGACTC AGGGACCCAG GCTCCATCTC 540 *CATATGAGCT TCCATAGTCA CCAGGACACG GGCTCTGAAA GTGTCCTCCA TGCAGGGACA 600 CATGCCTCTT CCTTTCATTG GGCAGAGCMA GTCACTTATG GCCAGAAGTC ACACTGCAGG 660 GCAGTGCCAT CCTGCTGTAT GCCTGAGGAG GCATCACCCG A 701 0 INFORMATION FOR SEQ ID NO:174: SEQUENCE CHARACTERISTICS: LENGTH: 700 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174: TCGGGTGATG CCTCCTCANG CCCCTAAATC AGAGTCCAGG GTCAGAGCCA CAGGAGACAG GGAAAGACAT AGATTTTMAC CGGCCCCCTT CAGGAGATTC TGAGGCTCAG T-TCACTTTGT 120 150 0 *000 0 0 *0*0*0 *000 0 *000 0 *000 0 *00**0 0 ~0 *0 0 0 TGCAGTTTGA ACAGAGGCAG CAAGGCTAGT GGTTAGGGGC ACGGTCTCTA AAGCTGCACT GCCTGGATCT GCCTCCCAGC TCTGCCAGGA ACCAGCTGCG TGGCCT[GAG CTGCTGACAC GCAGAMAGCC CCCTGTGGAC CCAGTCTCCT CGTCTGTMAG ATGAGGACAG GACTCTAGGA ACCCTTCCC TTGGTMGGC CTCACTTTCA CAGGCTCCCA TCTTGAACTC TATCTACTCT TTTCCTGAAA CCTTGTMAAA GAAAAAAGTG CTAGCCTGGG CAACATGGCA MAACCCTGTC TCTACAAAPA ATACAAMAAT TAGTTGGGTG TGGTGGCATG TGCCTGTAGT CCCAGCCACT TGGGAGGTGC TGAGGTGGGA GGATCACTTG AGCCCGGGAG GTGGAGGTTG CAGTGAGCCA AGATCATGCC ACTGCACTCC AGCCTGAGTA ATAGAGTMAG ACTCTGTCTC AAAAACAACA ACAACMACAG TGAGTGTGCC TCTGTTTCCG GGTTGGATGG GGCACCACAT TTATGCATCT CTCAGATTTG GACGCTGCAG CCTGAGGAGG CATCACCCGA INFORMATION FOR SEQ ID NO:175: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 484 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear 180 240 300 360 420 480 540 600 660 700 Cxi) SEQUENCE DESCRIPTION: SEQ ID NO:175: TATAGGGCGA ATTGGGCCCG AGTTGCATGN TCCCGGCCGC CATGGCCGCG GGATTCGGGT GATGCCTCCT CAGGCTTGTC TGCCACAAGC TACTTCTCTG AGCTCAGAAA GTGCCCCTTG ATGAGGGMAA ATGTCCTACT GCACTGCGMA TTTCTCAGTT CCATTTVACC TCCCAGTCCT 151 CCTTCTAAAC CAGTTMATM ATTCATTCCA CMAGTATTTA CTGATTACCT GCTTGTGCCA 240 GGGACTATTC TCAGGCTGAA GAAGGTGGGA GGGGAGGGCG GMCCTGAGG AGCCACCTGA 300 GCCAGCTTTA TATTTCAACC ATGGCTGGCC CATCTGAGAG CATCTCCCCA CTCTCGCCPA 360 CCTATCGGGG CATAGCCCAG GGATGCCCCC AGGCGGCCCA GGTTAGATGC GTCCCTTTGG 420 CTTGTCAGTG ATGACATACA CCTTAGCTGC TTAGCTGGTG CTGGCCTGAG GAGGCATCAC 480 CCGA 484 INFORMATION FOR SEQ ID NO: 176: SEQUENCE CHARACTERISTICS: C(A) LENGTH: *432 base pairs TYPE: nucleic acid 0000 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176: :TCGGGTGATG CCTCCTCAGG GCTCMAGGGA TGAGAAGTGA CTTCTCTG GAGGGACCGT TCATGCCACC CAGGATGAAA ATGGATAGGG ACCCACTTGG AGGACTTGCT GATATGTTTG 120 GACAAATGCC AGGTAGCGGA AT-TGGTACTG GTCCAGGAGT TATCCAGGAT AGA1TTTCAC 180 CCACCATGGG ACGTCATCGT TCAAATCAAC TCTTCMTGG CCATGGGGGA CACATCATGC 240 CTCCCACACA ATCGCAGTTT GGAGAGATGG GAGGCMAGTT TATGAAAAGC CAGGGGCTMA 300 GCCAGCTCTA CCATMACCAG AGTCAGGGAC TCTTATCCCA GCTGCAAGGA CAGTCGAAGG 360 152 ATATGCCACC TCGGTTTTCT AAGAAAGGAC AGCTTMATGC AGATGAGATT AGCCTGAGGA 420 GGCATCACCC GA. 432 INFORMATION FOR SEQ ID NO:177: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 788 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177: TAGCATGTTG AGCCCAGACA CAGTAGCATT TGTGCCAATT TCTGGTTGGA ATGGTGACMA CATGCTGGAG CCAAGTGCTA ACATGCCTTG GTTCMAGGGA TGGAAAGTCA CCCGTMAGGA 120 S...*TGGCAATGCC AGTGGMACCA CGCTGCTTGA GGCTCTGGAC TGCATCCTAC CACCAACTCG 180 CCCAACTGAC AAGCCCTTGC GCCTGCCTCT CCAGGATGTC TACAAAATTG GTGGTATTGG 240 TACTGTTCCT GTTGGCCGAG TGGAGACTGG TGTTCTCAMA CCCGGTATGG TGGTCACCTT 300 5*4TGCTCCAGTC AACGTTACMA CGGMAGTAAA ATCTGTCGAA ATGCACCATG MAGCTTTGAG 360 TGAAGCTCTT CCTGGGGACA ATGTGGGCTT CMTGTCAAG AATGTGTCTG TCAAGGATGT 420 TCGTCGTGGC MACGTTGCTG GTGACAGCMA AAATGACCCA CCMATGGMAG CAGCTGGCTf 480 CACTGCTCAG GTGATTATCC TGAACCATCC AGGCCAAATA AGTGCCGGCT ATGCCCCTGT 540 ATTGGATTGC CACACGGCTC ACATTGCATG CMAGTTTGCT GAGCTGAAGG AAAAGATTGA 600 TCGCCGTTCT GGTAAAAAGC TGGAAGATGG CCCTAMATTC TTGJ'AGTCTG GTGATGCTGC 660 153 CATTGTTGAT ATGGTTCCTG GCMAGCCCAT GTGTGTTGAG AGCTTCTCAG ACTATCCACC 720 TTTGGGTCGC TTTGCTGTTC GTGATATGAG ACAGACAGTT GCGGTGGGTG TCTGGGCTCA 780 ACATGCTA 788 INFORMATION FOR SEQ ID NO:178: SEQUENCE CHARACTERISTICS: LENGTH: 786 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi SEUNEDSRPIO:*QI O18 *ACTGT 0GCAGC CCGGTCTGACC GCGGC ATA G 6 *1*TGGC GCCMGATAAAT GTTTT ATATGTTTA 2 TGCATGTG AGCCAGACA CTGTTTC TGGAC GGAGTGGCG GATTCATATGAAGGT 360 CACTGTGGGCTGCCTTTGG TGAACACTT GGACTTTGATTTAATTAT TCTTTACAAA 120 TAGTC GTATTTTT ATGTAAAGTT TAATACAGAAGATCAGCAG TCAATTTTG 180 GTTTCG MAGCTT AGC AGTGAC GTTCCA TACT TAGTTATATAG AGGAGGATA 360 154 GACACTTTCT TGTTGACACC TTGMATATTA ATGTTCAAGG GTGCAATGTG TATTCCTTTA 600 GATTGTTAAA GCTTAATTAC TATGATTTGT AGTAAATTMA CTTJTAAAT GTATTTGAGC 660 CCTTCTGTAG TGTCGTAGGG CTCTTACAGG GTGGGAAAGA TTTTMT[TT CCAGTTGCTA 720 ATTGMACAGT ATGGCCTCAT TATATATTTT GATTTATAGG AGMTGTGTC TGGGCTCMAC 780 ATGCTA 786 INFORMATION FOR SEQ ID NO:179: i) SEQUENCE CHARACTERISTICS: LENGTH: 796 base pairs TYPE: nucleic acid STRANOEDNESS: single CD) TOPOLOGY: linear .0000:(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179: TAGCATGTTG AGCCCAGACA CTGGTTACMA GACCAGACCT GCTTCCTCCA TATGTAAACA GCTTTTAAAA AGCCAGTGAA CCTFTTAAT ACTTGGCAA CCTTCTTTCA CAGGCMAAGA 120 ACACCCCCAT CCGCCCCTTG TTTGGAGTGC AGAGTTTGGC TTTGGTTCTT TGCCTTGCCT 180 GGAGTATACT TCTAATTCCT GTTGTCCTGC ACMAGCTGAA TACCGAGCTA CCCACCGCCA 240 CCCAGGCCAG GTTCCACTC ATTTATTACT TTATGTTTCT GTTCCATTGC TGGTCCACAG 300 AAATMAGTTT TCCTTTGGAG GMATGTGATT ATACCCCTTT AMCCTCC T1TTGCTTTT 360 TTTTMATATC ATTGGTATGT GTTTGGCCCA GAGGAAACTG AAATTCACCA TCATCTTGAC 420 TGGCMATCCC ATTACCATGC 1TTFTTAAA MAACGTM.TT TTTCTTGCCT TACATTGGCA 480 GAGTAGCCCT TCCTGGCTAC TGGCTTAATG TAGTCACTCA GTTTCTAGGT GGCATTAGGC ATGAGACCTG MAGCACAGAC TGTCTTACCA CAAAAGGTGA CAAGATCTCA AACCTTAGCC MAAGGGCTAT GTCAGGTTTC AATGCTATCT GCTTCTGTTC CTGCTCACTG TTCTGGAT[ TGTCCTTCTT CATCCCTAGC ACCAGAM CCCAGTCTCC CTCCCTACCT TCCCTTGTTT TMATTCTAAT CTATCAGCMA AATAACTTTT CAMATGTTTT AACCGGTATC TCCATGTGTC TGGGCTCAAC ATGCTA INFORMATION FOR SEQ ID NO:180: SEQUENCE CHARACTERISTICS: LENGTH: 488 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 540 600 660 720 780 796 120 180 240 300 360 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18G: GGATGTGCTG CMAGGCGATT MAGTTGGGTA ACG CCAGGGT TTTCCCAGTC ACGACGTTGT APAACGACGG CCAGTGMATT GTMTACGAC TCACTATAGG GCGMATTGGG CCCGACGTCG CATGCTCCCG GCCGCCATGG CCGCGGGATA GCATGTTGAG CCCAGACACC TGCAGGTCAT TTGGAGAGAT TTTTCACGTT ACCAGCTTGA TGGTCTTTT CAGGAGGAGA GACACTGAGC ACTCCCMAGG TGAGGTTGAA GATTCCTCT AGATAGCCGG ATAAGAAGAC TAGGAGGGAT GCCTAGAAAA TGATTAGCAT GCAAATTTCT ACCTGCCATT TCAGMACTGT GTGTCAGCCC 156 ACATTCAGCT GCTTCTTGTG MACTGAAAAG AGAGAGGTAT TGAGACTTT CTGATGGCCG 420 CTCTMACATT GTMACACAGT MTCTGTGTG TGTGTGGGTG TGTGTGTGTG TCTGGGCTCA 480 ACATGCTA 488 INFORMATION FOR SEQ ID NO:181: SEQUENCE CHARACTERISTICS: LENGTH: 317 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181: TAGCATGTTG AGCCCAGACA CGGCGACGGT ACCTGATGAG TGGGGTGATG GCACCTGTGA AAAGGAGGAA CGTCATCCCC CATGATATTG GGGACCCAGA TGATGAACCA TGGCTCCGCG 120 TCMATGCATA TTTAATCCAT GATACTGCTG ATTGGMAGGA CCTGAACCTG AAGTTTGTGC 180 TGCAGGTTTA TCGGGACTAT TACCTCACGG GTGATCAAAA CTTCCTGAAG GACATGTGGC 240 CTGTGTGTCT AGTAAGGGAT GCACATGCAG TGGCCAGTGT GCCAGGGGTA TGGTTGGTGT 300 CTGGGCTCAA CATGCTA. 317 INFORMATION FOR SEQ ID NO:182: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 507 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear 157 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182: TAGCATGTTG AGCCCAGACA CTGGCTGTTA GCCMAATCCT CTCTCAGCTG CTCCCTGTGG TTTGGTGACT CAGGATTACA GAGGCATCCT GTTCAGGGA ACAAAMAGAT TTTAGCTGCC 120 AGCAGAGAGC ACCACATACA TTAGAATGGT MAGGACTGCC ACCTCCTTCA AGMACAGGAG 180 TGAGGGTGGT GGTGAATGGG MATGGAAGCC TGCATTCCCT GATGCATTTG TGCTCTCTCA 240 MTCCTGTCT TAGTCTTAGG AAAGGAAGTA MAGTTTCAAG GACGGTVCCG MCTGCTTT 300 TGTGTCTGGG CTCMCATGC TATCCCGCGG CCATGGCGGC CGGGAGCATG CGACGTCGGG 360 *CCCMATTCGC CCTATAGTGA GTCGTATTAC MATTCACTGG CCGTCGTFT ACAACGTCGT 420 GACTGGGAAA ACCCTGGCGT TACCCAACTT MATCGCCTTG CAGCACATCC CCCTTTCCCA 480 GCTGGCGTMA TANCGAAAAG GCCCGCA 507 INFORMATION FOR SEQ ID NO:183: Ci) SEQUENCE CHARACTERISTICS: CA) LENGTH: 227 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183: -GATTTACGCT GCMACACTGT GGAGGTAGCC CTGGAGCMAG GCAGGCATGG ATGCTTCTGC -AATCCCCAMA TGGAGCCTGG TATTTCAGCC AGGMATCTGA GCAGAGCCCC CTCTAATTGT 120 158 AGCAATGATA AGTTATTCTC TTTGTTCTTC AACCTTCCAA TAGCCTTGAG CTTCCAGGGG 180 AGTGTCGTTA ATCATTACAG CCTGGTCTCC ACAGTGTTGC AGCGTAA 227 INFORMATION FOR SEQ ID NO:184: SEQUENCE CHARACTERISTICS: LENGTH: 225 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184: TTACGCTGCA ACACTGTGGA GCAGATTAAC ATCAGACTTT TCTATCAACA TGACTGGGGT TACTAAAAAG ACAACAAATC AATGGCTTCA AAAGTCTAAG GAATAATTTC GATACTTCAA 120 CTTTATAAAA CCTGACAAAA CTATCAATCA AGCATAAAGA CAGATGAAGA ACATTTCCAG 180 ATTTTGGCCA ATCAGATATT TTACCTCCAC AGTGTTGCAG. CGTAA 225 INFORMATION FOR SEQ ID NO:185: SEQUENCE CHARACTERISTICS: LENGTH: 597 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185: GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA 159 CTGGGACCCA TAGGCTAGTC AGAGTATTTA GAGTTGAGTT CCTTTCTGCT TCCCAGAATT 120 TGAMAGAAAA GGAGTGAGGT GATAGAGCTG AGAGAICAGA TFVGCCTCTG AAGCCTGTTC 180 MAGATGTATG TGCTCAGACC CCACCACTGG GGCCTGTGGG TGAGGTCCTG GGCATCTATT 240 TGAATGAATT GCTGAAGGGG AGCACTATGC CAAGGAAGGG GMACCCATCC TGGCACTGGC 300 ACAGGGGTCA CCTTATCCAG TGCTCAGTGC TTCTTTGCTG CTACCTGGTT TTCTCTCATA 360 TGTGAGGGGC AGGTMAGAAG AAGTGCCCRG TGTTGTGCGA GTTTTAGAAC ATCTACCAGT 420 AAGTGGGGMA GTTTCACMAA GCAGCAGCTT TGTTTTGTGT ATTCACCT TCAGTTAGAA 480 GAGGAAGGCT GTGAGATGAA TGTTAGTTGA GTGGAAAAGA CGGGTAAGCT TAGTGGATAG 540 AGACCCTAAC GPATCACTAG TGCGGCCGCC TTGCAGGTCG ACCATATGGG AGAGCTC 597 INFORMATION FOR SEQ ID NO:186: SEQUENCE CHARACTERISTICS: LENGTH: 597 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186: GGCCCGA.AGT TGCATGTTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA CTACCTAAAA AATCCCMAAC ATATAACTGA ACTCCTCACA CCCMATTGGA CCMATCCATC 120 ACCCCAGAGG CCTACAGATC CTCCTTTGAT ACATMAGAAA AT1TCCCCMA ACTACCTAAC 180 160 TATATCATTT TGCMAGATTT GTTTTACCMA ATTTTGATGG CCTTTCTGAG TGMACCACTA TTACGAACGA TCGGATATTA ACTGCCCCTC ACCGTCCAGG MACATCMAGT GCAGTMAATA TTCATTMAGT TTTCACCTAC TMAGGTGCTT GGGTGCCATG TCGGTAGCAG ATCTTTTGAT TVGTTTTTAT TTCCCATAAG MAGGTCAATC ATACATGTAG TGTGAGCAGC TAGTCACTAT CGCATGACTT MATAGAGGCC TCCTTTGCTG TTAAAGMACT CTTGTCCCAG CCTGTCAAAG CCCTAACGMA TCACTAGTGC GGCCGCCTGC AGGTCGACCA TATGGGAGAG INFORMATION FOR SEQ ID NO:187: SEQUENCE CHARACTERISTICS: LENGTH: 324 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear

CTTGTCAGTG

TGTAGCTGGC

MACACCCTA

GGTCCTGTTC

GGAGGGTGAT

TGGATAGAGA

CTCCCAA

240 300 360 420 480 540 597 120 180 240 300 324 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187: TCGTTAGGGT CTCTATCCAC TTGCAGGTMA MTCCMTCC TGTGTATATC TTATAGTCTT CCATATGTAG TGGTTCAAGA GACTGCAGTT CCAGAAAGAC TAGCCGAGCC CATCCATGTC TTCCACTTAA CCCTGCTTTG GGTTACACAT CTTAACTTTT CTGTTCMAGT TTCTCTGTGT AGTTTATAGC ATGAGTATTG GGAWMATGCC CTGAAACCTG ACATGAGATC TGGGAAACAC AMACTTACTC MTMGAATT TCTCCCATAT TTTTATGATG GAAAMTTT C ACATGCACAG AGGAGTGGAT AGAGACCCTA ACGA 161 INFORMATION FOR SEQ ID NO:188: SEQUENCE CHARACTERISTICS: LENGTH: 178 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SEQUENCE DESCRIPTION: SEQ ID NO:188: GCGCGGGGAT TCGGGGTGAT ACCTCCTCAT GCCAAAATAC AACGTNTAAT TTCACAACTT GCCTTCCAAT TTACGCATTT TCAATTTGCT CTCCCCATTT GTTGAGTCAC AACAAACACC 120 ATTGCCCAGA AACATGTATT ACCTAACATG CACATACTCT TAAAACTACT CATCCCTT 178 INFORMATION FOR SEQ ID NO:189: SEQUENCE CHARACTERISTICS: LENGTH: 367 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189: TGACACCTTG TCCAGCATCT GACACAGTCT TGGCTCTTGG AAAATATTGG ATAAATGAAA ATGAATTTCT TTAGCAAGTG GTATAAGCTG AGAATATACG TATCACATAT CCTCATTCTA 120 AGACACATTC AGTGTCCCTG AAATTAGAAT AGGACTTACA ATAAGTGTGT TCACTTTCTC 180 AATAGCTGTT ATTCAATTGA TGGTAGGCCT TAAAAGTCAA AGAAATGAGA GGGCATGTGA 240 162 AAAAAAGCTC MCATCACTG ATCATTAGAA MACTTCCATT CAAACCCCCA ATGAGATACC 300 ATCTCATACC AGTCAGAATG GCTATTATTA AMAAGTCAAA AAATAACAGA TGCTGGACAA 360 GGTGTCA 367 INFORMATION FOR SEQ ID NO:190: SEQUENCE CHARACTERISTICS: LENGTH: 369 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190: GACACCTTGT CCAGCATCTG ACAACGCTAA CAGCCTGAGG AGATCTTTAT TTATTTATTT AGTTTTACT CTGGCTAGGC AGATGGTGGC TAWXACATTC ATTTACCCAT TTATTCATTT 120 :O*AATTGTTCCT GCAAGGCCTA TGGATAGAGT ATTGTCCAGC ACTGCTCTGG AAGCTAGGAG 180 CATGGGGATG MACMGATAG GCTACATCCT GTTCCCACAG MACTTCCACT TTAGTCTG3G 240 AAACAGATGA TATATACIIAA TATATAAATG MTTCAGGTA GTTTTMAGTA CGAAAAGAAT 300 MGAMAGCAG AGTCATGATT TANAATGCTG GAAACAGGGG CTATTGCTTG AGATATTGMA 360 GGTGCCCAA 369 INFORMATION FOR SEQ ID NO:191: SEQUENCE CHARACTERISTICS: LENGTH: 369 base pairs 163 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191: TGACACCTTG TCCAGCATCT GCACAGGGMA AAGAAACTAT TATCAGAGTG AACAGGCAAC CTACAGAATG GGAGAAAATT TTGCMATCT ATCCATCTGA CAMAGGGCTA ATATCCAGMA 120 see *TCTACAAAGA ACTTATACAA ATTTACMAGA AACAAACAAA CAAACMACTC CTCAAAAAGT 180 .:GGGTGMAGGA TGTGMACAGA CACTTCTCAA AAGAAGACAT TTATGGGGCC AACAAACATA 240 TGAAAAAAAG CTCATCATCA CTGGTCACTA GATAMATGCA MATCAAAACC ACAATGAGAT 30.0 *ACCATCTCAT TCCAGTTAGA ATGGCMATCA TTAAAAAGTC AGGAAACMAC AGATGCTGGA 360 00.:CMGGTGTC 369 INFORMATION FOR SEQ ID NO:192: SEQUENCE CHARACTERISTICS: LENGTH: 449 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192: TGACGCTTGG CCACTTGACA CTTCATCTT GCACAGAAAA ACTTCTTTAC AGATTTMATT CMAGACTGGT CTAGTGACAG TCCTCCAGAC ATTTTCAT TTGTTCCATA TACGTGGAAT 120 164 TTAAMATCA TGTTTCATCA GTTTGAAATG ATTTGGGCTG CTAATCAACA CAATTGGATC 180 GACTGTTCTA CTAMACMCA GGAAMATGTG TATCTGGCAG CCTGTGGAGA AACACTAAAC 240 ATTGATTTTT CTTTGCCTTT TACGGACTTT GTTCCAGCTA CATGTAATAC CAAGTTCTCT 300 TTAAGAGGAG MAGATGTTGA TCTTCATTTG TTTCTACCAG ACTGCCACCC TAGTPAATAT 360 TCTTATTTA TGCTGGTAAA AMATTGCCAT CCAAATMAGA TGATTCATGA TACTGGTATT 420 CCTGCTGAGT GTCMGTGGC CAAGCGTCA 449 INFORMATION FOR SEQ ID NO:193: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 372 base-pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear xi) SEQUENCE DESCRIPTION: SEQ ID NO:193: 0TGACGCTTGG CCACTTGACA CCAGGGATGT AKCAGTTGMA TATAATCCTG CMTTGTACA TATTGGCAAT TTCCCATCMA ACATTCTAGA AAGAGACMAC CAGGATTGCT AGGCCATPAA 120 AGCTGCMATA AATMACTGGT AATTGCAGTA ATCATTTCAG GCCMATTCMA TCCAGTTGG 180 CTCAGAGGTG CCTTTGGCTG AGAGMAGAGG TGAGATATMA TGTGTTTTCT TGCAACTTCT 240 TGGMAGAATA ACTCCACMAT AGTCTGAGGA CTAGATACAA ACCTAT1GC CATTAAAGCA 300 CCAGAGTCTG TTAATTCCAG TACTGATMAG TGTTGGAGAT TAGACTCCAG TGTGTCAAGT 360 GGCCMAGCGT CA 372 165 INFORMATION FOR SEQ ID NO:194: SEQUENCE CHARACTERISTICS: LENGTH: 309 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194: TGACGCTTGG CCACTTGACA CTTATGTAGA ATCCATCGTG GGCTGATGCA AGCCCTITAT TTAGGCTTAG TGTTGTGGGC ACCTTCAATA TCACACTAGA GACAAACGCC ACAAGATCTG 120 CAGMAACATT CAGTTCTGAN CACTCGMATG GCAGGATMAC TTTTTGTGTT GTMATCC1TC 180 ACATATACAA AAACAAACTC TGCANTCTCA CGTTACAAAA AAACGTACTG CTGTAAAATA 240 *too*:TTMAGAAGGG GTAAAGGATA CCATCTATAA CA.AAGTAACT TACAACTAGT GTCMAGTGGC 300 '0:,CAAGCGTCA 309 INFORMATION FOR SEQ ID NO:195: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 31? base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195: -TGACGCTTGG CCACTTGACA CCCMATCTCG CACTTCATCC TCCCAGCACC TGATGAAGTA 166 GGACTGCAAC TATCCCCACT TCCCAGATGA GGGGACCAAN GTACACATTA GGACCCGGAT 120 GGGAGCACAG ATTTGTCCGA TCCCAGACTC CAAGCACTCA GCGTCACTCC AGGACAGGG 180 CTTTCAGATA AGGTCACAMA CATGAATGGC TCCGACMACC GGAGTCAGTC CGTGCTGAGT 240 TAAGGCAATG GTGACACGGA TGCACGTGTN ACCTGTAATG GTTCATCGTA AGTGTCMAGT 300 GGCCAAGCGT CA 312 INFORMATION FOR SEQ ID NO:196: SEQUENCE CHARACTERISTICS: LENGTH: 288 basepar TYPE: nucleic acid STRANDEDNESS: single *0.000CD) TOPOLOGY: linear SEQUENCE DESCRIPTION: SEQ ID NO:196: %0 TGTATCGACG TAGTGGTCTC CTCAGCCATG CAGAACTGTG ACTCAATTAA ACCTCTTCC TTTATGMATT ACCCMATCTC GGGTAGTGTC TTTATAGTAG TGTGAGAATG GACTMTACA 120 AGTACATTTT ACTTAGTMAT MATAATAAAC AMATATATTA CATTTTTGTG TATTTACTAC 180 ACCATATTTT TTATTGTTAT TGTAGTGTAC ACCTTCTACT TATTAAAAGA MTAGGCCCG 240 AGGCGGGCAG ATCACGAGGT CAGGAGATGG AGACCACTAC GTCGATAC 288 INFORMATION FOR SEQ ID NO:197: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 289 base pairs 'A67 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197: TTGGGCACCT TCAATATCAT GACAGGTGAT GTGATMACCA AGMAGGCTAC TAAGTGATTA ATGGGTGGGT MTGTATACA GAGTAGGTAC ACTGGACAGA GGGGTAATTC ATAGCCAAGG 120 CAGGAGAAGC AGMATGGCMA MCATTTCAT CACACTACTC AGGATAGGAT GCAGTTTAAA 180 *ACCTATAAGT AGTTTATTTT TGGMATTTTC: CACTTMATAT TTTCAGACTG CAGGTMACTA 240 AACTGTGGAA CACMAGAACA TAGATAAGGG GAGACCACTA CGTCGATAC 289 INFORMATION FOR 'SEQ ID NO:198: SEQUENCE CHARACTERISTICS: LENGTH: 288 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198: GTATCGACGT AGTGGTCTCC CMAGCAGTGG GMAGAAAACG TGAACCMATT AAAATGTATC AGATACCCCA AAGAAAGGCG CTTGAGTAAA GATTCCMAGT GGGTCACAAT CTCAGATCTT 120 MAATTCAGG CTGTCAMAGA GA1TTGCTAT GAGGTTGCTC TCAATGACTT CAGGCACAGT 180 CGGCAGGAGA TTGMAGCCCT GGCCATTGTC AAGATGAAGG AGC1TTGTGC CATGTATGGC 240 168 AAGAAAGACC CCAATGAGCG GGACTCCTGG AGACCACTAC GTCGATAC 288 INFORMATION FOR SEQ ID NO:199: SEQUENCE CHARACTERISTICS: LENGTH: 1027 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199: 0:00.: GCTTTTTGGG AAAAACNCAA NTGGGGGAAA GGGGGNTTNN TNGCAAGGGG ATAAAGGGGG AANCCCAGGG MTTCCCCATT CAGGGAGGTG TAPAAAGNCG GCCAGGGGAT TGTAANAGGA 120 o TTCAATAATA GGGGGAATGG GCCCNGAAGT TGCAAGGTTC CNGCCCGCCA TGNCCGCGGG 180 A1TTAGTGAC ATTACGACGS TGGTAATAAA GTGGGSCCAA WAAATATTTG TGATGTGATT 240 TSGACCAG TGAACCCATT GWACAGGACC TCATTTCCTY TGAGATGRTA GCCATAATCA 300 GATAAAAGRT TAGAAGTYTT TCTGCACGTT AACAGCATCA TTAAATGGAG TGGCATCACC 360 AATTTCACCC TTTGTTAGCC- GATACCTTCC CCTTGAAGGC ATTCAATTAA GTGACCAATC 420 GTCATACGAG AGGGGATGGC ATGGGGATTG ATGATGATAT CAGGGGTGAT ACCTTCACAG 480 GTGAAAGGCA TATCCTCTTG TCTATACTGA ATACCACAAG TACCCTTTTG ACCATGTCGA 540 CTAGCAAATT TGTCTCCAAT CTGTGTWATC CCTAACAGAG CGTACCCTTA TTTTACAAAA 600 TTTATATCCT TCCTGATTGA GAGTTACCAT AACCTGATCC ACAATGCCCG TCTCGCTWGT 660 TCTGAGAAAA GTGCTACAGT CTCTCTTGGT ATAGCGTCTA TTGGTGCTCT CCAATTCATC 720 169 TTCATTFTTC AGGCAAGGTG AACTGTT1TG CCTATAATAA CMTCATCTCC TGATACMCGA 780 MACCCCKGGA RCTATCNIAC CATCATCATC CAGCGTTCKT WATGTYMCTA AATCCCTATT 840 GCGGCCGCCT GCAGGTCMAC ATATNGGAAA ACCCCCCACC CCTVNGGAGC NTACCTTGAA 900 TTTCCATAT GTCCCNTAAA TTANCTNGNC TTANCCTGGC CNTAACCTNT TCCGGTMTM 960 ATTGTTTCCG CCCCCNTTCC CCNCCTTNNA ACCGGAAACC TTAAT]TTNA ACCNGGGGTT 1020 *CCTATCC 1027 INFORMATION FOR SEQ ID NO:200: SEQUENCE CHARACTERISTICS: LENGTH: 207 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

*O

AGTGACATTA CGACGCTGGC CATC1TGAAT CCTAGGGCAT GAAGTTGCCC CAAAGTTCAG CACTTGGTFTA AGCCTGATCC CTCTGGTTTA TCACAMAGM TAGGATGGGA TAAAGAAAGT 120 GGACACTTMA ATMGCTATA MTTATATGG TCCTTGTCTA GCAGGAGACA ACTGCACAGG 180 TATACTACCA GCGTCGTAAT GTCACTA 207 INFORMATION FOR SEQ ID NO:201: SEQUENCE CHARACTERISTICS: LENGTH: 209 base pairs 170 TYPE: nucleic acid STRANIEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201: TGGGCACCTT CAATATCTAT TAAAAGCACA AATACTGAAG AACACACCAA GACTATCAAT GAGGTTACAT CTGGAGTCCT CGATATATCA GGAAAAAATG AAGTGAACAT TCACAGAGTT 120 TTACTTCT GGGAACTCAA ATGCTAGAAA AGAAAAGGGT GCCCTCTTTC TCTGGCTTCC 180 TGGTCCTATC CAGCGTCGTA ATGTCACTA 209 INFORMATION FOR SEQ ID NO:202: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 349 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202: NTACGCTGCA ACACTGTGGA GCCACTGGTT TTTATTCCCG GCAGGTTATC CAGCAAACAG TCACTGAACA CACCGAAGAC CGTGGTATGG TAACCGTTCA CAGTAATCGT TCCAGTCGTC 120 TGCGGGACCC CGACGAGCGT CACTGGGTAC AGACCAGA1T CAGCCGGAAG AGAAAGCGCC 180 GCAGGGAGAG ACTCGAACTC CACTCCGCTG GTGAGCAGCC CCATGTTTTC AACTCGAAGT 240 TCAAACGGCA TTGGGTTATA TACCATCAGC TGAACTTCAC ACACATCTCC TTGAACCCAC 300 I I_ _lp 171 TGGAAATCTA TTTTCTTGTT CCGCTCTTCT CCACAGTGTT GCAGCGTAA 349 INFORMATION FOR SEQ ID NO:203: SEQUENCE CHARACTERISTICS: LENGTH: 241 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203: *i TGCTCCTCTT GCCTTACCAA CCCAAAGCCC ACTGTGAAAT ATGAAGTGAA TGACAAAATT CAGTTTTCAA CGCAATATAG TATAGTTTAT CTGATTCTTT TGATCTCCAG GACACTTTAA 120 ACAACTGCTA CCACCACCAC CAACCTAGGG ATTTAGGATT CTCCACAGAC CAGAAATTAT 180 TTCTCCTTTG AGTTTCAGGC TCCTCTGGGA CTCCTGTTCA TCAATGGGTG GTAAATGGCT 240 A 241 INFORMATION FOR SEQ ID NO:204: SEQUENCE CHARACTERISTICS: LENGTH: 248 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204: TAGCCATTTA CCACCCATCT GCAAACCSWG ACMWWCARGR CYWGWACKYA GGCGATTTGA 172 AGTACTGGTA ATGCTCTGAT CATGTTAGTT ACATAAGTGT GGTCAGTTTA CAAAAATTCA CAGAACTAAA TACTCAATGC TATGTGTTCA TGTCTGTGTT TATGTGTGTG TAATGTTTCA ATTAAGTTTT TTTAAAA AGAGATGATT TCCAAATAAG AAAGCCGTGT TGGTAAGGCA

AGAGGAGC

INFORMATION FOR SEQ ID NO:205: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 505 base pairs TYPE: nucleic acid CC).STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205: TACGCTGCAA CACTGTGGAG CCATTCATAC AGGTCCCTAA TTAAGGAACA AGTGATTATG CTACCTTTGC ACGGTTAGGG TACCGCGGCC GTTAAACATG TGTCACTGGG CAGGCGGTGC CTCTAATACT GGTGATGCTA GAGGTGATGT TTTTGGTAAA CAGGCGGGGT AAGATTTGCC GAGTTCCTTT TACTTTTTTT AACCTTTCCT TATGAGCATG CCTGTGTTGG GTTGACAGTG GGGGTAATAA TGACTTGTTG GTTGATTGTA GATATTGGGC TGTTAATTGT CAGTTCAGTG TTTTAATCTG ACGCAGGCTT ATGCGGAGGA GAATGTTTTC ATGTTACTTA TACTAACATT AGTTCTTCTA TAGGGTGATA GATTGGTCCA ATTGGGTGTG AGGAGTTCAG TTATATG1TT GGGATTTTTT AGGTAGTGGG TGTTGANCTT GAACGCTC TTMTTGGTG GCTGCTTA RGCCTACTAT GGGTGGTAAA TGGCT 120 180 240 248 120 180 240 300 360 420 480 505 173 INFORMATION FOR SEQ ID NO:206: SEQUENCE CHARACTERISTICS: LENGTH: 179 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206: TAGACTGACT CATGTCCCCT ACCAAAGCCC ATGTAAGGAG CTGAGTTCTT AAAGACTGAA GACAGACTAT TCTCTGGAGA AAAATAAAAT GGAAATTGTA CTTTAAAAAA AAAAAAAATC 120 GGCCGGGCAT GGTAGCACAC ACCTGTAATC CCAGCTACTA GGGGACATGA GTCAGTCTA 179 INFORMATION FOR SEQ ID NO:207: SEQUENCE CHARACTERISTICS: LENGTH: 176 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207: AGACTGACTC ATGTCCCCTA CCCCACCTTC TGCTGTGCTG CCGTGTTCCT AACAGGTCAC AGACTGGTAC TGGTCAGTGG CCTGGGGGTT GGGGACCTCT ATTATATGGG ATACAAATTT 120 AGGAGTTGGA ATTGACACGA TTTAGTGACT GATGGGATAT GGGTGGTAAA TGGCTA 176 INFORMATION FOR SEQ ID NO:208: 174 Ci) SEQUENCE CHARACTERISTICS: LENGTH: 196 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi SEQUENCE DESCRIPTION: SEQ ID NO: 208: AGACTGACTC ATGTCCCCTA TTTMACAGGG TCTCTAGTGC TGTGAAAAAA AAAAATGCTG :7.AACATTGCAT ATMACTTATA TTGTAAGAAA TACTGTACAA TGACTTTATT GCATCTGGGT 120 CATGAAGGAT GCCAAGAAGT TTAAGGAATA TGGGTGGTAA ATGGCTAGGG 180 GACATGAGTC AGTCTA 196 INFORMATION FOR SEQ ID NO:209: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 345 base pairs TYPE: nucleic acid.

CC) STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209: GACGCTTGGC CACTTGACAC CTTTTATTTT 1TMAGGATTC TTMAGTCATT TANGTNACTT TGTAAGTTTT TCCTGTGCCC CCATMAGMT GATAGCTTTA AMAATTATGC TGGGGTAGCA 120 MAGAAGATAC TTCTAGCTTT AGAATGTGTA GGTATAGCCA GGATTCTTGT GAGGAGGGGT 180 GATTTAGAGC MATTTCTTA TTCTCCTTGC CTCATCTGTA ACATGGGGAT MTMTAGAA 240 175 CTGGCTTGAC AAGGTTGGAA TTAGTATTAC ATGGTAAATA CATGTAAAAT GTTTAGAATG 300 GTGCCAAGTA TCTAGGAAGT ACTTGGGCAT GGGTGGTAAA TGGCT 345 INFORMATION FOR SEQ ID NO:210: SEQUENCE CHARACTERISTICS: LENGTH: 178 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210: SGACGCTTGGC CACTTGACAC TAGAGTAGGG TTTGGCCAAC TTTTTCTATA AAGGACCAGA GAGTAAATAT TTCAGGCTTT GTGGGTTGTG CAGTCTCTCT TGCAACTACT CAGCTCTGCC 120 ATTGTAGCAT AGAAATCAGC CATAGACAGG ACAGAAATGA ATGGGTGGTA AATGGCTA 178 INFORMATION FOR SEQ ID NO:211: SEQUENCE CHARACTERISTICS: LENGTH: 454 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211: TGGGCACCTT CAATATCTAT CCAGCGCATC TAAATTCGCT TTTTTCTTGA TTAAAAATTT CACCACTTGC TGTTTTTGCT CATGTATACC AAGTAGCAGT GGTGTGAGGC CATGCTTGTT 120 176 T1TTGATTCG ATATCAGCAC CGTATMAGAG CAGTGCTTTG GCCATTAATT TATCTTCATT 180 GTAGACAGCA TAGTGTAGAG TGGTATCTCC ATACTCATCT GGAATATTTG GATCAGTGCC 240 ATGTTCCAGC AACATTAACG CACATTCATC T[CCTGGCAT TGTACGGCCT TTGTCAGAGC 300 TGTCCTCT TTGTTGTCMA GGACATTMAG TTGACATCGT CTGTCCAGCA CGAGTTTTAC 360 TACTTCTGMA TICCCATTGG CAGAGGCCAG ATGTAGAGCA GTCCTCTTTT GCTTGTCCCT 420 CTTGTTCACA TCAGTGTCCC TGAGCATMAC GGMA 454 INFORMATION FOR SEQ ID NO:212: SEQUENCE CHARACTERISTICS: LENGTH: 337 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear *Voo:(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212: oo* 0 TCCGTTATGC CACCCAGAAA ACCTACTGGA GTTACTTATT MACATCAAGG CTGGMCCTA TTTGCCTCAG TCCTATCTGA TTCATGAGCA CATGGTTATT ACTGATCGCA TTGAAAACAT 120 TGATCACCTG GGTTTCTTTA TTTATCGACT GTGTCATGAC AAGGAAACTT ACAAACTGCA 180 ACGCAGAGMA ACTATTAMAG GTATTCAGAA ACGTGAAGCC AGCAATTGTT TCGCAATTCG 240 GCATTrGAA AACAAMG CCGTGGAAAC TTTMATTTGT TCTTGAACAG TCAAGAAAAA 300 CATTATTGAG GAAAATTMAT ATCACAGCAT MACGGAA 337 177 INFORMATION FOR SEQ ID NO213: SEQUENCE CHARACTERISTICS: LENGTH: 715 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213: TCGGGTGATG CCTCCTCAGG CATCTTCCAT CCATCTCTTC AAGATTAGCT GTCCCAAATG TTTTTCCTTC TCTTCTTTAC TGATAAATTT GGACTCCTTC TTGACACTGA TGACAGCTTT 120 AGTATCCTTC TTGTCACCTT GCAGACTTTA AACATAAAAA TACTCATTGG TTAAAAGG 180 AAAAAAGTAT ACATTAGCAC TATTAAGCTT GGCCTTGAAA CA1TTTCTAT CTTTTAT 240 ATGTCGGTTA GCTGAACAGA ATTCATTTTA CAATGCAGAG TGAGAAAAGA AGGGAGCTAT 300 *ATGCATTTGA GAATGCAAGC ATTGTCAAAT AAACATTTTA AATGCTTTCT TAAAGTGAGC 360 ACATACAGAA ATACATTAAG ATATTAGAAA GTGTTTTTGC TTGTGTACTA CTAATTAGGG 420 AAGCACCTTG TATAGTTCCT CTTCTAAAAT TGAAGTAGAT TTTAAAAACC CATGTAATTT 480 AATTGAGCTC TCAGTTCAGA TTTTAGGAGA ATTTAACAG GGATTTGGTT TTGTCTAAAT 540 TTTGTCAATT TNTTTAGTTA ATCTGTATAA TTTATAAAT GTCAAACTGT ATTTAGTCCG 600 TTTTCATGCT GCTATGAAAG AAATACCCAN GACAGGGTTA mATAANG GAAAGANGTT 660 AATTTGACTC CCAGTTCACA GGCCTGAGGA NGNATCNCCC GAAATCCTTA TTGCG 715 INFORMATION FOR SEQ ID NO:214: SEQUENCE CHARACTERISTICS: LENGTH: 345 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear a a a a a a a a a a a r a a a a a a a a (xi) SEQUENCE DESCRIPTION: SEQ ID ND:214: GGTAANGNGC ATACNTCGGT GCTCCGGCCG CCGGAGTCGG GGGATTCGGG TCAGGCCCAC TTGGGCCTGC TTTTCCCAAA TGGCAGCTCC TCTGGACATG TCCCACCTGC CTGATTCTTC ATATGTTGGG TGTCCCTGTT TTTCTGGTGC CTGCTGTTCA GCTGCCACTG TCCTGCAAAG CCTGCCTTTT TAAATGCCTC CATTGTTTC TTAAATATGG GAAGTGAAAG TGCCACCTGA GGCCGGGCAC GCCTGTAATC CCAGCACTTT GGGAGCCTGA GGAGGCATCA CCCGA INFORMATION FOR SEQ ID NO:215: i) SEQUENCE CHARACTERISTICS: LENGTH: 429 base pairs TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear

TGATGCCTCC

CCATTCCTTC

TATTTCCTGA

ACCATTCCTT

AGTGGCTCAC

120 180 240 300 345 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215: GGTGATGCCT CCTCAGGCGA AGCTCAGGGA GGACAGAAAC CTCCCGTGGA GCAGAAGGGC AAAAGCTCGC TTGATCTTGA TTTTCAGTAC GAATACAGAC CGTGAAAGCG GGGCCTCACG 179 ATCCTTCTGA CCTTTTGGGT TTAAGCAGG AGGTGTCAGA AAAGTTACCA CAGGGATMAC 180 TGGCTTGTGG CGGCCMAGCG TTCATAGCGA CGTCGCTTTT TGATCCTTCG ATGTCGGCTC 240 TTCCTATCAT TGTGMAGCAG AATTCACCMA GCGTTGGATT GTTCACCCAC TMATAGGGMA 300 CGTGAGCTGG GTTTAGACCG TCGTGAGACA GGTTAGTT1T ACCCTACTGA TGATGTGTKG 360 TTGCCATGGT MATCCTGCTC AGTACGAGAG GAACCGCAGG TTCASACATT TGGTGTATGT 420 GCTTGCCTT 429 INFORMATION FOR SEQ ID NO:216: SEQUENCE CHARACTERISTICS: LENGTH: 593 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216: TGACACCTAT GTCCNGCATC TGTTCACAGT TTCCACAAAT AGCCAGCCTT TGGCCACCTC TCTGTCCTGA GGTATACMAG TATATCAGGA GGTGTATACC TTCTCTTCTC TTCCCCACCA 120 AAGAGMACAT GCAGGCTCTG GAAGCTGTCT TAGGAGCCT[ TGGGCTCAGA ATTTCAGAGT 180 CTTGGGTACC TTGGATGTGG TCTGGAAGGA GAAACATTGG CTCTGGATAA GGAGTACAGC 240 CGGAGGAGGG TCACAGAGCC CTCAGCTCAA GCCCCTGTGC CTTAGTCTAA MAGCAGCTTT 300 GGATGAGGAA GCAGGTTMAG TAACATACGT MAGCGTACAC AGGTAGMAAG TGCTGGGAGT 360 180 CAGAATTGCA CAGTGTGTAG GAGTAGTACC TCAATCAATG AGGGCAAATC AACTGAAAGA 420 AGAAGACCNA TTAATGAATT GCTTANGGGG AAGGATCAAG GCTATCATGG AGATCTTTCT 480 AGGAAGATTA TTGTTTANAA TTATGAAAGG ANTAGGGCAG GGACAGGGCC AGAAGTANAA 540 GANAACATTG CCTATANCCC TTGTCTTGCA CCCAGATGCT GGACAAGGTG TCA 593 INFORMATION FOR SEQ ID NO:217: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 335 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217: TGACACCTTG TCCAGCATCT GACGTGAAGA TGAGCAGCTC AGAGGAGGTG TCCTGGATTT CCTGGTTCTG TGGGCTCCGT GGCAATGMT TCTTCTGTGA AGTGGATGAA GACTACATCC 120 AGGACAAATT TAATCTTACT GGACTCAATG AGCAGGTCCC TCACTATCGA CAAGCTCTAG .180 ACATGATCTT GGACCTGGAG CCTGATGAAG AACTGGAAGA CAACCCCAAC CAGAGTGACC 240 TGATTGAGCA GGCAGCCGAG ATGCTTTATG GATTGATCCA CGCCCGCTAC ATCCTTACCA 300 ACCGTGGCAT CGCCCAGATG CTGGACAAGG TGTCA 335 INFORMATION FOR SEQ ID NO:218: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 248 base pairs TYPE: nucleic acid 181 STRANDEDNESS: single TOPOLOGY: linear (xi SEQUENCE DESCRIPTION: SEQ ID NO: 218: TACGTACTGG TCTTGMAGGT CTTAGGTAGA GAAMTGT GAATATTTAA TCAAAGACTA TGTATGMAAT GGGACTGTMA GTACAGAGGG AAGGGTGGCC CTTATCGCCA GMAGTTGGTA 120 GATGCGTCCC CGTCATGMAA TGTTGTGTCA CTGCCCGACA TTTGCCGAAT TACTGAAATT 180 CCGTAGAATT AGTGCAMATT CTMACGTTGT TCATCTAAGA TTATGGTTCC ATGTFCTAG 240 *TACTTTTA 248 INFORMATION FOR SEQ ID NO:219: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 530 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219: TGACGCTTGG CCACTTGACA CAAGTAGGGG ATAAGGACAA AGACCCATNA GGTGGCCTGT CAGCCTTTTG TTACTGTFGC TTCCCTGTCA CCACGGCCCC CTCTGTAGGG GTGTGCTGTG 120 CTCTGTGGAC ATTGGTGCAT TTCACACAT ACCATTCTCT TTCTGCTTCA CAGCAGTCCT 180 GAGGCGGGAG CACACAGGAC TACCTTGTCA GATGANGATA ATGATGTCTG GCCAACTCAC 240 CCCCCAACCT TCTCACTAGT TATANGMAGA GCCANGCCTA NMACCTTCTA TCCTGNCCCC 300 182 TTGCCCTATG ACCTCATCCC TGTTCCATGC CCTATTCTGA TTTCTGGTGA ACTTTGGAGC 360 AGCCTGGTTT NTCCTCCTCA CTCCAGCCTC TCTCCATACC ATGGTANGGG GGTGCTGTTC 420 CACNCAAANG GTCAGGTGTG TCTGGGGAAT CCTNANANCT GCCNGGAGTT TCCNANGCAT 480 TCTTAAAAAC CTTCTTGCCT AATCANATNG TGTCCAGTGG CCMCCNTCN 530 INFORMATION FOR SEQ ID NO:220: SEQUENCE CHARACTERISTICS: LENGTH: 531 base pairs TYPE: nucleic acid STRANDEDNESS: single CD) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220: TGACGCTTGG CCACTTGACA CTAAATAGCA TCTTCTAAAG GCCTGATVCA GAGTTGTGGA AAATTCTCCC AGTGTCAGGG ATTGTCAGGA ACAGGGCTGC TCCTGTGCTC ACTTTACCTG 120 CTGTGTTTCT GCTGGAAAAG GAGGGAAGAG GAATGGCTGA TTTTTACCTA ATGTCTCCCA 180 G1 TTTCATA TTCTTCTTGG ATCCTCTTCT CTGACAACTG TTCCCTTTTG GTCTTCTTCT 240 TCTTGCTCAG AGAGCAGGTC TCTTTAAAAC TGAGAAGGGA GAATGAGCAA ATGATTAAAG 300 AAAACACACT TCTGAGGCCC AGAGATCAAA TATTAGGTAA ATACTAAACC GCTTGCCTGC 360 TGTGGTCACT TTTCTCCTCT TTCACATGCT CTATCCCTCT ATCCCCCACC TATTCATATG 420 GCTTATCT GCCAAGTTAT CCGGCCTCTC ATCAACCTTC TCCCCTAGCC TACTGGGGGA 480 183 TATCCATCTG GGTCTGTCTC TGGTGTATTG GTGTCAAGTG GCCAAGCGTC A INFORMATION FOR SEQ ID NO:221: SEQUENCE CHARACTERISTICS: LENGTH: 530 base pairs TYPE: nucleic acid STRANOEDNESS: single TOPOLOGY: linear 9 9 9 9* (xi) SEQUENCE DESCRIPTION: SEQ ID NO:221: ATTGACGCTT GGCCACTTGA CACCCGCCTG CCTGCAATAC TGGGGCAAGG GCCTTCACTG CTTTCCTGCC ACCAGCTGCC ACTGCACACA GAGATCAGAA ATGCTACCAA CCAAGACTGT TGGTCCTCAG CCTCTCTGAG GAGAAAGAGC AGAAGCCTGG AAGTCAGAAG AGAAGCTAGA TCGGCTACGG CCTTGGCAGC CAGCTTCCCC ACCTGTGGCA ATAAAGTCGT GCATGGCTTA ACAATGGGGG CACCTCCTGA GAAACACATT GTTAGGCAAT TCGGCGTGTG TTCATCAGAG CATATTTACA CAAACCTCGA TAGTGCAGCC TACTATCCAC TATTGCTCCT ACGCTGCAAA CCTGAACAGC ATGGGACTGT ACTGAATACT GGAAGCAGCT GGTGATGGTA CTTATTTGTG TATCTAAACA CAGAGAAGGT ACAGTAAGAA TATGGTATCA TAAACTTACA GGGACCGCCA TCCTATATGC AGTCTGTTGT GACCAAATG TGTCAAGTGG CCAAGCGTCA INFORMATION FOR SEQ ID NO:222: i) SEQUENCE CHARACTERISTICS: LENGTH: 578 base pairs TYPE: nucleic acid 120 180 240 300 360 420 480 530 184 STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222: TGTATCGACG TAGTGGTCTC CGGGCTACTA GGCCGTTGTG TGCTGGTAGT ACCTGGTTCA CTGAAAGGCG CATCTCCCTC CCCGCGTCGC CCTGMAGCAG GGGGAGGACT TCGCCCAGCC 120 AAGGCAGTTG TATGAGTTTT AGCTGCGGCA CTTCGAGACC TCTGAGCCCA CCTCCTTCAG 180 GAGCCTTCCC CGATTAAGGA AGCCAGGGTA AGGATTCCTT CCTCCCCCAG ACACCACGMA 240 CAAACCACCA CCCCCCCTAT TCTGGCAGCC CATATACATC AGAACGAAAC AAAAATMACA 300 AATAAACNMA MCCAAAAAA AAAAGAGAAG GGGAMATGTA TATGTCTGTC CATCCTGTTG 360 CTTTAGCCTG TCAGCTCCTA NAGGGCAGGG ACCGTGTCTT CCGAATGGTC TGTGCAGCGC 420 *CGACTGCGGG MGTATCGGA GGAGGMAGCA GAGTCAGCAG MAGTTGAACG GTGGGCCCGG 480 CGGCTCTTGG GGGCTGGTGT TGTACTTCGA GACCGCTTTC GCTTITGTC TTAGATTAC 540 GTTTGCTCTT TGGAGTGGGA NACCACTACN TCNATACA 578 INFORMATION FOR SEQ ID NO:223: SEQUENCE CHARACTERISTICS: LENGTH: 578 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223: TGTATCGACG TAGTGGTCTC CTCTTGCAAA GGACTGGCTG GTGMATGGTT TCCCTGMATT 185 ATGGACTTAC CCTAAACATA TCTTATCATC A1TACCAGTT GCAA AATATT AGAATGTGTT 120 GTCACTGTTT CATTTGATTC CTAGMAGGTT AGTCTTAGAT ATGTTACTTT MACCTGTATG 180 CTGTAGTGCT TTGAATGCAT TTTTTGTTTG CATTT1TGTT TGCCCAACCT GTCAATTATA 240 GCTGCTTAGG TCTGGACTGT CCTGGATAAA GCTGTTAAMA TATTCACCAG TCCAGCCATC 300 TTACAAGCTA ATTAAGTCMA CTAAATGCTT CCTTGTTTTG CCAGACTTGT TATGTCMATC 360 CTCAATTTCT GGGTTCATTT TGGGTGCCCT AMATCTTAGG GTGTGACTTT CTTAGCATCC 420 TGTMACATCC ATTCCCAAGC AAGCACAACT TCACATAATA CMTCCAGMA GTTCATTGCT 480 .GAAGCCTTTC CTTCACCCAG CGGAGCMACT TGATTTTCTA CAACTTCCCT CATCAGAGCC 540 ACAAGAGTAT GGGATATGGA GACCACTACG TCGATACA 578 INFORMATION FOR SEQ ID NO:224: SEQUENCE CHARACTERISTICS:.

LENGTH: 345 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:224: TGTATCGACG TANTGGTCTC CCAAGGTGCT GGGATTGCAG GCATGAGCCA CCACTCCCAG GTGGATCTTT TTCTTATAC TTACTTCATT AGGTTTCTGT TATTCAAGAA GTGTAGTGGT 120 AAAAGTCTT TCAATCTACA TGGTTAAATA ATGATAGCCT GGGAAATAAA TAGAAATTTT 180 -TTCTMTCATC TTTAGGTTGA ATAMAGAAAC AGAAAMAATA GAACATACTG AAAATMATCT 240 186 AAGTTCCAAC CATAGAAGAA CTGCAGAAGA AATGAAGAAA GTGATGATGA TTTAGATTTT 300 GATATTGATT TAGAAGACAC AGGAGGAGAC CACTACGTCG ATACA 345 INFORMATION FOR SEQ ID NO:225: SEQUENCE CHARACTERISTICS: LENGTH: 347 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225: TGTATCGACG TAGTGGTCTC CAAACTGAGG TATGTGTGCC ACTAGCACAC AAAGCCTTCC AACAGGGACG CAGGCACAGG CAGTTTAAAG GGAATCTGTT TCTAAATTAA TTTCCACCTT 120 CTCTAAGTAT TCTTTCCTAA AACTGATCAA GGTGTGAAGC CTGTGCTCTT TCCCAACTCC 180 C: CCTTTGACAA CAGCCTTCAA CTAACACAAG AAAAGGCATG TCTGACACTC TTCCTGAGTC 240 TGACTCTGAT ACGTTGTTCT GATGTCTAAA GAGCTCCAGA ACACCAAAGG GACAATTCAG 300 AATGCTGGTG TATAACAGAC TCCAATGGAG ACCACTACGT CGATACA 347 INFORMATION FOR SEQ ID NO:226: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 281 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226: 187 AGGNGNGGGA NTGTATCGAC GTAGTGGTCT CCCAACAGTC TGTCATTCAG TCTGCAGGTG TCAGTGTTT GGACAATGAG GCACCATTGT CACTTATTGA CTCCTCAGCT CTAAATGCTG 120 AAATTAAATC TTGTCATGAC MAGTCTGGAA TTCCTGATGA GGTTTTACAA AGTATTTTGG 180 ATCAATACTC CMACAMATCA GAAAGCCAGA MAGAGGATCC TTTCAATATT GCAGAACCAC 240 GAGTGGATTT ACACACCTCA GGAGACCACT ACGTCGATAC A 281 INFORMATION FOR SEQ ID NO:227: SEQUENCE CHARACTERISTICS: LENGTH: 3646 base pairs C TYPE: nucleic acid STRANDEONESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:227: GGGAAACACT TCCTCCCAGC CTTGTMAGGG TTGGAGCCCT CTCCAGTATA TGCTGCAGMA TTTTTCTCTC GGTTTCTCAG AGGATTATGG AGTCCGCCTT AAAAMAGGCA AGCTCTGGAC 120 ACTCTGCAAA GTAGAATGGC CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGMA 180 CCTCACMATT GTTCAAGCTG TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA 240 GTTTCCCTAC ATTGATCMAT GGCTGAGTTT GGTCAGGAGC ACCCCTTCCG TGGCTCCACT 300 CATGCACCAT TCATAATTTT ACCTCCMAGG TCCTCCTGAG CCAGACCGTG TTTTCGCCTC 360 -GACCCTCAGC CGGTTCGGCT CGCCCTGTAC TGCCTCTCTC TGPAGAAGAG GAGAGTCTCC 420 -CTCACCCAGT CCCACCGCCT TMAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT 480

S.

S S

OS..

*55*

S

S.

S S OgS S @55555

S

5550

S

S

54.5

S

S

05.5.,

S

C

0@O*

CS

S. 0 e.g.

S

*005 CGGCTATGTC CCCTGTAGGC TCATCACCC AAGTAGCCCC TCTACTACCA CTGAGAGAC- CCCCCTTCCT GGTTTATGTC CCTTCTTTC MATCCTCCCT TCTCTGAAAA GCCCCAGGC ACACATTGGC CCACCTGGGA TGACTGTCA GAGAGGGAAA GTATCCAAAG AGAGGCCAA' GAGGAGGAAG CTAGAGGMAT AGTGATTAG/ TTTCTCAAGT GGAGGGAGMA CTTTGACGA c3GGAGCTGCT CAGAAACCTA TAAACTTGTC TGAGTCACCA GGAGTGTTT TAGAGCACCT TGAGCTGGCA GCCCCCGAAA ATAGCGATGC CCCAGATAGT AAAAGGAMAC TCCAAAAACT AGCTTTTAGA GATAGCCTAA MGGTTTTTG CAGCTCAGGC AGCTGAAAAA AGCCACTGAT TAGATCAGCC TCATFTGACT TCCCCTCCCA CTGACTCAAA CTCCACTATT CCTGTTCATG CTGGCCGACC TGATCTTCMA MTGTGCCCC ACAGTAGCAG CTTCCTCGAG AAGGGACTAC 'A TTGCCTCTTG GTTGCAACCG TGGTGGGAGG ;G CACAAGTCCC TCTGGGTGAT GAGTGCTCCA T ACTTCTGACT TGTATAATTG GAAAACCCAT T TTGACCTCAC TGATGGAGTC TGTACTCTGG 4 CAGCTCCTTT TGACCCTTTT CACCTCTGAA N AAGTACAACC TCACATCAAC CMATAGGCCG k GACCCMATTG GGACCTAATT GGGACCCAMA TTCCACCGG TATCTCCTCG TGGGTATTCA TMAGGCGACT GAAGTCGTCC AGGGGCATGA CCAGGAGGCT TATCAGATTT ACACCCCTTT TCTTAATTTG GCATTTGTGG CTCAGGCAGC AGAGGGATTT TGCTGGAATG MATACCAGTC ACAGTCMAGA GGTTGAAAAA CAAAAACMAG AAAGCATCCT GGAGTATCAG AGTTTACTGT CATGGTGTTT AAATCCAGCT ACACTACTTC ACTGTCAGGA ACTGTTGGMA ACTACTGAAA TAGGAAAGGT GGATGCCACC ATGTTCACAG GAAAGGCCGG TGCAGCTGTT ACCATGGAGA 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 .189 CAGATGTGTT GTGGGCTCAG GCTTTACCAG CA AACACCTC AGCACAAAAG GCTGAATTGA 1620 TCGCCCTCAC TCAGGCTCTC CGATGGGGTA AGGATATTAA CGTTAACACT GACAGCAGGT 1680 ACGCCTTGC TACTGTGCAT GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT 1740 CAGCAGGTGG CTGTMATCCA CTGTAAAGGA CATCAAAAGG AMAACACGGC TGTTGCCCGT 1800 GGTAACCAGA MAGCTGA TTC AGCAGCTCAA GATGCAGTGT GACTT-TCAGT CACGCCTCTA 1860 MACTTGCTGC CCACAGTCTC CT-TTCCACAG CCAGATCTGC CTGACAATCC CGCATACTCA 1920 *ACAGAAGAAG AAAACTGGCC TCAGAACTCA GAGCCAATAA AAATCAGGAA GGTTGGTGGA 1980 TTCTTCCTGA CTCTAGMATC TTCATACCCC GAACTCTTGG GAAAACTMTA ATCAGTCACC 2040 TACAGTCTAC CACCCATTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA 2100 AGATCCCCCA TCTTCAAAGC CTMCAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC 2160 :.AGGTMAATGC CMAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCMA GAAAACTCAC 2220 CAGGAGAAMA GTGGGMAATT GACTTTACAG AAGTAAMACC ACACCGGGCT GGGTACAAAT 2280 ACCTTCTAGT ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAMAACG 2340 MACTGTCAA TATGGTAGTT AAGTTTTTAC TCAATGAAAT CATCCGTCGA CATGGGCTGC 2400 CTGTTGCCA TAGGGTCTGA TAATGGACCG GCCT-TCGCCT TGTCTATAGT TTAGTCAGTC 2460 AGTMAGGCGT TAAACATTCA ATGGMAGCTC CATTGTGCCT ATCGACCCCA GAGCTCTGGG 2520 -CAAGTAGAAC GCATGAACTG CACCCTMAAA MCACTCTTA CAMAATTMAT CTTAGAAACC 2580 -GGTGTAMATT GTGTMAGTCT CCTTCCTTA GCCCTACTTA GAGTMAGGTG CACCCCTTAC 2640 190 TGGGCTGGGT TCTTACCTTT TGAAATCATG TATGGGAGGG TGCTGCCTAT CTTGCCTMAG CTAAGAGATG CCCMATTGGC AAAAATATCA CAAACTMATT TATTACAGTA CCTACAGTCT CCCCAACAGG TACMAGATAT CATCCTGCCA CTTGTTCGAG GAACCCATCC CMATCCMATT CCTGMACAGA CAGGGCCCTG CCATICATTC CCGCCAGGTG ACCTGTTGTT TGTTMAAAAG TTCCAGAGAG MGGACTCCC TCCTGCTTGG MAGAGACCTC ACACCGTCAT CACGATGCCA ACGGCTCTGA AGGTGGATGG CATTCCTGCG TGGATTCATC ACTCCCGCAT CAAAAAGGCC MACAGAGCCC AACTAGAAAC ATGGGTCCCC. AGGGCTGGGT CAGGCCCCTT MAAACTGCAC CTMGTTGGG TGAAGCCATT AGATTAATTC TTTTTCTTAA TTTTGTAPAA CMATGCATAG CTTCTGTCMA ACTTATGTAT CAATGATTTG ATTCCCCCMA TMACCCTGTT TTTAGACTCT ACTCTCCCTT AGCTMAGAGC TTCCTCAAGG ACTTAACTTG GATMAGATAC TGTGGCMAGC CCCCTCTACC CTTCAGCAAC GGCCCTCCAC CAGCAAAAAG TAGCAGTAAA GTTTTTTTT CTTMAGACTC AATATAACCC CCTTGTTATA ACTGAGGAAT AAACACAAGT GGGGAATGTA GTGTCCAACC TGGTTTTTAC CCCTTTCCTT TMTCACTCA GCTT(GTTCC ACCTGAATTG GCCAGATGGA CTCCATCTTG GCTCTTCAC TGGCAGCCGC TGCMGCTGA*CTCCCAGCAC ATCCAAGMAT GCMATTAACT TATATCCGCA GTTCCCAGGA ATTCGTCCAA TTGATCACAG CACCACCCTG ATCAGTCAGC AGCCATCAGC ACCGAGGCMA ATTCTGACTC ACTGAAGACT TGGATGATCA TTAGTATM CTTTTTCTTT CT1TTTMCT CGTGCC 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3420 3480 3540 3600 3646

Claims (3)

1. An isolated DNA molecule, comprising: a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168- 176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227; a variant of said nucleotide sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ.ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198,

200-204,206, 207, 209-214, 216, 218, 219,221-227. 2. An isolated DNA molecule encoding an epitope of a polypeptide, wherein said polypeptide is encoded by a nucleotide sequence that: hybridizes to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168- 176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227 under stringent conditions; and is at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219,

221-227; and wherein RNA corresponding to said nucleotide sequence is expressed at a greater level in human breast tumor tissue than in normal breast tissue. 3. An isolated DNA molecule encoding an epitope of a polypeptide, wherein said polypeptide is encoded by: c 192 a nucleotide sequence transcribed from the sequence of SEQ ID NO: 141; or a variant of said nucleotide sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained. 4. An isolated DNA or RNA molecule comprising a nucleotide sequence complementary to a DNA molecule according to any one of claims 1-3. 5. A recombinant expression vector comprising a DNA molecule according to any one of claims 1-3. 6. A host cell transformed or transfected with an expression vector according to claim 7. A polypeptide comprising an amino acid sequence encoded by a DNA molecule according to any one of claims 1-3. 8. A polypeptide according to claim 7 wherein said polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227. 9. A monoclonal antibody that binds to a polypeptide according to claim 7. 193 A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, at least one polypeptide according to claim 7, and therefrom determining the presence of breast cancer in the patient. 11. A method for determining the presence of breast cancer in a patient comprising detecting within a biological sample, at least one polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that .hybridize thereto under stringent conditions. 12. The method of claims 10 or 11 wherein the biological sample is a portion of a breast tumor. 13. The method of claim 10 wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody according to claim 9. 14. The method of claim 11 wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody that binds to a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions. A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, an RNA molecule encoding at least one polypeptide according to claim 7, and therefrom determining the presence of breast cancer in the patient. 16. A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, at least one RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID 194 NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; and therefrom determining the presence of breast cancer in the patient. 17. The method of claims 15 or 16 wherein the biological sample is a portion of a breast tumor. 18. The method of claim 15 wherein the step of detecting comprises: preparing cDNA from RNA molecules within the biological sample; S and specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to. claim 7, and therefrom determining the presence of breast cancer in the patient. 19. The method of claim 16 wherein the step of detecting comprises: preparing cDNA from RNA molecules within the biological sample; and specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; and therefrom determining the presence of breast cancer in the patient. A polypeptide according to claim 7 for use within a method for detecting the presence of breast cancer in a patient. 21. A polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 21-5, 217, 220, and sequences that hybridize thereto under stringent conditions, for use within a method for detecting the presence of breast cancer in a patient. 22. A method for monitoring the progression of breast cancer in a patient, comprising: detecting an amount, in a biological sample, of at least one polypeptide according to claim 7 at a first point in time; repeating step at a subsequent point in time; and comparing the amounts of polypeptide detected in steps and and therefrom monitoring the progression of breast cancer in the patient. 23. A method for monitoring the progression of breast cancer in a patient, comprising: detecting in a biological sample an amount of at least one polypeptide at a first point in time, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; repeating step at a subsequent point in time; and comparing the amounts of polypeptide detected in steps and and therefrom monitoring the progression of breast cancer in the patient. 24. The method of claims 22 or 23 wherein the biological sample is a portion of a breast tumor. The method of claim 22 wherein the step of detecting comprises contacting a portion of the biological sample with a monoclonal antibody according to claim 9. 26. The method of claim 23 wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody that binds to a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 196 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions. 27. The method of either of claims 20 or 22 wherein said polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 SEQ ID NO:77 and SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-227. 28. A method for monitoring the progression of breast cancer in a patient, comprising: .detecting an amount, within a biological sample, of at least one RNA molecule encoding a polypeptide according to claim 7 at a first point in time; repeating step at a subsequent point in time; and comparing the amounts of RNA molecules detected in steps and and therefrom monitoring the progression of breast cancer in the patient. 29. The method of claim 28 wherein the step of detecting comprises: preparing cDNA from RNA molecules within the biological sample; and specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to claim 7. A method for monitoring the progression of breast cancer in a patient, comprising: detecting an amount, within a biological sample, of at least one RNA molecule at a first point in time, the RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions; 197 repeating step at a subsequent point in time; and comparing the amounts of RNA molecules detected in steps and and therefrom monitoring the progression of breast cancer in the patient. 31. A pharmaceutical composition, comprising a polypeptide according to claim 7 and a physiologically acceptable carrier. 32. A pharmaceutical composition for inhibiting the development of breast cancer, comprising a polypeptide and a physiologically acceptable carrier, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions. 33. A vaccine, comprising a polypeptide according to claim 7 and an immune response enhancer. 34. A vaccine, comprising a DNA molecule according to any one of claims 1-3. 35. A vaccine, comprising a recombinant expression vector comprising a DNA molecule according to any one of claims 1-3. 36. A vaccine for inhibiting the development of breast cancer, comprising a polypeptide and an immune response enhancer, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, and sequences that hybridize thereto under stringent conditions. 37. A diagnostic kit comprising: one or more monoclonal antibodies according to claim 9; and 198 a detection reagent. 38. A diagnostic kit comprising: one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID 78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220; and a detection reagent. 39. The kit of any one of claims 37 or 38 wherein the monoclonal antibody(s) are immobilized on a solid support. A diagnostic kit comprising a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of an RNA molecule according to claim 4. 0 41. A diagnostic kit comprising a first polymerase chain reaction primer and a second polymerase chain reaction primer, the first and second primers each comprising at least about 10 contiguous nucleotides of an RNA molecule encoding a polypeptide _encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205,208, 215, 217, 220. 42. A diagnostic kit comprising at least one oligonucleotide probe, the oligonucleotide probe containing at least about 15 contiguous nucleotides of a DNA molecule according to claim 4. 43. A diagnostic kit comprising at least one oligonucleotide probe, the oligonucleotide probe comprising at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NOS:78-86 and SEQ ID NOS:144, 145, 153, 167, 177, 193, 199, 205,208, 215, 217, 220. P: opcr\cjlamedcd\2064 4 2.cixmncwpagoddc-091 1/00 -199- An isolated DNA molecule according to any one of Claims 1-4 or a recombinant expression vector according to Claim 5 or a host cell according to Claim 6 or a polypeptide according to any one of Claims 7, 8, 20 and 21 or a monoclonal antibody according to Claim 9 or a method according to any one of Claims 10-19 and 22-30 or a pharmaceutical composition according to any one of Claims 31 and 32 or a vaccine according to any one of Claims 33-36 or a diagnostic kit according to any one of Claims 37-43 substantially as hereinbefore defined with reference to the Figures and/or Examples. DATED this ninth day of November 2000. 5* Corixa Corporation by DAVIES COLLISION CAVE Patent Attorneys for the Applicant o*